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Summary 
The role of immune system in seizures and epilepsy has been known for a long time. Inflammation is 
thought to play a role in many seizure disorders, such as in some severe childhood epilepsies and in 
fever and infection triggered seizures. Inflammation in these cases could be primary or secondary to 
the seizures themselves. Secondary inflammatory mechanisms are likely to be mediated "non-
specifically" by the innate immune system. 
The "specific" or adaptive immune system, which includes cell mediated and antibody mediated 
"humoral" mechanisms is now recognised to be important in some seizure disorders and recently the 
term "autoimmune epilepsy" has been used to imply involvement of the adaptive immune system, 
(particularly humoral) in the pathogenesis of epilepsy. Specific neuronal antibodies against cell 
surface proteins and receptors as well as some intracellular antigens are now well recognised in a 
proportion of adult patients with seizures. The seizures are often severe and not isolated, but rather 
accompanied by encephalopathy or other neurologic symptoms. Evidence of brain inflammation 
might be found in cerebrospinal fluid (pleocytosis or oligoclonal bands) or imaging (increased signal 
on magnetic resonance imaging). The best recognised disorders are limbic encephalitis (associated 
with antibodies against many neuronal antigens such as VGKC-complex proteins and GAD, and 
NMDAR encephalitis. However neuronal antibodies are also recognised in some adult patients with 
seizures and epilepsies in the absence of encephalopathy or other features. New antigenic targets are 
increasingly identified and at the time of reporting this includes: VGKC complex (LGI1, CASPR2 
and contactin2 or TAG1), NMDAR, AMPAR, GABABR, Glycine receptor and GAD. In disorders 
that are associated with antibodies to intracellular antigens (such as GAD), it is thought that cell 
mediated (cytotoxic) mechanisms are important rather than direct antigen-antibody interaction since 
the antigenic target is not readily exposed. 
Most reports describing autoimmune epilepsies come from adult studies. At the time when I 
commenced my project in March 2009 there was no reports of neuronal antibodies in children, apart 
from NMDAR encephalitis. The available reports from adult studies suggested that the disorders 
associated with neuronal antibodies are potentially treatable with immunotherapy. While 
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immunotherapeutic agents (mainly corticosteroids and to a lesser extent intravenous immunoglobulin) 
have been used for a long time to treat some of the severe paediatric epilepsies such as West 
syndrome, Landau Kleffner and Lennox Gastaut syndromes, the mechanisms of their action are not 
clear and these agents are not given to target the immune system in this context. 
My PhD project aimed to study and investigate neuronal antibodies in children with seizures in the 
context of encephalitis, or without encephalitis. This study hoped to help recognise children who may 
have ‘autoimmune seizures’. It was hoped that this could alter the treatment of patients with 
‘autoimmune epilepsy’, from symptomatic treatment with conventional antiepileptic medications to 
immunotherapy that targets the underlying immune disorder. 
The study was conducted at the Children Hospital at Westmead, which is one of the two tertiary 
children hospitals in Sydney. Based on the adult studies' findings, and the initial discovery of an index 
case, I first tested the acute serum of children presenting with unexplained encephalitis and severe 
seizures. I found serum VGKC-complex antibodies in four of the 10 patients tested. The clinical 
features of the affected children were similar to the adults described with VGKC encephalitis. I also 
used a paediatric control group to create a normal reference range for VGKC-complex antibodies in 
children. Secondly, I recruited a heterogeneous group of children with new onset seizures, and tested 
them for neuronal antibodies. 11 out of the 114 children (9.4%) tested positive for neuronal antibodies 
including VGKC complex, CASPR2 and NMDAR, mainly those with epilepsy of unknown cause 
(predominantly focal). This study also involved using the new ILAE classification system for 
epilepsy. Thirdly, I tested a separate miscellaneous group of patients who were suspected to have 
‘autoimmune epilepsy’ through the clinical practise at the hospital. These patients were suspected to 
have autoimmune epilepsy due to the presence of CNS inflammation or associated autoimmune 
disorders. Neuronal antibodies were found in seven out of the 13 patients tested. I proposed clinical 
guidelines that may help in the identification of patients with autoimmune seizures. 
The findings in this study are novel and have shed some light into the importance of neuronal 
antibodies in paediatric seizure disorders. While the pathogenic role of these antibodies remains a hot 
topic for debates and studies, we think that the presence of these antibodies can define a group of 
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patients where immune mechanisms are important, and where immunotherapy might improve the 
clinical outcome. 
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Chapter 1 Literature Review 
In this chapter I present a summary of the various topics that are relevant to this study including 
seizures and epilepsy, and their classifications. I then introduce the concept of channelopathies in 
relation to epilepsy, both genetic and acquired. I discuss the important antibodies against various 
neuronal channels and proteins that are implicated in seizures and epilepsies, and present their 
relevant stories as they evolved. This is followed by the hypothesis and aims of my autoimmune 
epilepsy study in children. 
1.1 Epilepsy 
Epilepsy is one of the most prevalent neurological disorder in children affecting about 0.5 to 1.0% of 
children (Shinnar and Pellock, 2002). Wider ranges of prevalence rates for epilepsy in childhood have 
been reported from 0.15 to 12.1 %. The variation is likely due to geographical variations as well as 
study designs (Eriksson and Koivikko, 1997). The incidence of epilepsy is higher for children under 
10 years and is highest for children less than one year (Camfield et al., 1996). Some of the childhood 
epilepsies remit during a predictable age group; however some epilepsies continue into adulthood. 
The majority of adults with epilepsy have onset in childhood (Shinnar and Pellock, 2002). Epilepsy 
causes significant morbidity and mortality in children. Co-morbidities are common in children with 
epilepsy including developmental disabilities, autism, attention deficit hyperactivity disorder 
(ADHD), depression and anxiety, migraine and accidental injuries (Pellock, 2004). Children suffering 
from epilepsy have a significantly increased mortality rate. The major causes of death are the 
underlying cause of the epilepsy itself, associated neurological compromise, injuries, status 
epilepticus and sudden death in epilepsy (SUDEP) (Shinnar and Pellock, 2002). 
1.1.1 Definitions 
An Epileptic seizure is defined as per the guidelines for epidemiologic studies, 1993 by the 
International League Against Epilepsy (ILAE) as “a clinical manifestation presumed to result from an 
abnormal and excessive discharge of a set of neurons in the brain”. The clinical manifestation consists 
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of “sudden and transitory abnormal phenomena, which may include alterations of consciousness, 
motor, sensory, autonomic, or psychic events, perceived by the patient or an observer” (Commission 
On et al., 1993). 
Epilepsy is defined as a condition characterized by recurrent (two or more) epileptic seizures, 
unprovoked by any immediate identified cause (Commission On et al., 1993). Multiple seizures 
occurring in a 24 hour period and an episode of status epilepticus are considered single events. Febrile 
seizures and neonatal seizures (occurring in the first 30 days of life) are excluded and not considered a 
form of epilepsy (Commission On et al., 1993). In other words epilepsy is the occurrence of two or 
more unprovoked seizures more than 24 hours apart in a child older than 1 month. The diagnosis of 
epilepsy implies a persistent epileptogenic abnormality of the brain that is able to spontaneously 
generate paroxysmal activity (Engel, 2006). 
1.1.2 Epilepsy Classifications 
Epilepsy has many types and different causes. Classification and terms vary considerably in different 
parts of the world. The International League Against Epilepsy (ILAE) Commission on Terminology 
has organised meetings of worldwide experts since 1964 to put in place a standard classification 
system that can be used internationally. The system defines seizure types according to their proposed 
origin in the brain and according to their clinical phenotype. It also classifies epilepsies according to 
their aetiology and according to the presence of recognisable constellations of features that may be 
defined as distinctive syndromes (Gastaut et al., 1964, Gastaut, 1970). The ILAE classification system 
is widely used and has been revised a few times since its implementation in 1969 to meet the ongoing 
developments in the understanding of epilepsy and its causes. In 1981 the commission on 
classification and terminology of the International League Against Epilepsy proposed a revised 
clinical and electroencephalographic classification of epileptic seizures, which is known as the 
International Classification of Epileptic Seizures (ICES) (Bancaud et al., 1981) . In 1989 there was a 
proposal for revised classification of epilepsies and epileptic syndromes, which is known as the 
International Classification of Epilepsy and Epileptic Syndromes (ICE) (Roger et al., 1989). ICES and 
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ICE have been widely used and accepted internationally. Further revisions were made in 2001 mainly 
defining some of the terminology used (Engel, 2001). A recent revision in 2010 proposed major 
changes in the terminology and concepts used for seizure and epilepsy classification (Berg et al., 
2010). These different classifications are presented below. 
1.1.2.1 International Classification of Epileptic Seizures (ICES)-1981 
Epilepsy is classified according to seizure type, generalised or focal and each type is further sub 
classified according to seizure phenotype or “semiology”. The following is the ILAE classification of 
seizures proposed in 1981(ICES) (Bancaud et al., 1981).  
1) Partial (focal) seizures: 
a. Simple partial seizures (no impairment of consciousness) 
b. Complex partial seizures 
1. With impairment of consciousness at onset 
2. Simple partial onset followed by impairment of consciousness 
c. Partial seizures evolving to generalised tonic-clonic convulsions (GTC) 
1. Simple evolving to GTC 
2. Complex evolving to GTC 
2) Generalised seizures (convulsive or nonconvulsive): 
a. Absence seizures and atypical absence 
b. Myoclonic seizures 
c. Clonic seizures 
d. Tonic seizures 
e. Atonic seizures (Astatic) 
3) Unclassified epileptic seizures 
This includes all seizures that cannot be classified because of inadequate or incomplete data. 
This classification term also includes some neonatal seizures. 
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1.1.2.2 International Classification of Epilepsies and Epileptic Syndromes (ICE)-1989 
In 1989, a proposal for classification of epilepsies and epileptic syndromes was made. The 
International Classification of Epilepsies and Epileptic Syndromes (ICE) was created to supplement 
the International Classification of Epileptic Seizures (ICES)-1981 (Roger et al., 1989).  
The ICE (1989) classified epilepsies according to their aetiology, as follows:  
 Idiopathic epilepsy; when there is no underlying or primary cause for the epilepsy other than a 
proposed hereditary predisposition. Idiopathic is derived from the Greek “idios”, meaning 
self, own, or personal. Idiopathic epilepsies and syndromes are described as disorders “not 
preceded or occasioned by another,” in the Oxford English Dictionary (quoted from ICE 
1989) (Roger et al., 1989). In idiopathic epilepsies there is no underlying structural brain 
abnormality or other neurologic signs or symptoms. Idiopathic epilepsies are age related 
(Engel, 2001). 
 Symptomatic epilepsy; when there is a known or suspected underlying disorder of the central 
nervous system (CNS) (Roger et al., 1989) This includes structural brain abnormalities such 
as cortical malformation, brain tumours or other space occupying lesions, traumatic or 
ischaemic brain injuries, inflammatory conditions including meningitis and encephalitis and 
metabolic conditions. 
 Cryptogenic epilepsy; cryptogenic refers to a disorder whose cause is hidden or occult. 
Cryptogenic epilepsies are presumed to be symptomatic, but the aetiology is not known (ICE 
1989) (Roger et al., 1989). 
An “epilepsy syndrome” is defined as a an epileptic disorder characterised by a cluster of signs and 
symptoms occurring together; these include items such as the type of seizure, aetiology, anatomy, 
precipitating factors, age of onset, severity, chronicity, diurnal and circadian cycling, and sometimes 
prognosis (Roger et al., 1989). An "epilepsy syndrome" does not necessarily have the same 
aetiologies or prognosis. 
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The following list is the international classification of epilepsy and epileptic syndromes as per ILAE 
International Classification of Epilepsies and Epileptic Syndromes (ICE)-1989: 
1) Localisation related (partial, focal, local) 
1.1 Idiopathic (with age related onset) 
a. Benign childhood epilepsy with centro-temporal spikes 
b. Childhood epilepsy with occipital paroxysms 
c. Primary reading epilepsy 
1.2 Symptomatic temporal, frontal, parietal and occipital lobe epilepsies 
1.3 Cryptogenic temporal, frontal, parietal and occipital lobe epilepsies 
2) Generalised epilepsies and syndromes 
2. 1 Idiopathic  
a. Benign neonatal familial convulsions 
b. Benign neonatal convulsions 
c. Benign myoclonic epilepsy in infancy 
d. Childhood absence epilepsy  
e. Juvenile absence epilepsy 
f. Juvenile myoclonic epilepsy (impulsive petit mal) 
g. Epilepsy with grand mal (GTC) seizures on awakening 
h. Other generalised idiopathic epilepsies not defined above 
2.2 Cryptogenic or symptomatic  
a. West syndrome  
b. Lennox-Gastaut syndrome 
c. Epilepsy with myoclonic-astatic seizures 
d. Epilepsy with myoclonic absences 
2.3 Symptomatic 
2.3.1 Non-specific aetiology 
a. Early myoclonic encephalopathy 
b. Early infantile epileptic encephalopathy with suppression burst 
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c. Other symptomatic generalised epilepsies not defined above 
2.3.2 Specific syndromes 
Epileptic seizures may complicate many disease states. Under this heading are included 
diseases in which seizures are a presenting or predominant feature 
3) Epilepsies and syndromes undetermined whether focal or generalised 
3.1 With both generalised and focal seizures  
a. Neonatal seizures 
b. Severe myoclonic epilepsy in infancy 
c. Epilepsy with continuous spike-waves 
d. Acquired epileptic aphasia (Landau-Kleffner- syndrome) 
e. Other undetermined epilepsies not defined above 
3.2 Without unequivocal generalised or focal features.  
This category includes cases with generalised tonic clonic (GTC) seizures in which clinical 
and EEG findings do not permit classification as clearly generalised or localization related. 
Examples are many cases of sleep grand mal seizures which are considered to have equivocal 
generalised or focal features. 
4) Special syndromes 
4.1 Situation-related seizures  
a. Febrile convulsions 
b. Isolated seizures or isolated status epilepticus 
c. Seizures occurring only when there is an acute metabolic or toxic event due to factors 
such as alcohol, drugs, eclampsia, nonketotic hyperglycemia 
Studies trying to use the classification found that a considerable number of cases fell into the 
nonspecific categories of ICES (cryptogenic, symptomatic), which limits the value of this epilepsy 
and syndrome classification (Manford et al., 1992, Eriksson and Koivikko, 1997).  
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1.1.2.3 ILAE classification updates (Engel 2001 and 2006) 
The ILAE Classification of Epileptic Seizures (ICES) in 1981 and the ILAE Classification of 
Epilepsies and Epileptic Syndromes (ICE) in 1989 provided universal terminology that facilitated 
communication on clinical and research levels (Engel, 2001). In 1997 a Task Force on Classification 
and Terminology was appointed to revise the ILAE classification to accommodate the changes that 
occurred since the adoption of the classification used at the time, ICES and ICE. The Task Force 
divided itself into four working groups concerned with  
1. Descriptive Terminology for Ictal Events, 
2. Seizures, 
3. Syndromes and Diseases, and 
4. Impairment.  
The Task Force decided that it was not possible to replace the current international classifications 
(ICE and ICES) with similar revised and updated classifications that would be universally accepted. 
Instead the Task Force focused on defining the terminology and proposed a diagnostic scheme for 
people with epileptic seizures and epilepsy that makes use of standardized terminology and concepts 
to describe individual patients (Engel, 2001) (for detailed reference see Tables 1 to 4 in Appendix 1). 
The Task Force also came up with a standardized glossary of descriptive terminology for ictal 
semiology  (Blume et al., 2001), see Appendix 2. 
The classification system was revisited again in 2006 and the ILAE commission commented then that 
the original classification of ICE and ICES remained acceptable and was not to be discarded unless a 
better classification was revised, although some modifications were anticipated (Engel, 2006). 
1.1.2.4 Latest proposed ILAE classification (Berg 2010) 
With major technologic understanding in the preceding decade, and improvement in the 
understanding of epilepsy (particularly the genetics of epilepsy), the need for a new classification 
system was recognised. In 2010 ILAE Commission on Classification and Terminology introduced a 
new version of revised terminology and concepts for classification of seizures and epilepsy syndromes 
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(Berg et al., 2010). The new report proposed changing a few existing terms and tried to use a 
simplified meaningful approach.  
Seizures were broadly classified into focal, generalised and unknown; 
1) Focal seizures; which were further classified according to the degree of impairment during seizures 
a. Without impairment of consciousness, 
b. With impairment of consciousness (dyscognitive- replaces the term complex partial), 
c. Evolving into bilateral convulsive seizure (replaces the term secondarily generalised). 
2) Generalised Seizures 
a. Tonic- clonic 
b. Absence  
 Typical 
 Atypical 
 Absence with special features: myoclonic absence and eyelid myoclonia 
c. Myoclonic 
 Myoclonic 
 Myoclonic atonic 
 Myoclonic tonic 
d. Clonic 
e. Tonic 
f. Atonic 
3) Unknown 
 Epileptic spasms: which were previously called infantile spasms, however as they can 
continue beyond infancy the term ‘epileptic spasms’ was used instead.  ’Epileptic spasms’ 
were difficult to group into focal or generalised seizures, so were classified as unknown. 
Previous classifications listed infantile spasms under generalised seizures. 
24 
 
 The new classification by Berg et al recommended new terminology in epilepsy aetiology 
classification to replace the existing terms symptomatic, idiopathic and cryptogenic. The 
following terms were recommended: 
 Genetic (replaces Idiopathic) epilepsy is the direct result of a known or presumed genetic 
defect(s) in which seizures are the core symptom of the disorder. This may be supported by 
additional evidence. 
 Structural/metabolic (replaces Symptomatic) epilepsy when there is a distinct structural or 
metabolic condition or disease that has been demonstrated to be associated with a 
substantially increased risk of developing epilepsy. Structural lesions can be acquired such as 
stroke, trauma and infection, or can be genetic such as Tuberous sclerosis. 
 Unknown cause (replaces Cryptogenic) epilepsy where the underlying cause is not known as 
yet but it may be an unrecognised genetic, structural or metabolic cause (Berg et al., 2010, 
Berg and Scheffer, 2011). 
The epilepsy syndromes were also revised and included the following subcategories (for more details 
see Table 5, Appendix 1): 
 Electroclinical syndromes: This term replaced the term Epilepsy Syndromes in ICE 1989. An 
electroclinical syndrome is a complex of clinical features, signs and symptoms that together 
define a distinctive recognizable clinical disorder. They are identifiable based on typical age 
of onset, EEG characteristics, seizure type and other features. Examples include benign 
familial neonatal epilepsy, myoclonic epilepsy of infancy, Panayotopoulos syndrome and 
childhood absence epilepsy. 
 Distinctive constellations: These are conditions that have distinctive features to recognise 
them as specific entities but are not exactly electroclinical syndromes; for example mesial 
temporal lobe epilepsy with hippocampal sclerosis, Rasmussen syndrome and Gelastic 
seizures.  
 Epilepsies attributed to a known structural or metabolic cause such as malformation of 
cortical development, tumours, infection, trauma, stroke, etc. 
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 Epilepsies of unknown cause, which account for one third of all epilepsies. It was 
recommended that these epilepsies should be characterised according to the relevant features. 
 Condition with epileptic seizures that are not traditionally diagnosed as epilepsy such as 
febrile seizures and benign neonatal seizures were kept in a separate group. 
This new classification system was met with variable degrees of acceptance and criticism in the 
international community (Panayiotopoulos, 2011, Shorvon, 2011, Panayiotopoulos, 2012). 
1.1.3 Status Epilepticus 
The term “status epilepticus” is used whenever a seizure persists for a sufficient length of time or is 
repeated frequently enough that recovery between attacks does not occur. Status epilepticus may be 
divided into partial (e.g., Jacksonian), or generalised (e.g., absence status or tonic-clonic status). 
When very localized motor status occurs, it is referred to as epilepsia partialis continua (Roger et al., 
1989). 
Status epilepticus was further defined as a single epileptic seizure of more than 30 minute duration or 
a series of epileptic seizures during which function is not regained between ictal events over a period 
of at least 30 minutes (Commission On et al., 1993). 
Status epilepticus (SE) is the most common neurological emergency in childhood and often requires 
intensive care treatment. Longer duration of seizures is associated with increased risk of morbidity 
and mortality (Chin et al., 2004). 
SE is traditionally classified into convulsive and non-convulsive based on the presence of a motor 
component to the prolonged seizure. Though the term “convulsive” is considered a lay term it was 
endorsed in the new ILAE classification as it is used widely throughout medicine (Berg et al., 2010). 
1.1.3.1 Status epilepticus classification 
A useful classification system for the causes of convulsive status epilepticus (CSE) in childhood 
based on the aetiology was proposed as follows (Gastaut, 1983, Chin et al., 2004, Chin et al., 2006): 
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1. “Prolonged febrile seizure” is convulsive status epilepticus (CSE) in a previously neurologically 
healthy child aged between 6 months and 5 years during a febrile (temperature >38°C) illness and in 
the absence of defined CNS infection. 
2. “Acute symptomatic” is CSE in a previously neurologically normal child within a week of an 
identified acute neurological insult including bacterial meningitis, viral CNS infection, metabolic 
derangements, drug-related effects, head injury, hypoxia or anoxia, or cerebrovascular disease. 
3. “Remote symptomatic” is CSE in the absence of an identified acute insult but with a history of a 
pre-existing CNS abnormality more than 1 week previously. 
4. “Acute on remote symptomatic” is CSE within a week of an acute neurological insult or febrile 
illness in a child with previous neurological abnormality, including epilepsy. This category includes 
children with cerebral palsy with a febrile illness not of CNS origin, and children with hydrocephalus 
and obstructed ventriculoperitoneal shunts. 
5. “Idiopathic epilepsy related” is CSE that is not symptomatic and occurs in children with a previous 
diagnosis of idiopathic epilepsy or when the episode of convulsive status epilepticus is the second 
unprovoked seizure that has led to a diagnosis of idiopathic epilepsy 
6. “Cryptogenic epilepsy related” is CSE that is not symptomatic and occurs in children with a 
previous diagnosis of cryptogenic epilepsy or when the episode of convulsive status epilepticus is the 
second unprovoked seizure that has led to a diagnosis of cryptogenic epilepsy. 
7. “Unclassified” is CSE that cannot be classified into any other group. 
1.1.4 Epileptic Encephalopathy 
The term “epileptic encephalopathy” (EE) is used to describe a condition in which the epileptiform 
abnormalities themselves are believed to contribute to the progressive disturbance in cerebral function 
(Engel, 2001). Epileptic encephalopathies refer to a group of conditions where the neurological 
function is impaired mainly due to epileptic activity which can be clinical seizures or prominent 
interictal epileptic activity (Dulac, 2001). Epileptic encephalopathies can occur at any age however it 
is most common and severe in infancy and early childhood (Berg et al., 2010) where they may have 
detrimental effects on the developing brain. The seizures in these conditions are severe and often 
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manifest as infantile or epileptic spasms. The electroencephalogram (EEG) in these conditions is 
usually very abnormal including burst suppression and high voltage chaotic pattern (hypsarrythmia 
and modified hypsarrythmia). It is thought that the epileptic activity itself leads to the severe cognitive 
and behavioural impairment beyond what is expected from the underlying condition itself. The cause 
of the encephalopathy might be the underlying disease, the epileptic process or a combination of both 
(Berg et al., 2010). 
1.1.4.1 Epileptic encephalopathies in infants and young children 
Epileptic encephalopathies as listed by the ILAE Task Force report in 2001 (Engel, 2001)  included 
the following: 
 Early myoclonic encephalopathy (may contribute to progressive dysfunction) 
 Ohtahara syndrome 
 West syndrome 
 Dravet syndrome (previously known as severe myoclonic epilepsy in infancy) 
 Myoclonic status in non progressive encephalopathies 
 Lennox–Gastaut syndrome 
 Landau–Kleffner syndrome 
 Epilepsy with continuous spike–waves during slow-wave sleep 
Epileptic encephalopathy (EE) is associated with many conditions including genetic, structural and 
metabolic aetiologies. Idiopathic cases are also described where no cause can be found. Structural 
causes associated with EE include congenital disorders such as malformations of cortical 
development, as well as acquired disorders such as hypoxic ischaemic insults. Metabolic causes 
known to result in EE include biotinidase deficiency, pyridoxine/pyridoxal 5-phosphate dependency, 
and GLUT1 (glucose transporter 1) deficiency, as well as disorders of biopterin synthesis, creatine 
synthesis and folate metabolism (Pearl, 2009, Holland and Hallinan, 2010). It is important to 
recognise these disorders as many of them are potentially treatable. More genes are now identified 
and recognised in association with early onset epileptic encephalopathies and epileptic spasms, 
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particularly in children with normal brain imaging. Identified genetic causes of Epileptic 
encephalopathy include ARX (Aristaless-related homeobox), CDKL5 (Cyclin-Dependent Kinase-
Like 5), STXBP1 (Syntaxin binding protein 1), SCN1A (Sodium channel neuronal type 1a subunit), 
PCDH19 (Protocadherin 19) and others (Holland and Hallinan, 2010, Mastrangelo and Leuzzi, 2012). 
In many cases of EE with epileptic spasms the cause is unknown despite extensive investigations. Out 
of 207 patients enrolled in United Kingdom Infantile Spasms Study (UKISS) 68 had no cause found 
(33%) (Osborne et al.). 
Epileptic encephalopathy and epileptic spasms are usually difficult to treat and often do not respond to 
conventional AEDs. Steroids are considered to be the first line and are probably the most effective 
treatment used for epileptic encephalopathy and epileptic spasm (Go et al., 2012). Vigabatrin is also 
commonly used in treatment of EE and IS particularly in patients with tuberous sclerosis (Go et al., 
2012). Different centres in the world tend to use different forms of steroids including intramuscular 
adrenocorticotropic hormone (ACTH) and high dose oral prednisolone. High dose oral prednisolone 
at 40-60 mg/day as used in the 2004 United Kingdom Infantile Spasms Study (UKISS) has been 
shown to be as effective but less expensive than ACTH in the treatment of epileptic spasms (Kossoff 
et al., 2009). The mechanism of action of steroids in treating epileptic spasms is unclear although 
different theories are proposed. It is possible that steroids have both anticonvulsant as well as anti-
inflammatory and immune modulation effects (Vezzani et al., 2011). 
1.1.4.2 Epileptic encephalopathy in older children- FIRES and related conditions 
In older children a spectrum of epileptic syndromes and encephalopathies affecting previously normal 
children and leading to epileptic encephalopathy are recognised. These include Devastating Epileptic 
Encephalopathy in School-aged Children (DESC) reported by French authors (Mikaeloff et al., 2006), 
Acute Encephalitis with Refractory Repetitive Partial Seizures (AERRPS) reported by Japanese 
authors (Sakuma, 2009), Febrile-Infection Related Epilepsy Syndrome (FIRES) (van Baalen et al., 
2009, van Baalen et al., 2010) and Fever-Induced Refractory Epileptic Encephalopathy in School-
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aged children (FIRES) (Nabbout et al., 2010, Nabbout et al., 2011). A similar condition has also been 
described in adults with new-onset refractory status epilepticus (NORSE) (Wilder-Smith et al., 2005).  
These terms seem to be used interchangeably to describe similar conditions, though the recent reports 
are increasingly using the term FIRES. The affected children are previously healthy, and usually 
school age children (rather than infants). They develop acute or subacute new onset refractory status 
epilepticus, often preceded by fever or infection and the fever usually persists during the acute phase. 
Encephalitis is often suspected due to the presence of fever, encephalopathy and status epilepticus. 
The term “pseudoencephalitis” has been used in some of these cases for that reason (Mikaeloff et al., 
2006). Extensive investigations usually fail to reveal any cause for the refractory epilepsy including 
infectious, metabolic, genetic or structural aetiologies (van Baalen et al., 2010, Nabbout et al., 2011, 
van Baalen et al., 2012). Cerebrospinal fluid (CSF) is normal or shows mild pleocytosis and MRI of 
the brain is normal or shows non-specific changes. The EEG shows high voltage slow background 
activity and focal seizures often with switching between hemispheres. The patients typically continue 
to have frequent seizures over many weeks. The seizures are usually focal with onset in the 
perisylvian or rolandic areas, sometimes with evolution to generalised seizures. Patients go on to 
develop chronic epilepsy without going through a latent phase and continue to have refractory focal 
seizures in the chronic phase. 
The seizures are extremely resistant to multiple antiepileptic drugs. The only treatment reported to 
stop the seizures in the acute phase is barbiturate induced suppression coma. Ketogenic diet has been 
reported to be effective in some cases (Nabbout et al., 2010, Howell et al., 2012). The outcome is 
often poor and severe degrees of developmental and cognitive impairment are common (Ismail and 
Kossoff, 2011).   
Sakuma proposed diagnostic criteria for this condition (AERRPS), which can be used for FIRES as 
they are probably the same condition (Sakuma, 2009). 
Sakuma included the following mandatory findings: 
 Acute onset of seizures or impairment of consciousness 
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 No preceding developmental delay or epilepsy   
 Frequent and refractory focal seizures, necessitating long-term (2 weeks or more) anaesthesia 
with intravenous barbiturates or benzodiazepines to achieve burst-suppression coma on EEG  
 Continuous switchover to refractory epilepsy without a latent period.  
Supportive findings included: 
 Preceding fever that may persist during the acute phase of illness 
 CSF findings of mild pleocytosis or increased protein 
 EEG findings of slow background acutely and multifocal spikes in the chronic phase with 
variable locations of seizures onset and frequent secondary generalisation 
 Non-specific MRI abnormalities or occasional hyperintensities in mesial temporal lobe may 
be observed. 
 Profound neurologic, cognitive and psychiatric impairment as well as occasional motor 
disability. 
The cause for FIRES/AERRPS/DESC is unknown. An immune-mediated or inflammatory process 
has been hypothesized but is unproven (Sakuma, 2009, Sakuma et al., 2010, Specchio et al., 2010, 
Nabbout et al., 2011). Neuronal autoantibodies have been reported in sporadic cases with FIRES 
including anti glutamic acid decarboxylase (GAD) (Specchio et al., 2010), anti-GluR-epsilon-2 
(antibody to glutamate receptor epsilon 2 subunit of N-methyl-D-aspartate receptor) (Sakuma et al., 
2010), neuropil type anti neuronal antibodies (Milh et al., 2011), and voltage gated potassium channel 
(VGKC) Abs (Illingworth et al., 2011). However more typically patients with FIRES or DESC are 
negative for neuronal autoantibodies when tested (Kramer et al., 2011, Nabbout et al., 2011, Howell et 
al., 2012, van Baalen et al., 2012). Immunotherapy including intravenous immunoglobulin (IVIG) and 
steroids has been tried in a proportion of patients with FIRES. Out of 77 patients from multiple 
previous studies reported by Kramer et al 30 patients received IVIG and 29 received steroids (Kramer 
et al., 2011). Two patients out of the 30 treated with IVIG had benefit and no benefit was seen in 
those who received steroids. Four out of seven patients reported recently by Howell et al received 
immunotherapy in the form of IVIG, steroids and rituximab (one patient) and had no benefit (Howell 
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et al., 2012). The absence of neuronal antibodies and the negative response to immunotherapy do not 
strongly support an immune mediated process. Instead, the “neuronal excitation” and “genetic 
channelopathy” hypothesis has been proposed recently as a cause for some of these cases of FIRES 
(Ismail and Kossoff, 2011, Howell et al., 2012). However it might be difficult to make larger 
conclusions about the irrelevance of immune mechanisms in FIRES due to the retrospective nature, 
the incomplete/late treatment with immunotherapy and the incomplete or absent neuronal antibody 
testing in these studies.  
1.1.5 Treatment of epilepsy 
Many antiepileptic drugs are available and are used widely to treat epileptic seizures. However about 
a third of seizures are resistant to anti epileptic medical treatment (Kwan and Brodie, 2000). Most of 
these drugs are considered “symptomatic” treatments, meaning that they stop seizures but do not 
modify the underlying process. It is thought that understanding the mechanisms involved in the 
generation of seizures and epilepsy should lead to novel treatments that modify the epileptic process  
(Vezzani et al., 2011). Other medical treatments used for severe and refractory seizures in children 
include steroids and intravenous immunoglobulins. The exact mechanisms of action of these agents in 
the treatment of severe epilepsy are not fully understood although anticonvulsant as well as immune 
modulatory effect is possible. Surgical treatment for medically refractory seizures with a structural 
lesion is increasingly performed and provides cure in many cases. 
1.2 Channelopathies and epilepsy  
Voltage gated ion channels, such as potassium, calcium, sodium and chloride channels, and ligand 
gated ion channels, such as nicotinic acetylcholine (Ach), gamma amino butyric acid (GABA), 
glycine and ionotropic glutamate receptors are important in the regulation of neuronal excitability and 
synaptic transmission in central and peripheral nervous system (Collingridge et al., 2009).  
Defects in the function of these transmembrane ion channels can lead to dysfunction in the central and 
peripheral nervous systems. Defects in these channels are referred to as “channelopathies”. 
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The role of channelopathies in acute or transient neurological disorders including epilepsy is 
increasingly recognised, usually in relation to genetic mutations (Weber and Lerche, 2008). The 
concept of acquired channelopathies is now well recognised (Berkovic et al., 2006, Helbig et al., 
2008). Acquired causes of channelopathies include brain injury, stroke, tumours and infections. 
“Autoimmune channelopathies” are now recognised as an important cause of acquired 
channelopathies (Vincent et al., 2006). “Autoimmune channelopathies” are characterised by the 
presence of antibodies against neuronal channels (voltage or ligand gated) and various defects in the 
peripheral or central nervous system (or both). Autoimmune channelopathies are diagnosed by a 
simple laboratory test and are potentially treatable with immunotherapy that works on reducing the 
level of the pathogenic antibodies (Vincent et al., 2006). 
1.2.1 Genetic Channelopathies 
Many mutations involving genes encoding for voltage and ligand gated channels proteins are 
described and the list is expanding. Mutations associated with monogenic disease affect almost all ion 
channel families: voltage-gated potassium, calcium and sodium channels, as well as ligand gated 
glycine, GABA and nicotinic acetylcholine receptors. Mutations have not been reported in association 
with the ionotropic glutamate receptors (Kullmann and Waxman, 2010). 
 Different seizure disorders and epilepsy syndromes are associated with different single gene 
mutations, although the same epilepsy disorder might be caused by more than one genetic mutation. 
For example childhood absence epilepsy (CAE) is associated with genetic mutations of calcium and 
chloride channels as well as GABA receptor. Likewise the same genetic mutation might be associated 
with more than one epilepsy syndrome; for example mutation of the GABA receptor GABRG2 is 
associated with CAE as well as febrile seizures and Dravet syndrome (see Table 1-1).  
Genetic mutations involving the potassium channels are associated with benign familial neonatal 
seizures (BFNS) and generalised epilepsy with paroxysmal dyskinesia (GEPD) (Berkovic et al., 2006, 
Weber and Lerche, 2008). Leucine rich glioma inactivated-1 (LGI1) is part of the potassium channel 
complex. LGI1 gene mutation is associated with autosomal dominant lateral temporal lobe epilepsy 
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(ADLTE) or autosomal dominant partial epilepsy with auditory features (ADPEAF) (Morante-
Redolat et al., 2002). Mutations involving genes encoding for calcium channels are associated with 
juvenile myoclonic epilepsy (JME) and childhood absence epilepsy (CAE). Genetic mutations of the 
sodium channels are associated with benign familial neonatal-infantile seizures (BFNIS), febrile 
seizures, severe myoclonic epilepsy of infancy (SMEI) or Dravet syndrome,  and generalised epilepsy 
with febrile seizures plus (GEFS+) (Berkovic et al., 2006, Helbig et al., 2008, Weber and Lerche, 
2008). 
Many genetic "idiopathic" epilepsies however are not caused by a single-gene defect and complex 
inheritance is thought to play a role (Berkovic et al., 2006). 
Table ‎1-1 Genetic mutations of voltage and ligand gated channels 
(A) Examples of genetic mutations of voltage gated channels or related proteins that are associated 
with epilepsy, adapted from (Berkovic et al., 2006, Helbig et al., 2008, Weber and Lerche, 2008). 
Voltage gated channel type Gene Disorder  
Potassium channels KCNQ2, KCNQ3 Benign familial neonatal seizures (BFNS) 
 KCNMA1 Generalised epilepsy and paroxysmal 
dyskinesia (GEPD) 
Potassium channels related LGI1 Autosomal-dominant partial epilepsy with 
auditory features 
Calcium channels CACNB4 Juvenile myoclonic epilepsy (JME) 
 CACNA1H Childhood absence epilepsy (CAE) 
Sodium channels SCN1A GEFS+, febrile seizures, Dravet syndrome 
 SCN2A Benign familial neonatal-infantile seizures 
(BFNIS) 
 SCN1B Generalised epilepsy with febrile seizures 
plus (GEFS+) 
Chloride channel CLCN2 Childhood absence epilepsy  (CAE) 
Idiopathic generalised epilepsy (IGE) 
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(B) Examples of genetic mutations of ligand gated channels associated with epilepsy, adapted from 
(Berkovic et al., 2006, Helbig et al., 2008, Weber and Lerche, 2008). 
Ligand type Gene  Disorder 
GABA receptor GABRG2 Childhood absence epilepsy (CAE) 
Dravet syndrome, febrile seizures, GEFS+ 
  GABRA1 Juvenile myoclonic epilepsy (JME) 
 GABRD Dravet syndrome, febrile seizures, GEFS+ 
 GABRB3 Childhood absence epilepsy (CAE) 
Acetyl choline receptor CHRNA4, CHRNB2 Autosomal dominant nocturnal frontal 
lobe epilepsy 
GEFS+ Generalised epilepsy with febrile seizures plus 
1.3 Epilepsy and inflammation 
It is thought that inflammatory processes within the brain might constitute a common and crucial 
mechanism in the pathophysiology of seizures and epilepsy (Vezzani et al., 2011). Several clinical 
facts support this hypothesis including the trigger of febrile seizures by proinflammatory agents 
(released by fever and infection), and the beneficial effect of steroids (which are anti-inflammatory 
agents) in some drug resistant epilepsies. Animal experimental models suggest that brain 
inflammation promotes neuronal hyper excitability and seizures. It has also been shown that seizures 
themselves initiate inflammation in the brain and cause damage of the blood brain barrier (Vezzani et 
al., 2011, Librizzi et al., 2012). 
Autoimmune mechanisms are thought to play important roles in the aetiology of some seizures. Many 
childhood epilepsy syndromes that are refractory to conventional antiepileptic treatment and drugs 
may be responsive to some forms of immunotherapy such as steroids and IVIG (including West, 
Lennox-Gastaut and Landau-Kleffner syndomes). The mechanisms of action of immunotherapy in 
these disorders are not clear, though immune involvement has been proposed (Palace and Lang, 
2000). Immune therapy may reduce refractory seizures by different mechanisms other than 
suppression of inflammation; immune therapeutic agents have significant anticonvulsant properties 
35 
 
either by direct effects on brain excitability and suppression of endogenous brain proconvulsants 
(Vezzani et al., 2011, Yu et al., 2013). 
The association of epilepsy with autoimmune disorders such as systemic lupus erythematosus, 
vasculitis, coeliac disease and multiple sclerosis might be caused by immune system activation 
leading to brain inflammation causing epilepsy, although this hypothesis is not confirmed. Rasmussen 
encephalitis is an example of chronic brain inflammation leading to epilepsy. Autoantibodies against 
glutamate receptor type 3 (GluR3) were initially described in patients with Rasmussen encephalitis 
(Rogers et al., 1994), although this finding has not been subsequently reproduced (Watson et al., 
2004). It is thought that T cell rather than antibody mediated immune mechanisms play a role in the 
chronic inflammation in Rasmussen syndrome.  
The discovery of autoimmune limbic encephalitis and NMDAR encephalitis (see below) in 
association with specific neuronal autoantibodies provides further evidence that inflammatory and 
autoimmune mechanisms are important in the pathogenesis of seizures. 
1.4 Neuronal antibodies associated with epilepsy and seizures, 
"autoimmune channelopathies" 
Autoimmune channelopathies associated with antibodies against voltage and ligand gated channels 
are increasingly recognised in the pathogenesis of many CNS disorders including seizures. "Immune 
mediated seizures" and "autoimmune epilepsies" are now described in association with antibodies to 
different neuronal surface proteins including receptors and synaptic proteins. The knowledge in this 
field has expanded rapidly in the last decade and new concepts and reports are published constantly. 
Below we discuss the different antibodies that are currently known to be associated with seizures and 
epilepsy. In the meantime the search continues and more antigenic targets are likely to be discovered.  
1.4.1 VGKC antibodies and associated disorders 
Voltage-gated potassium (K
+
) channels (Kv) are transmembrane signalling proteins that are specific 
for potassium and have pores that allow the passage of millions of ions per second across the cellular 
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membrane. Their “gates” are sensitive to changes in voltage and they play a crucial role during action 
potentials in returning the depolarized cell to a resting state (Yellen, 2002). In humans, the Kv 
channels are diverse and divided into 12 subfamilies: Kv1-12 with 40 encoding genes  (Gutman et al., 
2005, Wulff et al., 2009). 
Structurally the typical voltage-gated K channel (Kv) is an assembly of four identical transmembrane 
alpha subunits surrounding a central pore. Each alpha subunit has six transmembrane crossings (S1–
S6). The narrowest part of the pore, the selectivity filter, is formed by a loop between S5 and S6; the 
voltage sensor includes the S4 region with its multiple positive charges, see Figure 1.1 (Yellen, 2002). 
A variety of accessory proteins are associated with some of the Kv tetramers which modulate the 
activity of the K+ channels, including intracellular beta subunits (Gutman et al., 2005, Wulff et al., 
2009). 
 
 
 
 
 
 
 
Figure ‎1.1 The ultrastructure of a subunit of VGKC 
(adapted from  Yellen, 2002) 
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The main function of the VGKC is to repolarise neuronal membrane following activation and 
depolarization by sodium and calcium channels as well as excitatory neurotransmitters including 
glutamate and acetylcholine. Dysfunction of VGKC leads to unopposed activation of the excitatory 
system, which leads to seizures (Singh et al., 1998). 
Antibodies against voltage-gated potassium channel complex are one of the first recognised neuronal 
surface antibodies implicated in the pathogenesis of seizures and have been described in patients with 
peripheral and central nervous system disorders as described below. It should be noted that the actual 
antigenic target for VGKC-complex antibodies is often not the channel itself but other proteins that 
are part of the VGKC-complex, such as leucine -rich glioma inactivated 1(LGI1) and contactin-
associated protein-like 2 (CASPR2), see Figure 1.2 (Vincent et al., 2011a). This will be discussed 
later. 
 
 
 
 
 
  
 
 
Figure ‎1.2 The structure of the VGKC and associated proteins 
(adapted from Vincent et al 2011) 
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1.4.1.1 Neuromyotonia, Isaac Syndrome and Morvan Syndrome associated with VGKC Abs  
Neuromyotonia (NMT) which also known as Isaac Syndrome is a rare neuromuscular disorder that 
results from hyperexcitability of the peripheral nerve axons leading to repetitive activation of single 
muscle fibres. NMT manifests as muscle cramps, fasciculation, stiffness and pain in addition to 
excessive sweating. Limb and trunk muscles are usually affected most although diffuse muscle 
involvement is also common. Muscle cramps occur spontaneously or can be triggered by muscle 
contraction. NMT has characteristic electromyographic (EMG) features which consist of repetitive 
motor unit or single fibre discharges that can be doublet, triplet or continuous and have a high 
intraburst frequency (Newsom-Davis and Mills, 1993, Newsom-Davis, 1997). There are hereditary 
cases of NMT associated with hereditary peripheral neuropathies however most cases are acquired. 
Acquired neuromyotonia (ANMT) is thought to be autoimmune in origin for a number of reasons as 
follows (Newsom-Davis and Mills, 1993). ANMT is described with other autoimmune disorders such 
as myasthenia gravis (MG) and with thymoma. Oligoclonal bands were found in cerebrospinal fluid 
(CSF) of some of the patients with ANMT and there was improvement of ANMT in patients who 
received plasma exchange (Newsom-Davis and Mills, 1993). Spontaneous remission occurred in 
patients with ANMT, which is a feature of some autoimmune disorders but not genetic disorders. In 
addition, ANMT can be seen in some patients with cancers as a paraneoplastic process. Antibodies 
against VGKC were found in 12 out of 12 patients with ANMT but not in controls and VGKC 
antibodies were proposed as the potential cause for ANMT (Hart et al., 1997). 
Morvan Syndrome describes neuromyotonia that is accompanied by dysautonomia and central 
nervous system involvement. Morvan syndrome was first described in 1890 by Morvan and is also 
called Morvan’s Fibrillary Chorea (MFC) or La chorée ﬁbrillaire. Morvan syndrome is therefore 
characterised by neuromyotonia, hyperhidrosis and encephalopathy. Patients can have agitation, 
insomnia, confusion, hallucination, as well as tachycardia, pruritis and constipation. Morvan 
syndrome can be a paraneoplastic manifestation of thymoma and other tumours such as lung cancer. 
Morvan syndrome can also be associated with other autoimmune diseases (Lee et al., 1998).VGKC 
antibodies were identified in some patients with Morvan syndrome (Barber et al., 2000, Liguori et al., 
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2001, Loukaides et al., 2012), although antibody negative cases are also described. Morvan syndrome 
is quite rare, often severe and the outcome is usually poor particularly in paraneoplastic cases. 
1.4.1.2 Autoimmune limbic encephalitis and VGKC Abs 
Limbic encephalitis (LE) is a syndrome characterised by involvement of the limbic areas of the brain 
including the hippocampus, amygdala, hippocampal gyrus and cingulate gyrus. Patients have subacute 
memory disturbance, temporal lobe seizures, behavioural and personality changes as well as sleep 
disturbance (Bakheit et al., 1990, Gultekin et al., 2000, Buckley et al., 2001, Thieben et al., 2004). In 
the past LE was considered to be rare inflammatory and immune mediated paraneoplastic syndrome 
associated with tumours including occult small-cell carcinoma of the lung, thymoma, or testicular 
cancer. MRI and EEG in paraneoplastic limbic encephalitis (PLE) usually demonstrate abnormalities 
involving the temporal lobes. Patients with PLE usually have antibodies to intracellular neuronal 
antigens such as Hu, CV2 and Ma2, however these antibodies are thought to be markers of the 
paraneoplastic process rather than directly pathogenic autoantibodies. The diagnosis of PLE is 
confirmed by biopsy, which shows neuronal loss, reactive gliosis, and perivascular lymphocytic 
cuffing restricted to the limbic areas (Gultekin et al., 2000). No treatment is effective for PLE apart 
from early detection and treatment of the underlying neoplasm. PLE is unresponsive to immune 
therapy and often has different pathology compared to the immune responsive non paraneoplastic LE 
which is described below in more detail (Bien et al., 2012).  
In 2001 Buckley et al described VGKC antibodies in two adult patients with reversible limbic 
encephalitis (LE) (Buckley et al., 2001). There were similarities noted between the PLE and the CNS 
symptoms of Morvan syndrome. This prompted Buckley et al to test two women with LE for VGKC 
Abs (which are found in some patients with Morvan syndrome), and these two women were positive 
for VGKC antibodies (Buckley et al., 2001). The first patient (47 years) had Myasthenia gravis and a 
thymoma that was previously excised. She was followed over the years and the onset of LE followed 
recurrence of her MG. LE symptoms responded to immunotherapy with plasma exchange, which was 
given to treat Myasthenia crisis. The VGKC antibodies in her serum were within normal range (<100 
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pM) until the onset of LE when they became elevated to 750 pM. The VGKC antibodies level fell 
with plasma exchange and this was associated with clinical improvement. The second patient (66 
years) had no tumour and her serum had tested negative for the paraneoplastic antibodies. She 
improved spontaneously 15 months later. Retrospective testing of her acute serum for VGKC 
antibodies showed high titres (6000 pM) and her VGKC Ab subsequently spontaneously dropped 
after 18 months to 500 pM which also correlated with clinical improvement. Immunohistochemistry 
using the acute serum showed staining of the hippocampus, particularly the middle one-third of the 
molecular layer of the dentate gyrus. This pattern of staining was similar to that seen with anti-Kv1.2 
antibody. This was the first report of LE associated with VGKC antibodies and it was proposed that 
this form of LE is potentially reversible or treatable, unlike the PLE (Buckley et al., 2001). 
Vincent et al subsequently described 10 patients with VGKC Ab positive limbic encephalitis (LE) 
(nine male, one female; age range 44±79 years) (Vincent et al., 2004). The patients presented with 1-
52 week histories of memory loss, confusion and seizures. Low plasma sodium concentrations, 
initially resistant to treatment, were present in eight out of the 10 patients and was thought to be 
secondary to inappropriate ADH (antidiuretic hormone) secretion. Brain MRI at onset showed signal 
changes in the medial temporal lobes in eight out of 10 cases. CSF was normal or only mildly 
abnormal and pleocytosis was uncommon. Five out of the ten patients had oligoclonal bands in the 
CSF with matching serum bands in four. EEGs showed non-specific changes including focal sharp 
waves mainly in the temporal regions, and slow waves that were mostly generalised but focal 
(temporal) in one patient. Paraneoplastic antibodies were negative, but VGKC-Ab titres were elevated 
and ranged from 450 to 5128 pM (neurological and healthy controls <100 pM). The VGKC antibodies 
were measured by radioimmunoassay which measures antibodies to the VGKC subtypes Kv1.1, 1.2 
and 1.6 that bind 
125
I-labelled dendrotoxin. Formal neuropsychology testing showed severe and global 
impairment of memory, with sparing of general intellect in all but two patients, and of nominal 
functions in all but one. Variable regimes of steroids, plasma exchange and intravenous 
immunoglobulin were associated with variable falls in serum VGKC-Abs to values between 2 and 
88% of the initial values, together with marked improvement of neuropsychological functioning in six 
41 
 
patients, slight improvement in three and none in one. The improvement in neuropsychological 
functioning in seven patients correlated broadly with the fall in antibodies. However, varying degrees 
of cerebral atrophy particularly of mesial temporal structures and residual cognitive impairment were 
common (Vincent et al., 2004). 
Around the same time Thieben et al 2004 described seven patients with encephalitis associated with 
autoantibodies to voltage-gated potassium channels (VGKCs) who were aged 44-73 years (2 females 
and 5 males) (Thieben et al., 2004) . Six out of the seven patients had cognitive impairment. Seizures 
of temporal lobe-onset ‘complex partial’ type were documented in six patients, and all seven patients 
had EEG abnormalities. Brain MRI showed mesial temporal lobe abnormalities in all seven patients. 
Four patients had additional neurologic autoantibody markers (muscle acetylcholine receptor, voltage 
gated calcium channel, or GAD), and two had anti thyroperoxidase antibodies. Two patients had a 
history of cancer; one had active prostate adenocarcinoma, and the second had a remote history of 
tongue carcinoma. One patient improved spontaneously and six were treated with IV 
methylprednisolone of whom three improved remarkably with treatment. At follow-up evaluation, one 
patient had no cognitive deficits, four had mild persistent short-term memory dysfunction, and two 
had persistent disabling behavioural deficits (Thieben et al., 2004). 
Autoimmune LE became an increasingly recognised syndrome that is potentially reversible and 
treatable. VGKC- Abs are the most common neuronal antibodies associated in LE although LE has 
also been reported in association with other neuronal antibodies including, GABABR and alpha 
amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) antibodies, see below (Lai 
et al., 2009, Lancaster et al., 2010, Boronat et al., 2011). These antibodies are targeted against 
extracellular surface antigens, compared to onconeuronal antibodies targeted against intracellular 
antigens in paraneoplastic LE. The nature of these antibodies might explain the immunopathologic 
differences between these two conditions. Autoimmune non paraneoplastic LE however is also 
described in association with antibodies against GAD which is an intracellular antigen (Malter et al., 
2010). The pathogenic role of these antibodies is discussed later. 
42 
 
LE is recognised as a potential cause of temporal lobe epilepsy (TLE) and mesial temporal sclerosis 
(MTS) in adults (Bien et al., 2007a, Bien et al., 2007b). Patients with LE develop unilateral or 
bilateral temporal lobe swelling and high signal on T2 and FLAIR (fluid attenuation inversion 
recovery) MRI sequences. This is often followed by atrophy and sclerosis of the mesial temporal 
lobes on serial MRI scans which may lead to the development of TLE in the subsequent years 
(Urbach et al., 2006, Bien et al., 2007b).  
Bien et al proposed diagnostic criteria for both paraneoplastic and autoimmune LE in adults. The 
criteria included the presence of a recent onset (less than 5 years) limbic syndrome with at least one of 
the following clinical features: memory disturbance, temporal lobe seizures or affective and mood 
alteration. In addition there needed to be one of four diagnostic features including the presence of 
tumour (for PLE), the presence of onconeuronal or neuronal surface antibodies, MRI abnormality in 
temporal lobes, or lymphocytic inflammatory cells in the temporal lobes on histopathology (Bien et 
al., 2007a). 
Many cases of VGKC-complex Ab associated LE have been reported since its first detailed 
description in 2004 by Vincent et al. The syndrome of VGKC Ab associated LE is now a well-defined 
syndrome that is generally thought to have a favourable outcome.  
The VGKC antibody assay was based on immunoprecipitation of protein complexes that contain 
Kv1.1, Kv1.2, and Kv1.6 subunits of the VGKC which bind to the 
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-I labelled dendrotoxin. In 2010 
the VGKC antibodies in adults were found to bind other antigens and proteins closely related to the 
potassium channel rather than the potassium channel subunits themselves. The proteins identified 
were leucine -rich glioma inactivated 1 (LGI1), contactin-associated protein-like 2 (CASPR2) and 
contactin 2 (Irani et al., 2010a, Lai et al., 2010). Lai et el showed that 57/57 patients with LE who 
previously tested positive for the VGKC antibodies had antibodies against LGI1 (100%). LGI1 was 
therefore proposed to be the autoantigen associated with limbic encephalitis previously associated 
with antibodies against voltage-gated potassium channels (Lai et al., 2010). Irani et al studied 96 sera 
that previously tested positive to VGKC-Abs. Binding to LGI1 transfected human embryonic kidney 
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(HEK293) cells was demonstrated in 55 of the 96 VGKC-antibody positive sera (57%). Binding to the 
surface of HEK293 cells transfected with CASPR2 was found in19 out of the 96 VGKC-antibody 
positive sera (20%). Five of these 96 patients had antibodies to contactin-2 and three had antibodies to 
Kv1 subunits (Irani et al., 2010a). CASPR 2 Abs have generally been associated with peripheral 
nervous system disease whereas LGI1 Abs have been associated with LE (Lai et al., 2010, Irani et al., 
2011b). The term "VGKC-complex Abs" is now used to reflect the variety of proteins that bind to the 
previously detected VGKC antibodies, other than the channel itself. It is likely that other proteins in 
the VGKC complex are involved in antibody binding, as described later in this thesis. 
1.4.1.3 Seizures and epilepsy associated with VGKC Abs 
As described above VGKC-complex Abs were identified first in patients with neuromyotonia and 
Morvan syndrome, then in patients with LE presenting with memory disturbance, confusion and 
seizures.  
Further reports suggested that VGKC-Abs are present in some patients with epilepsy without a 
preceding LE. Increased titres of VGKC antibodies (>100 pM) were detected in 16 of 139 (11%) 
patients with complex epilepsy but only 1 control (0.5%) (McKnight et al., 2005). Half of these 
VGKC Ab positive patients described by McKnight et al had short duration of their epilepsy (1-16 
week) and half had long duration (more than 6 years). Ten out of the 16 VGKC Ab positive patients 
had associated immune-mediated disorders such as systemic lupus erythematosus (SLE), 
antiphospholipid syndrome and Hashimoto encephalopathy. MRI was normal in most patients but 
three of the positive patients had unilateral or bilateral hippocampal high signal. Three patients 
improved spontaneously and six received immunotherapy for their associated neurological conditions, 
five of which were reported to have some improvement (McKnight et al., 2005). 
In a separate study, six out of 106 women with long standing intractable epilepsy (Majoie et al., 2006) 
were positive for VGKC-Abs with a range of 118-1406 pM (normal <100). The sera for VGKC- Ab 
testing were obtained many years after the onset of seizures which was in childhood or adolescence in 
five out of the six positive patients. The authors suggested that antibody titres might have been higher 
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if tested at the onset of seizures. None of these six patients had MRI abnormalities unlike what has 
been described in adults with VGKC- Ab associated limbic encephalitis (Majoie et al., 2006). 
VGKC antibodies were found in an adult case with new onset refractory epilepsy that responded to 
immunotherapy (Barajas et al., 2010). In this case the seizures were of unusual semiology; described 
as unilateral twitches of shoulder and occasionally the ipsilateral face and occurred up to 30 per 
minute. MRI showed high signal in the mesiotemporal structures and the patient developed 
behavioural and personality changes. It is likely that the seizures preceded the onset of LE in this case, 
and the seizure semiology is reminiscent of faciobrachial dystonic seizures as described below (Irani 
et al., 2011b). 
In a recent study of cohorts of adults with new onset and with established epilepsy VGKC complex 
antibodies were present in 5% of the patients (Brenner et al., 2013).  
1.4.2 LGI1 and CASPR2 antibodies 
Leucine -rich glioma inactivated 1 (LGI1), contactin-associated protein-like 2 (CASPR2) and 
contactin 2 are proteins that are closely associated with the VGKC and are now recognised as part of 
the so called VGKC-complex (see Figure 1.2). 
1.4.2.1 LGI1 antibodies  
After the description of leucine rich glioma inactivated-1 (LGI1), a neuronal secreted protein as a 
major autoantigen for VGKC-complex Abs, attention has subsequently focused on LGI1. LGI1 had 
been identified as a subunit of pre-synaptic Kv1 voltage gated potassium channels (Schulte et al., 
2006). Mutations in LGI1 are linked to autosomal dominant partial epilepsy with auditory features 
(ADPEAF), which is also known as autosomal dominant lateral temporal lobe epilepsy (ADLTE) 
(Morante-Redolat et al., 2002). It has been proposed that LGI1 is an anti-epileptogenic secreted 
protein that connects pre and postsynaptic protein complexes and regulates synaptic transmission 
(Fukata et al., 2010). 
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LGI1 antibodies are now recognised in adults to be associated predominantly with limbic encephalitis 
with seizures and cognitive impairment. Distinctive seizure semiology has been described in 
association with LGI1 antibodies and sometimes precedes the onset of cognitive impairment or 
encephalopathy. These were called faciobrachial dystonic seizures (FBDS) (Irani et al., 2008, Irani et 
al., 2011b). Irani et al described 29 adult patients with these seizures. The episodes of FBDS were 
frequent, brief dystonic seizures that predominantly affected the arm and ipsilateral face. They 
occurred up to 50 per day and some were associated with loss of consciousness. These seizures 
preceded the onset of LE in most patients. Investigation in the pre LE stage showed normal sodium in 
13 patients tested, normal MRI in 9 patients performed and ictal epileptiform activity in 7 out of the 
29 patients in the frontotemporal region. These seizures deteriorated during the evolution to LE in 26 
patients after a mean of 36 days. LE was similar to what had been previously described in association 
with VGKC-complex Ab with amnesia, confusion and sleep disturbance. VGKC-complex Abs were 
detected by radioimmunoprecipitation in 24 patients and LGI1 Abs were found in 22 of them (2 of 
them also had Abs against CASPR2, and one also had Abs against contactin-2) whereas in two 
patients the target antigen was not identified, two patients tested negative for the VGKC-complex 
antibodies however one of them was positive for LGI1 antibodies by the cell-based assay. 
Investigations of the 26 patients after LE onset showed hyponatraemia in 23 (88%). Interictal EEG 
showed abnormalities including diffuse mild slowing in nine, bilateral frontotemporal slowing in six, 
and temporal sharp waves in two. In nine patients, no EEG abnormalities were found. In 14 out of the 
26 patients (54%) MRI showed abnormalities during the LE stage including bilateral or unilateral 
medial temporal lobe high signal in 13 and right caudate and putamen high signal in one patient. 
Follow up MRI showed atrophy in the high signal areas in five patients including the one with the 
caudate abnormality. MRI was normal in 12 out of the 26 patients (46%). These distinctive seizures 
were resistant to multiple AEDs but immune responsive, and the authors emphasized the importance 
of their recognition (Irani et al., 2011b). 
Similar episodes of seizures associated with LGI1 antibodies were described by Andrade et al  
although they were called "tonic seizures" (Andrade et al., 2011b). Three adult females were 
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described with abnormal movements of face, shoulders, arms and legs occurring up to 100 per day 
with preserved consciousness. These movements were associated with electrodecrement events on 
EEG and were thought to be tonic seizures. The three patients had high LGI1 levels however it was 
not clear if they had coexisting LE and whether these seizure episodes preceded their LE. Debates 
about the origin of these seizures and whether they actually represent extra pyramidal movements 
rather than epileptic tonic seizures were raised (Striano et al., 2011). Moreover as these movements 
were thought to be similar to the previously described FBDS, and disagreement about terminology 
were discussed between the authors (Andrade et al., 2011a, Irani et al., 2011c). 
1.4.2.2  CASPR2 antibodies  
Contactin-associated protein-like 2 (CASPR2) is a membrane protein with a large extracellular 
component and is closely complexed with the VGKCs (see Figure 1.2) (Vincent et al., 2011a). 
CASPR2 has a role in neuronal growth and synaptogenesis. Mutation in the CASPR2 gene has been 
found in patients with focal epilepsy and cortical malformations (Strauss et al., 2006).  
CASPR2 antibodies were found in patients with Morvan syndrome in association with thymoma 
(Vincent, 2009, Vincent and Irani, 2010) . CASPR2 has been identified as one of the auto antigens for 
VGKC-complex antibodies and is associated with disorders previously attributed to VGKC Abs 
including encephalitis, peripheral nerve dysfunction, or a combination of both (Morvan syndrome) 
(Lancaster et al., 2011a). CASPR2 antibodies are found in patients with LE and seizures although less 
commonly than LGI1 antibodies. More often patients with CASPR2 antibodies have Morvan’s 
phenotype with neuromyotonia, confusion, amnesia, insomnia and autonomic dysfunction or 
neuromyotonia alone. By contrast, neuromyotonia is less common in patients with LGI1 Abs (Irani et 
al., 2010a). 19 out of 96 patients who previously tested positive for VGKC Abs were positive for 
CASPR2 Abs (Irani et al., 2010a). Three out of the 19 patients with positive CASPR2 Abs had 
Morvan’s syndrome, seven had neuromyotonia, seven had LE and two had epilepsy alone (Irani et al., 
2010a). Lancaster et al described eight patients with CASPR2 Abs; five had CNS involvement 
(encephalitis, seizures) as well as peripheral nervous system (PNS) involvement (neuromyotonia, 
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neuropathy), two had pure CNS syndrome and one had neuromyotonia alone (Lancaster et al., 2011a). 
Patients with CASPR2 Abs can have associated tumours particularly thymomas and small lung cancer 
(Vincent et al., 2011a). While most patients with the distinctive FBDS had LGI1 antibodies, two had 
CASPR2 antibodies in addition to LGI1 antibodies (Irani et al., 2011b). Seizures are usually not a 
prominent feature of patients with CASPR2 Abs. 
1.4.3 VGKC-complex Abs in Children  
At the time of commencing this study in 2009 there had been no significant reports of VGKC Abs or 
other neuronal antibodies in children. However, in the last few years there have been a few reports 
examining VGKC-complex antibodies in children with epilepsy and seizures, which are discussed 
below for completeness. Limbic encephalitis associated with antibodies to potassium channels leading 
to bilateral hippocampal sclerosis was reported in a prepubertal girl (Kroll-Seger et al., 2009). The girl 
presented with a subacute syndrome comprising memory impairment, affective disturbances, and 
refractory temporal lobe seizures, similar to adults with LE. In 2011, Limbic encephalitis was also 
described in 10 children of whom four were positive for VGKC Abs (Haberlandt et al., 2011). In this 
study, serum values for VGKC Abs were defined as normal (<100 pmol/l), low positive (100–150 
pmol/l), positive (150–400 pmol/l) and high positive ( >400 pmol/l) (Haberlandt et al., 2011). Two of 
the VGKC Abs positive patients were also positive for GAD antibodies, and two patients tested 
positive for GAD antibodies alone. These patients had poor outcomes, despite immunotherapy which 
was given relatively late in the course of their illness (median 4 months) (Haberlandt et al., 2011).  
As part of the publications arising from this thesis; we described four patients with status epilepticus 
in the context of unexplained encephalitis who had antibodies against the VGKC- complex. In these 
patients, antibodies were not targeted against LGI1 or CASPR2 (Suleiman et al., 2011a),  ( see 
Chapter 2). Our four patients had poor outcome including cognitive impairment, psychiatric disorder 
and ongoing epilepsy (mostly TLE). None of these patients received early or aggressive 
immunotherapy (Suleiman et al., 2011a).  
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In a lab based study reporting the clinical phenotypes of children with positive VGKC-complex 
antibodies, three out of 12 children with positive VGKC-complex antibodies had seizures including 
one with limbic encephalitis and two with symptomatic generalised epilepsy (Dhamija et al., 2011). 
The other children with positive VGKC Abs in this study had variable neurological manifestations 
including developmental regression and movement disorders (Dhamija et al., 2011). We also reported 
VGKC-complex antibodies in a case of epileptic encephalopathy and epileptic spasms, which were 
refractory to AED but responsive to steroids (Suleiman et al., 2011b). This was the first report of 
specific autoimmunity in children with epileptic encephalopathy. Other paediatric reports include a 
previously normal 4 year old boy who presented with febrile illness, encephalopathy and multifocal 
seizures followed by status epilepticus and was thought to have FIRES (Fever-induced refractory 
epileptic encephalopathy in school-age children) (Illingworth et al., 2011). This child was positive to 
VGKC-complex antibodies and responded to immunotherapy in the form of steroids and 
immunoglobulin. We suggest that this case was more reminiscent of limbic encephalitis than FIRES 
as the patient responded to immune therapy, and had a good outcome. 
There are no reports in children who are positive for LGI1 or CASPR2 antibodies at the time of 
writing. The reported children positive to VGKC-complex antibodies that were also tested for LGI1 
and CASPR2 were negative (Dhamija et al., 2011, Illingworth et al., 2011, Suleiman et al., 2011a, 
Suleiman et al., 2011b) . It is likely that in children the antibodies that bind VGKC-complex are 
targeted against other antigens that are yet to be identified. 
1.4.4 NMDAR antibodies 
The N-methyl-D-aspartate (NMDA) receptors are ligand-gated channels that have important roles in 
synaptic transmission and plasticity. NMDAR mediates the post synaptic excitatory effects of 
glutamate (Bliss and Collingridge, 1993, Lynch et al., 1994). The NMDA receptors are heteromers of 
NR1 subunits that bind glycine, and NR2 (A, B, C, or D) subunits that bind glutamate (Dalmau et al., 
2008), see Figure 1.3. 
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Figure ‎1.3 NMDA type glutamate receptor at the post-synaptic region   
(adapted from Wandinger et al., 2011) 
1.4.4.1 NMDAR Ab encephalitis 
A form of severe and potentially lethal paraneoplastic encephalitis was recognised and reported in 
2005 (Vitaliani et al., 2005). Affected patients were young women who developed prominent 
psychiatric symptoms, seizures, memory deficits, and decreased level of consciousness often 
requiring ventilatory support. They had associated ovarian teratomas. Unlike other paraneoplastic 
encephalitis syndromes where patients have onconeuronal antibodies these patients had antibodies to 
unknown antigens predominantly expressed in the cell membrane of hippocampal neurons (also 
referred to as neuropil antigens) that were detected in the sera and CSF of these patients (Vitaliani et 
al., 2005). The target autoantigens were later identified to be NR1 and NR2 subunits of the N-methyl-
D-aspartate receptor (NMDAR) (Dalmau et al., 2007). Dalmau et al in 2007 reported 12 female 
patients with severe form of paraneoplastic encephalitis similar to that reported by Vitaliani et al. The 
affected women were of young age median 27 and range 14-44 years. They all had teratomas (11 
ovarian and one mediastinal). All the 12 women had psychiatric symptoms including personality and 
behavioural change, agitation, or paranoid thoughts and six of them were evaluated initially by a 
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psychiatrist. Eleven patients developed seizures, which were generalised or complex partial. Nine 
patients had reduced level of consciousness requiring mechanical ventilation. Seven patients had 
abnormal movements including choreoathetosis, myoclonic movements, dystonia, dyskinesias in face 
and arms, rhythmic contractions of the abdominal wall, opisthotonic-like postures, and catatonic-like 
episodes. Hyperthermia was present in eight patients, and other autonomic disturbance including 
tachycardia, tachypnea, diaphoresis, or hypertension, and hypotension were seen in five patients 
(Dalmau et al., 2007). EEG showed generalised slowing with occasional epileptiform activity. MRI 
brain was often normal, although hyperintensities involving mesial temporal lobes, frontal and 
parietal lobes, cerebellum, and subtle meningeal enhancement were also described. CSF showed 
pleocytosis in all patients, but all patients were negative for viral, bacterial and autoimmune 
investigations including VGKC antibodies. The 12 patients were treated with tumour resection and 
immunotherapy (seven cases), surgery alone (three cases) or immunotherapy alone (two cases). Seven 
patients made a complete recovery, two had a partial recovery and three died. Patients who received 
both surgery and immunotherapy had generally better outcomes (Dalmau et al., 2007). These patients 
had neuropil antibodies which were found to be directed against the NR1 and NR2 subunits of the 
NMDAR and these antigens were also expressed by the associated tumours. It was suggested that this 
severe form of paraneoplastic encephalitis is antibody mediated and potentially reversible. The main 
epitope targeted by the antibodies was found to be in the extracellular N-terminal domain of the NR1 
subunit of the NMDAR heteromers (Dalmau et al., 2008). 
More patients were identified with NMDAR-Ab encephalitis and the syndrome became well 
characterized. Men are affected to a lesser extent than women and they can have associated tumours 
including testicular teratoma or lung cancer (Dalmau et al., 2008). Patients had a better outcome when 
recognised and treated early with tumour removal and immunotherapy. Non paraneoplastic cases 
affecting both males and females are also increasingly described (Dalmau et al., 2008, Irani et al., 
2010b). A high proportion of non-Caucasians were affected which may suggest that genetic factors 
are involved in the susceptibility to the disease (Irani et al., 2010b, Irani and Vincent, 2011). 
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The syndrome of anti-NMDAR encephalitis was described to have characteristic temporal progression 
from the analysis of clinical and paraclinical features of 44 patients (Irani et al., 2010b, Irani and 
Vincent, 2011). An early “cortical phase” was dominated by psychiatric disturbance, memory and 
cognitive impairment, and seizures. EEG epileptic changes, MRI cortical changes (rare) and CSF 
pleocytosis (but not oligoclonal bands) may be seen during this early phase. This is followed after 10-
20 days by a “subcortical phase” where movement disorder, autonomic disturbance and reduced level 
of consciousness are the dominant clinical features. EEG shows diffuse slowing; MRI may show 
subcortical changes and oligoclonal bands appear in the CSF in the late phase. MRI changes however 
are absent in about 70% of cases, and abnormalities when present are non-specific consisting mainly 
of T2 hyperintensities in the white matter (Irani and Vincent, 2011). It was suggested that the early 
stage represents diffusion of antibodies from serum into the cortical grey matter, and the later stage 
results from secondary immunological expansion within the intrathecal compartment (Irani et al., 
2010b). 
Seizures are present in 76 to 83 % of patients with NMDAR- Ab encephalitis and can be focal, focal 
dyscognitive or generalised (Dalmau et al., 2007, Dalmau et al., 2008, Florance et al., 2009, Irani et 
al., 2010b). Incomplete syndromes can occur in which one feature predominates including seizures, 
movement disorder or psychosis (Lancaster et al., 2011b).  
A characteristic EEG pattern has been described in some patients with NMDAR encephalitis which 
consists of generalised slowing in the delta range (1-3 Hz) with superimposed rhythmic fast activity 
usually in beta range (20-30 Hz). This pattern has been called "extreme delta brush" due to its 
resemblance to "delta brush" waveforms seen in premature infants (Schmitt et al., 2012), however 
"extreme delta brush" pattern is more symmetric and synchronous and detected predominantly in 
frontal regions (Rosenfeld et al., 2012, Armangue et al., 2013). 
Immune therapy and resection of the underlying neoplasm when present are proven to provide the 
best outcome. Relapses can occur in 15-25 % of cases and is thought to be more common in patients 
without adequate immunotherapy (Gabilondo et al., 2011, Irani and Vincent, 2011).  
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Anti-NMDA receptor encephalitis has been reported in children and adolescents with a similar 
phenotype to adult cases (Florance et al., 2009). In children both females and males (to a lesser 
extent) are affected and tumours are uncommon (Dale et al., 2009b, Florance et al., 2009). The 
common early symptoms include behavioural and speech problems, seizures, and abnormal 
movements. Dysautonomia and hypoventilation are less common or severe than in adults (Florance et 
al., 2009). The syndrome had been recognised for many years in children and given other names such 
as dyskinetic encephalitis lethargica (Dale et al., 2009b) and immune chorea encephalopathy 
syndrome (Hartley et al., 2002).   
A recent study by Titulaer et al studied a large number of patients (577) including 211 children with 
NMDAR encephalitis (Titulaer et al., 2013). Median age at disease onset was 21 years (range 8 
months to 85 years). 81% of patients were females and male sex was more common in those younger 
than 12 years and older than 45 years. Similar to previous studies, Titulaer et al showed that tumours 
were present mostly in females but infrequent in children and men. 220 patients (38%) had an 
underlying neoplasm (94% of which were ovarian teratomas), of whom 213 (97%) were females, 
mostly between 12 years and 45 years (46% of all girls and women). Only 6% of girls less than 12 
years of age and 6% of men had tumours. The majority of adult patients (65%) presented with 
behavioural problems while the majority of children younger than 12 years (50%) presented with 
seizures or movement disorder. Similar spectrum of symptoms was seen within four weeks of onset 
irrespective of age though central hypoventilation and memory deficits occurred more frequently in 
adults, while movement disorders and speech problems were common in children. Atypical rare 
symptoms such as cerebellar ataxia or hemiparesis were more common in children than in adults.  
Significant neurological improvement was seen in 81% of patients with NMDAR encephalitis in this 
study by Titualer et al at 24 months follow up and the factors predicting good outcome were no 
admission to intensive care unit, early treatment, and low severity of disease. 501 out of the 577 were 
followed up for longer than 4 months. Twenty nine patients received no treatment with 
immunotherapy or tumour surgery (due to delayed or retrospective diagnosis). A proportion of these 
patients showed spontaneous improvement, however 29% had a poor outcome. 472 patients received 
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first line immunotherapy (steroids, IVIG, plasmapheresis or combination) and tumour removal, when 
applicable.  251 patients (53% of treated patients) had good outcome. 125 patients out of the 
remaining 221 patients who did not respond to first line treatment received second-line 
immunotherapy with rituximab, cyclophosphamide, or both, while 96 had no further immunotherapy 
or continued to receive first-line immunotherapy.  Patients who had second line immunotherapy had 
better outcome.  Relapses occurred in about 12% (which is lower than reported in previous studies) 
and occurred at higher frequencies in patients who had no tumours and those who received no 
immunotherapy. The use of immunotherapy particularly second line immunotherapy was associated 
with reduced relapse rate. Children were similar to the rest of the cohort in prognostic and risk factors 
(Titulaer et al., 2013).                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  
1.4.4.2 Epilepsy and NMDAR Abs 
In addition to the characteristic NMDAR encephalitis, antibodies to NMDAR were found in women 
with new onset epilepsy (Niehusmann et al., 2009). Five out of 19 women aged 15-45 years with new 
onset epilepsy were positive for NMDAR antibodies. Only one patient had ovarian tumour. The five 
cases positive for NMDAR Abs had extratemporal epilepsies. Associated features included 
psychiatric disturbance (in four out of five), speech dysfunction and decreased level of consciousness.  
Features that suggest subcortical CNS involvement were seen in two of the five patients (nystagmus, 
dyskinesia, dystonia and hypoventilation). The disease course was episodic and remitting- relapsing. 
Four of the five positive patients recovered completely either spontaneously or after immunotherapy 
(Niehusmann et al., 2009). 
1.4.5 AMPAR antibodies 
Alpha amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors are one member of 
the glutamate receptors. AMPA receptors mediate most of the fast excitatory neurotransmission in the 
brain (Shepherd and Huganirl, 2007). 
Antibodies against the glutamate receptor 1 (GluR1) and GluR2 subunits of AMPA receptor were 
found in patients with a limbic encephalitis syndrome (Lai et al., 2009). These neuronal surface 
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antigens were identified using immunohistochemistry and mass spectrometry and were confirmed to 
be the target antigens using cell based assay. Patients’ sera and CSF reacted with human embryonic 
kidney 293 cells expressing GluR1/2. Application of antibodies to cultures of rat hippocampal 
neurons caused a small decrease in overall AMPAR cluster density, which was reversed after 
antibody removal. The ten LE patients positive for AMPAR antibodies were nine women and one 
man with a median age of 60 years (range 38-87 years). They were selected from 43 patients with LE 
who had antibodies to unknown cell surface antigens. Four out of the 10 patients with AMPAR Abs 
had seizures, five had associated systemic autoimmunity and seven had underlying neoplasms. Nine 
patients received immunotherapy (six of whom also received tumour treatments) and all nine patients 
responded to treatment given. Five patients had relapses, and one patient died after a prolonged status 
epilepticus (Lai et al., 2009). Antibodies to AMPAR have not been reported in children. 
1.4.6 GABABR antibodies 
Gamma aminobutyric acid-B (GABAB) receptors are inhibitory receptors that are involved in 
regulation of synaptic plasticity. Disruption of GABAB receptors has been associated with seizures 
and memory dysfunction. Antibodies to GABAB receptor were found in 15 patients with limbic 
encephalitis who had seizures as the early or prominent presenting feature (Lancaster et al., 2010). 
Eight of the 15 patients were men and the median age was 62 years (range 24–75). Seizures were 
mostly of temporal lobe onset with secondary generalisation, and three patients had status epilepticus. 
One patient had childhood onset seizures. Seven of the 15 patients had tumours, five of which were 
small lung cancer (SCLC). Seven patients had other auto antibodies, including to GAD (3 patients), 
thyroid peroxidase (3 patients), voltage-gated calcium channels (3 patients), and sex determining 
region Y-box 1 (SOX1) (1 patient). Nine patients had a response to immunotherapy alone and three 
patients responded to treatment of tumour in addition to immunotherapy (Lancaster et al., 2010). 
In a separate cohort, GABABR Abs were also identified in 10 of 70 patients with LE (14%), eight of 
them had small cell lung carcinoma (SCLC) (Boronat et al., 2011). Nine of the 10 patients were men 
and the median age was 60 years (range 47–70 years). Seizures were the predominant and presenting 
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symptom in eight patients and two required intensive care treatment for their seizures. Seven patients 
were treated with immunotherapy and three of the eight patients with SCLC also received 
chemotherapy. Only two patients made a complete recovery (Boronat et al., 2011). GABABR Abs 
have not been reported in children at the time of writing. 
1.4.7 GAD antibodies and associated disorders 
GAD (glutamic acid decarboxylase) is an enzyme that catalyses the conversion of L-glutamic acid to 
gamma aminobutyric acid (GABA), the major inhibitory neurotransmitter (Kwan et al., 2000). GAD 
is present in GABAergic neurons and in pancreatic β-cells. Antibodies to GAD are present in many 
disorders including type 1 diabetes mellitus (T1DM) and various neurological disorders particularly 
stiff person syndrome but also cerebellar ataxia, epilepsy and limbic encephalitis (Solimena et al., 
1990, Brown and Marsden, 1999, Peltola et al., 2000, Honnorat et al., 2001, McKnight et al., 2005, 
Malter et al., 2010).  However GAD antibody titres in neurological disorders are much higher than 
those found in patients with T1DM (Peltola et al., 2000, Saiz et al., 2008). It is thought that GAD 
antibodies do not have a direct pathogenic role, as GAD is expressed in the cytoplasm rather than 
external surface of plasma membranes, however they are markers of an immunologic process in these 
patients with neurologic conditions (Vincent, 2008).  
1.4.7.1 Stiff person syndrome (SPS) and GAD antibodies 
Stiff person syndrome (SPS) is characterised by stiffness and rigidity of axial muscles, exaggerated 
lumbar lordosis, reflex spasms precipitated by voluntary movements as well as by emotional, tactile 
and auditory stimuli (Brown and Marsden, 1999). Signs suggestive of brain stem, pyramidal, 
extrapyramidal or spinal cord pathology are absent in the classic SPS. Patients often respond to 
diazepam and baclofen and the condition often has good prognosis. The pathophysiology of SPS is 
unclear though immune mediated mechanisms are thought to play a role. Antibodies to GAD are 
found in up to 90% of cases of stiff person syndrome, the majority of which are also diabetic 
(Solimena et al., 1990, Brown and Marsden, 1999). Up to 10 % of SPS patients with GAD Abs also 
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have epilepsy (Solimena et al., 1990). Paraneoplastic cases of stiff person syndrome have been 
reported with positive anti amphiphysin antibodies (Pittock et al., 2005).  
Stiff person plus syndrome describes severe cases of SPS with encephalomyelitis who also have 
rigidity that is not confined to the trunk but also involves distal limbs (Brown and Marsden, 1999). 
Patients have limb myoclonus, brain stem signs, long tract signs, lower motor neuron signs, cognitive 
and autonomic disturbance and CSF pleocytosis. Post mortem pathology findings showed 
inflammatory changes in the brain and spinal cord grey matter (Brown and Marsden, 1999). The term 
progressive encephalomyelitis with rigidity and myoclonus (PERM) is also used to describe these 
cases (Meinck and Thompson, 2002). Patients with SPS can progress to PERM. PERM can be 
associated with GAD antibodies less frequently than stiff person syndrome. Paraneoplastic cases of 
PERM are also described. Some patients with SPS and PERM spectrum were later found to have 
antibodies to glycine receptors (GlyR), see below (Hutchinson et al., 2008, McKeon et al., 2013). This 
is an example of a neurologic condition that is known to be associated with GAD antibodies where the 
GAD antibodies may not be the pathogenic antibodies but may suggest that another pathogenic 
autoantibody is present such as glycine receptor antibody (a cell surface antigen). Some of the patients 
with SPS who tested positive to GlyR Abs were also positive for GAD Abs (McKeon et al., 2013). 
1.4.7.2 Limbic encephalitis and GAD antibodies 
Due to the coexistence of type 1 diabetes mellitus in patients with stiff person syndrome and anti 
GAD antibodies, it was suggested to use a high titre cut-off of GAD antibodies (>2000 unit/ml) in 
patients with neurological conditions (Saiz et al., 2008). Saiz et al reported high GAD Ab levels in 61 
patients, 11 of whom had isolated diabetes and 50 (82%) had neurological conditions including SPS 
(n=22), cerebellar ataxia (n=17) and other neurological disorders (n=11). The other neurological 
disorders associated with high titre GAD antibodies in this report included eleven patients with 
epilepsy, non paraneoplastic limbic encephalitis and paraneoplastic neurological syndromes (Saiz et 
al., 2008). 
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Malter et al studied 53 adult patients (17-80 years) with limbic encephalitis (Malter et al., 2010). Nine 
out of the 53 patients had high-titre GAD Abs. In this report, the nine GAD antibody positive cases 
were compared to ten VGKC antibody positive cases. Patients with positive GAD Abs in this report 
were younger than those patients with VGKC Abs, and the illness of the GAD positive patients was 
dominated by seizures which was often the first sign, rather than cognitive impairment. Interestingly 
while there was no significant difference in CSF pleocytosis between GAD and VGKC Abs positive 
cases, the GAD positive cases were more likely to have oligoclonal bands and intrathecal synthesis of 
GAD antibodies. Mesial temporal MRI abnormalities were seen in both GAD and VGKC antibody 
positive groups (Malter et al., 2010). The two groups received comparable regimens of 
immunotherapy (monthly intravenous pulse methylprednisolone), however at 12 months follow up 
none of the GAD Ab positive group was seizure free, whereas all of the VGKC Ab positive patients 
were seizure free indicating resistant epilepsy in GAD Ab positive cases. The authors suggested that 
more intense immunotherapy might be needed in GAD Ab positive LE (Malter et al., 2010). 
In children limited reports are available about the GAD Abs in neurological disease. An adolescent 16 
year old female with immune limbic encephalitis presenting with new onset temporal lobe seizures 
and confusion was found to have elevated GAD Abs at >300 unit/ml (Akman et al., 2009). MRI 
revealed bilateral hippocampal high signal. Her seizures improved with IVIG, steroids and diazepam. 
The girl was found later to have common variable immune deficiency and steroids were withdrawn 
which was associated with gradual increase in her seizures. 12 months later her MRI showed mesial 
temporal sclerosis and she had ongoing seizures (Akman et al., 2009). 
1.4.7.3 Epilepsy and GAD antibodies 
Refractory epilepsy has been reported in association with SPS for many years (Martinelli et al., 1978) 
and GAD Abs have been found in patients with SPS, diabetes and epilepsy (Solimena et al., 1988). 
Refractory temporal epilepsy associated with GAD Abs was reported in a 19 year old man who had 
no diabetes or other organ specific autoimmunity (Giometto et al., 1998). In a separate study, GAD 
antibodies were found in eight out of 51 patients with focal epilepsy and none of 49 patients with 
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generalised epilepsy (Peltola et al., 2000). Two of the positive patients had high titre levels of GAD 
antibodies while six had low levels. The two patients with high GAD Ab levels had therapy resistant 
temporal lobe epilepsy (Peltola et al., 2000). 
In a separate cohort study, low titre GAD Abs were found in six out of 233 patients with epilepsy 
(Errichiello et al., 2009). Two of the six patients had idiopathic generalised epilepsy with coexisting 
T1DM and four had cryptogenic temporal lobe epilepsy. Intrathecal synthesis of GAD Abs was not 
detected in any of these GAD antibody positive patients (Errichiello et al., 2009). 
In the McKnight study described above, high levels of GAD antibodies (>1,000 U) were found in 3 
out of 139 patients (2.1%) with epilepsy. The GAD Ab positive patients had long-standing drug-
resistant epilepsy with young onset (<15 years), focal EEG abnormalities and normal MRIs 
(McKnight et al., 2005). 
1.4.7.4 Cerebellar Ataxia and GAD antibodies 
High level anti GAD Abs have been previously also reported in patients with cerebellar ataxia 
(Honnorat et al., 2001). In a lab based study of 9000 serum sample sent from four centres for testing 
of paraneoplastic neuronal antibodies, 36 samples tested positive for GAD Abs, 22 were from patients 
with typical stiff person syndrome and 14 were from patients with cerebellar ataxia as the main 
neurologic feature (Honnorat et al., 2001). The 14 patients with cerebellar ataxia were mostly women 
(13/14). They all had idiopathic late onset cerebellar ataxia. MRI brain in these GAD positive patients 
was either normal or showed cerebellar atrophy. All but two of them had other autoimmune disorders 
including T1DM, thyroiditis and coeliac disease indicating polyendocrine autoimmunity. The authors 
emphasized the fact that the role of GAD Abs in these patients is unclear and may merely reflect the 
presence of polyendocrine autoimmunity. However they suggested that the higher GAD Ab titres and 
the presence of oligoclonal bands and intrathecal synthesis of GAD Abs in these patients may indicate 
an active immune process in the nervous system (Honnorat et al., 2001). 
Cases of cerebellar ataxia associated with epilepsy and GAD antibodies are also reported (Vulliemoz 
et al., 2007, Nociti et al., 2010). Vulliemoz et al reported a 58 year old man with refractory focal 
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epilepsy who developed severe ataxia and upbeat nystagmus. In addition to high level GAD Abs the 
patient had multiple organ specific antibodies including anti-intrinsic factor, anti-thyroglobulin, anti-
thyroperoxidase and anti-Langerhans islet cells Abs. The patient’s ataxia responded to 
immunotherapy (steroids and azathioprine) and his seizures responded to the addition of 
benzodiazepines (Vulliemoz et al., 2007). A similar case of cerebellar ataxia and epilepsy with GAD 
antibodies was reported by Nociti et al in 2010. This was a 42 year old woman with type-1 diabetes 
mellitus, Hashimoto's thyroiditis, vitamin B12 deficiency, horizontal and upbeat nystagmus, 
cerebellar ataxia and drug resistant generalised seizures associated with anti-GAD Abs. Neurologic 
symptoms and seizures did not improve with B12 replacement and multiple anti-epileptic drugs, 
however they did improve with immunotherapy in the form of steroids and azathioprine (Nociti et al., 
2010). 
1.4.8 Glycine receptor antibodies 
Antibodies to glycine receptor (GlyR) have been described in patients with progressive 
encephalomyelitis with rigidity and myoclonus (PERM) (Hutchinson et al., 2008, Mas et al., 2011, 
Leite et al., 2012), as well as in patients with classic stiff person syndrome or SPS plus (McKeon et 
al., 2013). It is interesting to note that mutations in the α1 subunit of the glycine receptor gene GLRA1 
have been identified in hereditary hyperekplexia, which is characterised by stimulus sensitive 
myoclonus (Shiang et al., 1993). 
Myoclonus in PERM is thought to be non-epileptic in origin. Seizures however have been reported in 
association with GlyR antibodies. A rapidly fatal case with PERM was reported in a 28 year old man 
who had antibodies against both GlyR and NMDAR (Turner et al., 2011). Prior to progression into 
rigidity, myoclonus and hyperekplexia he presented with suspected generalised seizures and his EEG 
showed frequent left temporal sharp waves. Post mortem examination revealed encephalomyelitis, 
with particular involvement of hippocampal, pyramidal and cerebellar Purkinje cells and relative 
sparing of the neocortex (Turner et al., 2011). 
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A case of immunotherapy-responsive LE associated with GlyR Abs presenting with refractory 
convulsive status epilepticus was reported in a 25 y old Indian man (Zuliani et al., 2011). The authors 
suggested that GlyR Abs can affect limbic areas, as glycine receptors which are prominent in the 
brainstem and spinal cord, are also expressed in the hippocampus (Zuliani et al., 2011).  
In children one case of PERM associated with glycine receptor antibodies has been reported in a 14 
month old female infant who developed startle-induced episodes of generalised rigidity and 
myoclonus and axial hyperextension without impairment of consciousness (Damasio et al., 2013). 
Investigations were negative but glycine receptor antibodies were detected in serum and CSF. This 
case responded to immunotherapy in the form of IVIG and steroids; however she had relapses of 
symptoms. 
1.4.9 Summary of neuronal antibodies associated with seizures 
Antibodies to specific neuronal cell surface membrane proteins and GAD are found in many CNS 
disorders where seizures are important feature including different forms of encephalitis as well as 
epilepsy. These antibodies and associated disorders in children and adults are presented in Table 1-2 
(Graus et al., 2010, Vincent et al., 2010, Lancaster and Dalmau, 2012). This area is evolving and new 
reports are added regularly.  
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Table ‎1-2 Neuronal antibodies and associated phenotypes in adults and children 
Antibody 
type 
Associated disorders in 
adults 
Associations with 
tumours (mostly 
reported in adults) 
Associated disorders in 
children  
VGKC Limbic encephalitis, 
seizures, Morvan's 
syndrome, neuromyotonia 
Rare (thymoma, 
SCLC) 
Limbic encephalitis, 
seizures, status epilepticus, 
development regression 
LGI1 LE, FBDS Rare (lung cancer, 
thymoma) 
Not reported 
CASPR2 Morvan Syndrome, 
neuromyotonia, LE 
Thymoma, lung 
cancer 
Not reported 
NMDAR Encephalitis, Epilepsy, 
psychiatric disturbance 
Ovarian teratoma Encephalitis, movement 
disorder, psychiatric 
disturbance 
GAD LE, epilepsy, stiff person 
syndrome 
Rare (lung cancer) LE 
GABABR LE, seizures, memory loss SCLC, thymus Not reported 
AMPAR LE, psychiatric disorders Lung, breast, thymus Not reported 
GlyR Stiff person syndrome, 
PERM, myoclonic seizures, 
LE 
Rare (lung cancer, 
thymoma) 
Rare (one case of PERM) 
 
LE: limbic encephalitis 
FBDS: faciobrachial dystonic seizures 
PERM: progressive encephalomyelitis, rigidity and myoclonus 
SCLC: small cell lung cancer 
 
 
1.4.10 Methods in use for detection and measurement of neuronal antibodies 
VGKC antibodies are measured by radioimmunoassay (RIA) using mammalian brain tissue derived 
VGKCs labelled with iodinated dendrotoxin, a snake toxin specific for some subtypes of the Kv1 
family of potassium channels (subunits Kv1.1, 1.2 and 1.6) (Hart et al., 1997). The dendrotoxin-
labelled VGKCs immunoprecipitated by patient antibodies were later found to be a complex of at 
least three accessory surface proteins, LGI1, CASPR2 and contactin 2, that are closely complexed 
with the VGKC, hence the name ‘VGKC-complex’ (Irani et al., 2010a, Lai et al., 2010, Irani et al., 
2011a). Antibodies against these proteins within the VGKC complex (LGI-1, CASPR2 and contactin-
2) are detected using immunoﬂuorescence cell based assays (CBA) which detects the binding of 
62 
 
patients’ sera to the surface of cells transfected with cDNA encoding the relevant protein. This 
method, cell based assays using transfected cells is now the main method used for testing for 
antibodies against: LGI 1, CASPR2, NMDAR, GABAR, AMPAR and Gly-R. A microscopy scoring 
system is used and the binding is scored visually from 0 (no binding) to 4 (very strong binding) by 
two independent observers (Irani et al., 2010b).  
As for NMDAR, cell based assays done at different institutions have used different dilutions of serum 
and CSF. The Oxford Group uses a higher concentration of serum with a dilution ratio of 1:20 and 
undiluted CSF, as compared to Dalmau group who uses serum at 1:200 dilutions and CSF at 1:10 
dilution (Dalmau et al., 2008, Irani and Vincent, 2011).   
RIA, which is still used to measure VGKC Abs, is also used to measure antibodies against GAD, 
using 
125
I-labelled human recombinant GAD 65 (Saiz et al., 2008). 
Immunohistochemistry (IHC) maybe used first as a screening method to identify antibody binding in 
patients sera to brain tissue. This is followed by a quantitative assay specific to different antibodies as 
described above (CBA or RIA).  
The different methods that are currently in use for the detection of antibodies against different 
neuronal antigens are presented in Table 1-3 
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Table ‎1-3 Methods in use for neuronal antibodies detection and assays 
(adapted  from Vincent et al 2011). 
 IHC RIA CBA ELISA 
VGKC complex + +   
LGI1 +  +  
CASPR2 +  +  
NMDAR +  + + 
GAD + +  + 
GlyR   +  
 
IHC: immunohistochemistry 
RIA: radio-immuno assay 
CBA: cell based assay 
ELISA: enzyme linked immunosorbent assay 
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1.5 Principles of pathogenic antibodies 
The knowledge about the role of antibodies in diseases of the central nervous system is expanding. 
While the presence of autoantibodies in the CNS is usually associated with disease “disease 
associated antibodies”, there are also the so called” naturally occurring antibodies” which can be 
important in brain homeostasis, such as anti β-Amyloid antibodies which clear β-Amyloid aggregates 
and prevent their neurotoxicity (Gold et al., 2012). 
The presence “disease associated antibodies” alone does not necessarily establish a causal link 
between the antibodies and the disease (Archelos and Hartung, 2000). To prove the pathogenic role of 
autoantibodies in the disorders of the peripheral and central nervous systems many criteria need to be 
fulfilled which include “in addition to the presence of the antibodies”: demonstration of antibodies 
binding to a target antigen at the site of pathology and clinical benefit following removal of antibodies 
by plasma exchange. In addition the passive transfer of antibodies in question to experimental animals 
should transfer the disease phenotype (Archelos and Hartung, 2000).  
It is thought that antibodies against surface antigens including VGKC, LGI, CASPR2, NMDAR, 
AMPAR, GABABR and GlyR are likely to be pathogenic and usually predict immunotherapy 
responsive and reversible syndromes that are not frequently associated with neoplasms. In contrast 
antibodies against intracellular antigens (cytoplasmic or nuclear) such as Hu, Yo, CV2, Ma2 etc 
which are found in paraneoplastic disorders such as limbic encephalitis are thought to be markers of 
the associated tumours, rather than directly pathogenic autoantibodies involved in the CNS syndrome. 
These antibodies are called onconeuronal Abs due to their frequent association with tumours. It is 
thought that cytotoxic T cell mediated immunity is involved in paraneoplastic neurological syndromes 
rather than an antibody mediated process. Onconeuronal antibodies, which are more relevant to adults 
than paediatric population, are typically associated with treatment unresponsiveness and poor 
outcome (Irani and Vincent, 2011).  
GAD antibodies are targeted against an intracellular antigen, and it is unclear whether GAD 
antibodies are pathogenic or not. It has been suggested that GAD could be exposed on the cell surface 
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during exocytosis from GABA-ergic neurons, allowing a pathogenic antibody-antigen interaction 
(Malter et al., 2010). Other theories to explain the underlying immune mechanisms associated with 
GAD Abs include T-cell-mediated mechanisms (Lancaster and Dalmau, 2012). The presence of other 
antibodies in the sera of patients positive for GAD antibodies that bind to unknown surface antigens 
has also been suggested (Vincent et al., 2011b). Nevertheless, GAD antibodies are thought to be 
useful markers for immune mediated forms of epilepsy or limbic encephalitis and some of these 
syndromes are responsive to immunotherapy (Vincent et al., 2010). 
Intrathecal synthesis of antibodies may be a useful marker to the pathogenicity of antibodies detected 
in serum. It is proposed that CSF analysis improves the sensitivity and specificity of testing, 
particularly in NMDAR encephalitis (Lancaster and Dalmau, 2012). NMDAR Abs are often detected 
in CSF as well as serum (Dalmau et al., 2007, Dalmau et al., 2011). GAD antibodies were frequently 
detected in CSF as well as in serum of patients with variable neurologic conditions including LE and 
epilepsy (Saiz et al., 2008). The significance of this finding is debatable, and intrathecal synthesis of 
antibodies is not found in other syndromes associated with other autoantibodies such as VGKC and 
LGI1 antibodies (Vincent, 2008). The lack of intrathecal synthesis, as is the case in VGKC complex 
antibody associated limbic encephalitis, does not exclude an immune mediated process (Jarius et al., 
2008, Vincent, 2008). 
1.6 Epilepsy and other autoimmune diseases 
Epilepsy is reported in association with many systemic autoimmune disorders including multiple 
sclerosis, systemic lupus erythematosus (SLE), type 1diabetes mellitus (T1DM), coeliac disease and 
autoimmune thyroid disease (Palace and Lang, 2000, Vincent and Crino, 2011). In most cases the 
mechanisms of this association between autoimmune disorders and epilepsy is not clearly understood. 
It is possible that pathogenic neuronal antibodies might be present and responsible for the CNS 
involvement. However other causes such as coincidental coexistence, genetic predisposition for both 
conditions, or secondary effects of the primary disease might be the cause of epilepsy in these 
conditions (Vincent and Crino, 2011). 
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1.7 Treatment of autoimmune seizures and encephalopathies 
Many studies have shown that seizures of autoimmune origin respond to immune therapy better than 
to conventional antiepileptic drugs.  
There are currently no standard immunotherapy protocols for the treatment of immune mediated 
seizures, although similar regimens are used worldwide (Wong et al., 2010, Wong-Kisiel et al., 2012). 
Most people agree to the use of first line immunotherapy, which consist of steroids (usually in the 
form of high dose intravenous methyl prednisolone), intravenous immunoglobulin and 
plasmapheresis. These agents are used individually or in combination. Plasmapheresis use in children 
is limited due to its invasiveness and is usually limited to cases that do not respond to steroids, or to 
steroids and IVIG. This regimen is usually followed by variable length duration of tapered oral 
steroids. There is also consensus that failure of first line immunotherapy is an indication for 
consideration of second line immunotherapy, which consists of one or more of the 
immunosuppressant agents such as cyclophosphamide, mycophenolate or rituximab. Second line 
immunotherapy decision-making is often influenced by the treating clinicians’ previous experience, 
and cost versus benefit analyses. 
In addition to acute term treatment and treatment escalation to second line immunotherapy  in those 
who do not respond to first line immunotherapy, long term treatment is also adopted by some 
clinicians although there are no guidelines available. For example long term treatment with 
immunosuppression, such as mycophenolate or azathioprine for 12 months or so might be used for 
patients who responded to these treatment in order to prevent relapse. There is currently no evidence 
to support this practice. 
In addition to immune therapy, treatment of any underlying tumour is important to achieve good 
outcome (Dalmau et al., 2011). 
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It is well recognised that early and aggressive treatment of these disorders, including the use of second 
line treatment when the first line fails, will provide the best outcome. A recent large review of 
NMDAR encephalitis supports this approach (Titulaer et al., 2013). 
1.8 Vulnerability to autoimmune seizures and encephalopathies 
Many factors may give an individual a higher susceptibility to develop one or more of the 
autoimmune seizures and encephalopathies. The predisposing factors for many of the Ab autoimmune 
seizure disorders include genetic and environmental factors, and it is likely that this vulnerability and 
interaction between these factors is complex, as is the case in autoimmune diseases in general. The 
following factors are likely to be important: 
1. Ethnic origin, as NMDAR encephalitis is more common in non-Caucasian individuals, which may 
reflect an underlying genetic susceptibility (Irani and Vincent, 2011). 
2. Female sex, which is true of most autoimmune diseases and for most disorders associated with 
neuronal Abs except for VGKC encephalitis which is more common in males (Vincent et al., 2004, 
Vincent et al., 2010). 
3. The association with neoplasm, as is the case in NMDAR encephalitis, AMPAR Ab associated 
encephalitis and in some cases of VGKC-complex Ab encephalitis (particularly in association with 
CASPR2). Antigenic targets are expressed by the tumours, which provide the antigenic stimulus to 
produce the relevant antibodies and result in the neurological syndrome. The neurological syndrome 
might precede the diagnosis of the tumour, and occult tumours might be present in apparently ‘non-
paraneoplastic’ cases (Irani et al., 2010b). The association with tumours is less common in children 
than in adults. 
Black women with NMDAR encephalitis are more likely to have ovarian teratomas (Dalmau et al., 
2011, Titulaer et al., 2013). This might reflect that genetic susceptibility might also play a role in the 
predisposition to autoimmune response in the presence of neoplasms.  
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4. Preceding or concomitant infections which may act as a trigger for the autoimmune response. 
Serological evidence of mycoplasma infection in not uncommon in association with NMDAR 
encephalitis in children, though the significance of this finding is unclear (Florance et al., 2009, Gable 
et al., 2009). 
5. The association with other autoimmune diseases or autoimmune markers, which may indicate an 
increased genetic susceptibility to immune activation. Antinuclear antibodies are present in patients 
with VGKC encephalitis (Vincent et al., 2004, Suleiman et al., 2011a) and elevated ANA and thyroid 
Abs were found in some children with NMDAR encephalitis (Florance et al., 2009). T1DM and other 
autoimmune endocrinopathies are often present in association with neurological conditions where 
GAD Abs are thought to play a role. 
1.9 Study hypothesis and aims 
The findings of neuronal Abs in adult patients with seizures and epilepsy including limbic 
encephalitis, NMDAR encephalitis and autoimmune epilepsy prompted us to study these antibodies in 
children with seizures and epilepsies. The disorders associated with neuronal Abs are potentially 
treatable and reversible with early and prompt immune therapy. Therefore it is important to study 
their role in children to improve recognition, treatment and outcome of these disorders. 
This thesis examines the following hypotheses: 
1. A proportion of paediatric epilepsies are autoimmune in origin. 
2. Neuronal Abs play an important role in a proportion of children with seizures and epilepsy. 
3. Neuronal autoantibodies are associated with particular epilepsy phenotypes. 
4. These autoimmune childhood epilepsies might be treatable and reversible with 
immunotherapy, if recognised and treated promptly. 
The aims of this study are as follows: 
1. To study the presence of neuronal Abs in childhood epilepsy and seizure disorders. 
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2. To recruit a large cohort of patients with epilepsy, study their demographics and clinical 
features and classify them using standard ILAE system. 
3. To test the sera of these patients for autoantibodies against neuronal antigens and proteins 
including VGKC complex and its various components (LGI1, CASPR2, contactin2), 
NMDAR, GlyR and GAD (in addition to AMPAR, GABABR which became available later in 
the course of this study). 
4. To define the epilepsy phenotypes associated with the different neuronal Abs in children 
5. To study the patients' response to immune therapy (when given) and their outcome. 
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Chapter 2 VGKC-complex Antibody Associated Encephalitis in 
Children 
Acknowledgment 
This chapter is a detailed and a slightly modified version of the published work in paper 1 in 
Appendix 6 (Suleiman et al., 2011a). 
 
2.1 Introduction 
At the time of conducting this study in 2009, VGKC Ab associated encephalitis was not yet reported 
in children. In order to present the background to the current study, we present the background of 
VGKC-associated encephalitis in adults. Vincent et al 2004 described 10 patients predominantly 
males, above 40 years, with VGKC Ab associated LE (Vincent et al., 2004). These patients presented 
with subacute memory disturbance and confusion as well as seizures. Seizures were focal or 
generalised and were severe enough to require intensive care treatment in some patients. Most patients 
had significant memory disturbance on formal testing. MRI showed hippocampal and temporal lobe 
abnormalities in eight out of the 10 patients described by Vincent et al. Hyponatraemia was found in 
most of the patients described by Vincent et al and was attributed to syndrome of inappropriate 
antidiuretic hormone secretion (SIADH), which was sometimes resistant to treatment. Cerebrospinal 
fluid (CSF) was normal or only mildly abnormal. CSF pleocytosis was present in five of the ten cases 
and CSF oligoclonal bands were present in five out of the eight patients tested, with matching serum 
bands in four. EEGs showed non-specific changes including slowing, which was mostly generalised 
(but focal temporal in one case) and focal sharp waves mainly in the temporal regions in some cases. 
Neuromyotonia was found on electromyography (EMG) in one patient out of eight tested.  
As limbic encephalitis was known to be mostly a paraneoplastic syndrome, the sera of the 10 patients 
described by Vincent in 2004 were tested for the known onconeuronal antibodies and were negative. 
However some sera (two cases) showed a characteristic pattern of binding to the rat cerebellum on 
immunohistochemistry with strong binding to the molecular layer of the rat cerebellum and sparing of 
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the Purkinje cells. This pattern was different to any of the binding patterns of the known 
paraneoplastic antibodies but similar to a pattern found previously in some patients with Morvan's 
syndrome who had high VGKC-Abs. VGKC-Ab titres in all 10 patients were measured by the method 
in place at the time radioimmunoassay using whole rabbit-brain homogenate. The VGKC-Ab titre in 
the 10 patients ranged from 450 to 5128 pM (neurological and healthy controls <100 pM). Those with 
very high level (>2000pm) showed the same characteristic binding pattern described above on 
immunohistochemistry (positive). There was no evidence of a para-neoplastic process in any of the 
patients. The 10 patients described by Vincent et al 2004 received immune therapy using variable 
regimens including steroids, intravenous immunoglobulins and plasma exchange at variable times 
during their illnesses. These treatments were associated with falls in serum level of VGKC Ab, which 
also correlated with improvement in the neuropsychological profile in most patients. Of note was the 
rapid fall in serum Ab levels in patients who received steroid treatment early in the disease course, 
compared to a much slower fall in those patients who received steroids late or did not receive any. 
Nevertheless variable degrees of brain atrophy particularly involving the medial temporal structures 
as well as residual cognitive impairment were seen in some patients. This form of LE was thought to 
be immune responsive with good prognosis compared to the paraneoplastic LE. At present it is well 
recognised that early and aggressive treatment provides the best chance for a better outcome in VGKC 
Ab associated encephalitis (Wong et al., 2010). 
Subsequent studies showed that the VGKC antibodies found in patients with LE were in fact mostly 
targeted at other proteins that are tightly associated with the potassium channel rather than the channel 
itself, namely LGI1, CASPR2 and contctin2. The term VGKC-complex is now used to describe the 
VGKC and its associated proteins (see Chapter 1) (Irani et al., 2010a, Lai et al., 2010). 
Our index case and motivation for this study was a child at the Children’s Hospital at Westmead 
(CHW) who presented with encephalopathy along with status epilepticus and refractory seizures in 
November 2008. She was thought to have encephalitis however no infectious cause was found. Her 
case history is presented in details below. We thought that her presentation was reminiscent of the 
adult patients described with VGKC associated limbic encephalitis. Given the refractory nature of her 
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illness, she was tested for VGKC Abs and was found to be positive. She was the first child we 
identified with VGKC encephalitis. Her case prompted us to look for more cases in children 
presenting with unexplained encephalitis and status epilepticus. Although at the time only described 
in adults, we hypothesised that VGKC Abs associated encephalitis could potentially affect children as 
well. Based on the adult findings, we hypothesised that it was likely that affected children were at risk 
of poor outcome if not identified and treated early with appropriate immune therapy.  
2.2 Case Report of index case 
We report a paediatric case of VGKC-complex antibody associated encephalitis, presenting with 
status epilepticus, encephalopathy, dysautonomia and cognitive impairment. I have published this 
case in brief as part of the work arising from this PhD (Suleiman et al., 2011a), (see Appendix 6).   
2.2.1 Presentation of index case 
A 14 year old girl of Vietnamese origin presented with a subacute illness progressing over 14 days of 
headache, dizziness and confusion followed by new onset focal motor seizures with secondary 
generalised tonic-clonic seizures (GTCS) (Table 2-1). On presentation to the local hospital she was 
suspected to have encephalitis and was treated with cefotaxime and acyclovir. The seizures did not 
respond to intravenous boluses of midazolam, phenytoin and phenobarbitone.  She was transferred to 
our tertiary children’s hospital. On arrival she was encephalopathic and combative. She had a low 
grade fever but no focal neurologic deficit. She continued to have frequent GTCS lasting a few 
minutes every 30-90 minutes without intervening return of consciousness. She was intubated, 
ventilated and commenced on a midazolam infusion. There was no family history of epilepsy or 
febrile seizures. 
2.2.2 Investigations of index case 
The initial EEG showed left periodic epileptic discharges whilst subsequent EEGs showed generalised 
slowing and alternating right and left centro-temporal electrical seizures (Figure 2.1). 
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Video EEG monitoring performed during the first 5 days of hospital admission revealed diffuse 
slowing at 0.5-2 Hz with periodic focal sharp fast activity sometimes preceding the onset of focal 
electric seizures. Many focal seizures were captured with electrical onset from right or left centro-
temporal regions (independently). Clinically the seizures consisted of eye blinking, eye deviation, eye 
rolling, peri-oral automatism and clonic upper limb jerking. 
Brain MRI at presentation and three weeks into her admission was normal. Initial CSF examination 
revealed two polymorphonuclear and four mononuclear cells per mm
3
, normal protein and glucose, 
and negative PCR for herpes simplex virus and enterovirus. CSF neopterin was elevated at 
87.9nmol/L (normal 7-28) supporting the suspicion of an inflammatory process. Oligoclonal bands 
were not detected in CSF. The erythrocyte sedimentation rate was 40 mm/hr (normal <20), and C-
reactive protein was 42 mg/L (normal 0-10). Hyponatraemia was not a feature of the biochemistry. 
Liver transaminases were mildly elevated transiently. Serology for mycoplasma, cytomegalovirus, 
Epstein Barr virus, human herpes virus 6, toxoplasma, and cat scratch disease were negative. Anti-
nuclear antibody (ANA) titre was elevated at 1:640 with a speckled pattern. However, further 
autoimmune testing including complement, anticardiolipin and antibodies against extranuclear 
antigen, double stranded DNA, thyroglobulin and thyroid peroxidase antibodies were negative. Pelvic 
ultrasound revealed no ovarian teratoma. 
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Figure ‎2.1 EEG of index case showing generalised background slowing 
 (A) A focal electrical seizure of 90 second duration arises independently from the right 
centrotemporal region. (B) Two minutes later, a focal electrical seizure arises from the left temporal 
region. The electrical seizures were clinically associated with focal motor seizures characterised by 
blinking, eye rolling, oral automatisms, facial and limb jerking. “The‎recording‎is‎from day 4 of 
hospitalisation”. 
 
A
B
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Table ‎2-1 Summary of the clinical features and investigations of index case 
Clinical features of index case 
 
Headache 
Dizziness 
Seizures and status epilepticus 
Focal (temporal lobe onset) 
Generalised tonic clonic 
(secondary) 
Autonomic instability (hyperthermia and 
hypotension) 
Confusion, agitation, behavioural alteration and 
emotional lability  
Cognitive impairment 
Investigations of index case 
EEG 
 
 
MRI 
CSF 
 
Encephaloapthic,  generalised slowing  
Focal periodic epileptic discharges 
Alternating centro- temporal electrical seizures 
Normal 
Mild pleocytosis (6 WBC cells per mm
3
 ) 
High neopterin (87.9nmol/L ) 
 
2.2.3 Clinical Progress of index case 
During her 18 days of intensive care stay she had autonomic instability with hyperthermia up to 
41.5
o
C requiring vecuronium and cooling blankets, and hypotension requiring inotropic treatment. 
Extensive work up to look for a source of sepsis as a cause of high fever and hypotension was 
negative. Despite midazolam infusion, sodium valproate, phenytoin and levetiracetam, she continued 
to have up to 20 complex partial and generalised seizures per day. She had transient elevation of 
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hepatic transaminases which improved on withdrawal of phenytoin. She also had a generalised 
erythematous rash which was thought to be viral or drug related.  
Her seizures became less frequent from day 13 of hospital admission onwards and she was extubated 
and discharged to the ward at day 18. She was emotionally labile and had word finding difficulties. 
She was discharged home after a 25 day admission on levetiracetam and clobazam.  
The diagnosis of VGKC encephalitis was made retrospectively six months after the acute illness. Her 
serum VGKC antibodies from the acute illness (collected during intensive care stay) were 847 pM 
(normal <100), and remained elevated on convalescent testing after six months (679 pM). Antibodies 
against LGI-1, CASPR2, NMDA receptor and GAD were negative.  
2.2.4 Outcome of index case 
Formal neuropsychology assessment at three months revealed impairments of cognition and higher 
executive function, including problems with emotional control, attention and complex thinking. At six 
months, she had no further seizures and anti-epileptic drugs (levetiracetam and clobazam) were 
weaned. However she continued to have significant word finding difficulties, memory impairment 
and her school performance has deteriorated. A repeat ANA was down to 1:160.  
In view of the ongoing cognitive concerns and elevated VGKC Ab 14 months after her acute illness, 
she was given one course of intravenous immunoglobulin and oral steroids for 1 month. At 15 months 
follow-up after her encephalitis illness, she was back to her pre-morbid functioning according to her 
family and school, and has been weaned off all anti-epileptic drugs, and no further immunotherapy 
was given. Formal neuropsychology testing was not performed at the time. 
At the time of writing- 3 years following the acute illness, further follow up by her adult neurologist 
reported that she re-developed seizures. Her VGKC antibodies retested were low positive (150 pM), 
and she is receiving further monthly intravenous immunoglobulin. 
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2.2.5 Discussion of index case 
The clinical syndrome of our paediatric patient was similar to VGKC encephalopathy described in 
adults (Thieben et al., 2004, Vincent et al., 2004). Adults with VGKC encephalopathy may have 
associated autoimmune disorders (Tan et al., 2008), and our patient had transient elevation of ANA 
acutely but the remaining auto-antibody testing was negative. The CSF in our patient was abnormal 
with mild pleocytosis and elevated neopterin. It is recognised that the CSF is often normal or only 
mildly abnormal in VGKC encephalitis. In adults MRI may reveal hippocampal and temporal lobe 
abnormalities and some patients have hyponatraemia, although both were absent in our paediatric 
patient. 
The clinical course of our patient was complicated by refractory status epilepticus and dysautonomia. 
We initially feared she had Devastating Epileptic Encephalopathy in School-Aged Children (DESC) 
or Febrile infection–related epilepsy syndrome (FIRES) (Mikaeloff et al., 2006, van Baalen et al., 
2009). DESC/FIRES is a pseudo-encephalitis syndrome of unknown cause that affects previously well 
children and has severe morbidity and mortality. The subsequent course in our patient was however 
not consistent with DESC or FIRES. Although our patient made significant spontaneous improvement 
in her seizure control, she had residual cognitive impairment. In view of the continuing positive 
VGKC antibodies and her cognitive impairment, she was given intravenous immunoglobulin therapy 
2 g/kg over 2 days (one course only) followed by oral steroids 60mg/day for 2 days then a one month 
tapering course, This regimen which is a relatively short course of immunotherapy was used as she 
was thought to have returned to her pre-morbid state at the time of treatment 15 months following the 
acute illness. One could argue that this treatment was probably inadequate particularly given the fact 
that her seizures have recurred 20 months later. 
In conclusion, this was the first reported description of encephalitis with high titre VGKC antibodies 
in a child. We can conclude that VGKC Ab associated encephalitis occurs in children, and should be 
considered a cause of new onset severe epilepsy and status epilepticus.  
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2.3 Hypothesis and aim 
The increasingly recognised syndrome of VGKC Ab associated LE in adults and the positive result in 
our index case prompted us to look for further cases in children. We wondered if VGKC antibodies 
have an important unrecognised role in some paediatric patients who present with unexplained 
encephalopathy or encephalitis as well as seizures and status epilepticus. We wished to determine if 
this treatable form of encephalitis affects children.  
We aimed to study a cohort of paediatric patients with unexplained encephalitis and new onset status 
epilepticus, and test them for VGKC antibodies as well as other neuronal antibodies including N-
methyl-D-aspartate receptor (NMDAR), glutamic acid decarboxylase (GAD), and glycine receptor 
(GlyR) antibodies. AMPAR and GABAR antibody testing was not available in 2009/2010 at the time 
of this study. 
2.4 Methods 
2.4.1 Patients collection 
Based on the findings in our index case who presented with encephalitis and status epilepticus, we 
decided to look retrospectively for further similar cases. Initially we looked for patients who presented 
with status epilepticus to the CHW between January 2003 and June 2009 by searching our hospital 
medical records. We used the following International Classifications of Diseases (ICD)-10 codes: 
G41.0, G41.1, G41.2, G41.8 and G41.9 (WHO, 2010). 141 patients were identified with status 
epilepticus; only 36 had serum available for testing. We also looked for patients with encephalitis 
during the same time period using the following ICD-10 codes: G04.0, G04.8 and G04.9 and we 
selected those who had severe seizures or status epilepticus on presentation. Four more patients were 
identified with encephalitis and status epilepticus or severe seizures. The clinical data for the 40 
patients were studied and 13 patients with both encephalitis and status epilepticus (as defined below) 
who had serum available for testing were identified. Three of the 13 patients with encephalitis and 
status epilepticus had a defined aetiology for their encephalitis (Enterovirus n=2, H1N1 influenza 
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n=1) and were excluded leaving 10 patients with unexplained encephalitis and status epilepticus who 
were included in this study. 
We used the clinical criteria for encephalitis as defined by Glaser et al. (Glaser et al., 2003). This 
definition has been accepted and is used in large contemporary encephalitis cohorts (Granerod et al., 
2010). A case of encephalitis was defined by the presence of encephalopathy (depressed or altered 
level of consciousness lasting more than 24 hours, lethargy, or change in personality or behaviour) 
with 2 or more of the following symptoms: fever, seizure, focal neurologic findings, CSF pleocytosis, 
or electroencephalograph or neuroimaging findings consistent with encephalitis (Glaser et al., 2003).  
Status epilepticus (SE) was defined as a single seizure longer than 30 min or series of seizures without 
recovery of function in between lasting more than 30 min (Commission On et al., 1993).  
Approval by the Ethics Committee at The Children Hospital at Westmead was obtained as part of the 
approval for the autoimmune epilepsy study in children (see Appendix 3). Written consents to test 
acute stored sera were obtained from the patients or their families.  
Patients’ data were studied in detail using the electronic medical records system, including 
demographics (sex, age), past medical history and co-morbidities, presentation clinical information 
including seizures semiology/phenomenology, status duration, associated illness features, admission 
to hospital and intensive care unit, investigations performed (EEG, imaging, CSF, serology) and 
treatment given (see Appendix 4 ). The following associated illness features were recorded if reported 
by the carers or clinicians:  
 Encephalopathy, which was defined by the presence of lethargy, drowsiness or altered 
responsiveness.  
 Behavioural alteration, defined by the presence of agitation, emotional lability or irritability. 
 Cognitive alteration which was difficult to ascertain particularly for young children and 
infants and was defined by the presence of memory or intellectual concerns.  
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Given the retrospective nature of the study some clinical data were difficult to obtain with certainty by 
reviewing the clinical records including seizure semiology, status duration, as well as the presence of 
associated illness. Where no clinical information was recorded these features were considered absent.  
Clinical data were further studied and seizures were classified according to ILAE classification (Berg 
2010).  Seizure types were categorised into focal onset, focal with secondary generalisation or 
generalised at onset. 
Sera stored from the acute illness at the hospital laboratory were retrieved and stored for shipment to 
our collaborators for antibody assays. This was a collaborative study with Angela Vincent and Bethan 
Lang, Oxford UK who were one of the few labs in the world to perform VGKC-complex and other 
neuronal antibodies testing (methods below).  
2.4.2 Clinical features of cohort (n=10) 
The 10 patients with unexplained encephalitis and refractory seizures/status epilepticus (4 males, 
mean age 7.5 years, range 1–14) had no previous seizures; eight had no preceding neurologic 
abnormality and two had preceding mild developmental delay and learning difficulty. The mean 
length of hospital stay for the encephalitis event was 19.7 days (median 24.5 days, range 6–36). Nine 
of the 10 patients (90%) were admitted to the intensive care unit (ICU); the mean length of ICU stay 
was 9 days (median 5 days, range 2–25).  The SE was convulsive in all 10 patients, focal in 2, 
generalised in 6, and secondary generalised in 2. All patients had encephalopathy, eight had 
behavioural alteration and five had cognitive alteration. Eight patients had fever, and one had 
diarrhoea.  
2.4.3 Investigations of cohort (n=10) 
All 10 patients had EEG which was abnormally slow in all with focal features in seven, epileptic 
activity was seen in four and electrical seizures in one (see Tables 2-3 & 2-4). All 10 patients had CSF 
examination including microscopy, culture, and glucose and protein measurement. CSF pleocytosis 
(defined as more than 5 white cells per mm
3
) was present in nine out of the 10 patients. The mean 
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CSF white cell count was 14.7 cells per mm
3
). CSF protein was elevated (> 0.40 g/dl) in 5 patients. 
The mean CSF protein was 0.38 g/dl. CSF polymerase chain reaction (PCR) for Herpes Simplex 
Virus (HSV) and enterovirus was negative in eight patients tested. Serological testing including: 
mycoplasma pneumoniae (n=9), enterovirus (n=7), cytomegalovirus (n=6), Epstein-Barr virus (n=6), 
herpes simplex virus (n=5), human herpes virus 6 (n=3), influenza (n=4), and adenovirus (n=3) were 
negative. 
Magnetic Resonance Imaging (MRI) of the brain was performed acutely in all 10 patients, three were 
normal. The abnormal features on MRI consisted of the following: leptomeningeal enhancement 
(n=4), cerebral oedema (n=3) and white matter signal abnormality (n=2). Follow up MRI scans 
showed brain atrophy in one patient and mesial-temporal sclerosis in another. 
2.4.4 Control group 
The reference ranges for VGKC Ab testing were described only in adults and there was no reference 
range for children. We are aware that children’s normal titres might be different to adults hence we 
aimed to define a paediatric control reference range. 
We used 69 childhood controls including 15 healthy children (8 male, mean age 11 years, range 9–13 
years), 14 with non-inflammatory neurologic disorders (6 male, mean age 7.8 years, range 3–15 
years), 19 with immune mediated ataxia (11 male, mean age 6 years, range 1–11 years), 10 with 
encephalitis lethargica and parkinsonian features (6 male, mean age 9.4 years, range 5–15 years), and 
11 with NMDAR encephalitis (2 male, mean age 6.53 years, range 1.3–13 years). These patients were 
collected over the last 10 years as part of testing to define specificity of novel auto-antibodies.  
2.4.5 VGKC- complex antibody and other neuronal antibodies assays 
The stored serum used for neuronal antibody testing was acute serum from the first week of the 
encephalitis admission in all 10 patients. Sera were tested in Oxford by our collaborators for specific 
neuronal antibodies known at the time of the study including the following: VGKC complex, 
NMDAR, glutamic acid decarboxylase (GAD), and glycine receptor (GlyR) antibodies.  Sera were 
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also tested for Ab against leucine-rich glioma-inactivated 1(LGI1) and contactin-associated protein-
like 2 (CASPR2); which were identified to be tightly complexed with VGKCs in vivo (Irani et al., 
2010a, Lai et al., 2010).  
2.4.5.1 Methods used for antibodies assays 
The following section (in italic) was written by Dr Sukhvir Wright, Department of Clinical 
Neurosciences, John Radcliffe Hospital, Oxford, United Kingdom, and describes the methods used for 
neuronal antibodies assays at their laboratory. These methods were used for antibody assays in the 
different studies done as part of this PhD project (this Chapter, Chapter 3 and 4). 
2.4.5.1.1 Cell-based assay (CBA) 
This method was used for detection of cell surface antibodies to the NMDA, glycine receptors, and 
Lgi1 and Caspr2 proteins (as well as contactin2 and AMPAR in the later studies). 
Human‎embryonic‎kidney‎cells‎(HEK)‎293‎were‎grown‎and‎maintained‎in‎Dulbecco’s‎modified 
Eagle’s‎medium‎(DMEM)‎with‎10%‎fetal calf serum (FCS) and 1% penicillin-streptomycin-
amphotericin (PSA). The HEK 293 cells were plated at a concentration of approximately 400,000 
cells per well in 6 well plates containing poly-L- lysine (PLL) coated glass cover slips for transfection 
24 hours later. Each well was transfected with a total of 3µg of cDNA of the antigen of interest using 
polyethylenimine and glucose. A plasmid encoding for green fluorescent protein (EGFP) was co-
transfected to allow visualisation of cell uptake of the cDNA in the NMDAR-Ab CBA. After 16 hours 
the media was replaced by freshly supplemented DMEM. In the NMDAR transfected cell plates 
500µM of ketamine was added to prevent cell death due to activation of receptors by glutamate in the 
media. 
48 hours post transfection cover slips containing live antigenic protein expressing HEK cells were 
incubated in 24 well plates with patient sera at a 1:20 or 1:100 dilution with wash buffer (DMEM 
supplemented with  1% bovine serum albumin and  4-(2-hydroxyethyl)-1-piperazineethanesulfonic 
acid (HEPES) for 60 minutes. Cells were then washed and fixed in 3% formaldehyde for 10 minutes. 
Alexa Fluor 568 anti-human IgG was applied as a secondary antibody for 45 minutes at room 
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temperature. The cells were then washed again and mounted using aqueous mounting medium 
containing a 1:1000 dilution of 4',6-diamidino-2-phenylindole (DAPI) as a nuclear counter-stain. The 
mounted cover slips were visualised on a fluorescence microscope by two independent observers and 
binding was scored on a scale from 0-4‎where‎0‎is‎“no-binding”‎and‎4‎is‎“strong‎binding”(Irani et 
al., 2010a). Examples of binding patterns and scoring for the CASPR2 assay are shown in Figure 2.2. 
2.4.5.1.2 Radioimmunoprecipitation assay (RIA) 
To determine the VGKC-complex antibodies a radioimmunoprecipitation assay was used as 
previously described (Hart et al., 1997, Vincent et al., 2004). The extract containing VGKC-
complexes was prepared by solubilising whole rabbit brain membranes using 2% digitonin in DTX-
buffer (100mM NaCl, 20mM Tris, 5mM KCl adjusted to pH 7.1) at 37
o
C for 20 minutes and then 
centrifuging at 13,000g for 15 min at room temperature. The supernatant was harvested, diluted 1:2 
with PTX (0.02M phosphate buffer and 0.1% Triton X100, pH 7.2) and incubated with I
125
-αDTX‎
(dendrotoxin). This extract was further diluted with DTX-buffer to give 50,000 counts per minute 
(cpm) per 50µl or 1 million cpm per ml. The extract was incubated at 4
0
C until use. 
50µl of a 1 in 10 dilution of patient serum was incubated with 50µl of I
125
-αDTX-labelled extract  
overnight at 4
0
C.  Secondary anti-human antibody was added and incubated at room temperature for 
1 hour and 20 minutes. 500µl of PTX was added and samples spun at 13,000g for 5 minutes to form 
the pellet. Samples were washed immediately twice with 500µl of PTX. The final wash was removed 
before counting the radioactivity of the formed pellets on the gamma counter.  The level of 
radioactivity remaining in the tube is proportional to the antibody level in the sample. 
To try and negate the effects of non-specific‎binding‎a‎‘hot-cold’‎assay was also performed on the 
samples. This assay subtracted non-specific surface-bound 
125
I-αDTX‎from‎total‎surface-bound 125I-
αDTX‎to‎estimate‎specific‎surface-bound 125I-αDTX.‎To‎achieve‎this,‎patient‎samples‎were‎incubated‎
with unlabelled DTX to saturate binding of VGKC-complex receptors before addition of labelled 
extract as above. 
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For the GAD antibody RIA, I
125
-GAD was used. 50µl of a 1 in 10 dilution of patient serum was 
incubated with 50µl I
125
-GAD overnight at 4
0
C.  Secondary anti-human antibody was added and 
incubated at room temperature for 1 hour. 500µl of PTX was added and samples spun at 11,000g for 
5 minutes to form the pellet. Samples were washed immediately three times with 500µl of PTX. The 
final wash was removed before counting as above. 
  
 
Figure ‎2.2 Scoring of the cell-based assay, using CASPR2 as an example 
(courtesy of Sukhvir Wright, John Radcliffe Hospital, Oxford, UK). Left column is EGFP, centre 
column is human IgG after incubation and right column is overlay. The top row shows binding score 
3, the middle row shows binding score 1.5 and the bottom row shows binding score 0. 
 
3 
1.5 
0 
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2.4.5.2 Creating a normal reference range for VGKC-complex antibody in children  
The routine laboratory cutoff for VGKC Ab is 100 pM, which is the adult healthy control mean + 3 
SD. The mean VGKC Ab in our paediatric healthy control group (15 out of 69 controls) was 18 pM 
(SD 26, mean + 3 SD = 96). As our control mean +3SD was 96 pM, we therefore used the established 
cut-off of 100 pM to define positive cases.  
2.4.6 Statistics 
Fisher's exact nonparametric 2 x 2 test was used to compare categorical data and calculate P values. 
2.5 Results 
Four of 10 patients with encephalitis and status epilepticus had a positive VGKC Ab titre (>100 pM) 
compared with only 1/69 of the paediatric control group (mean 20 pM, SD 32, p<0.001, 95% 
confidence interval). The positive control (VGKC Ab 173 pM) had NMDAR encephalitis with 
refractory clinical seizures. The 10 encephalitis/SE patients were all negative for antibodies against 
LGI-1, CASPR2, NMDAR, GAD, and GlyR.  
The clinical features of the VGKC Ab-positive patients are presented in Table 2-2 (1 male, age range 
1–14 years, mean 9 years). All four patients were normal before the acute encephalitis illness. All had 
SE at presentation. The duration of SE was 30–60 minutes in one patient, 60 minutes–24 hours in one 
patient, and longer than 24 hours in 2 patients. Patients had ongoing refractory seizure clusters for 5–
20 days with up to 15 seizure clusters per day (Table 2-2). In addition to seizures, all patients had 
encephalopathy and behavioural or cognitive alteration during the acute illness. The four patients had 
a mean hospital admission of 20 days (range 7–28 days), and all required admission to intensive care 
for a mean of 7 days (range 2–18 days). The CSF was abnormal in all four VGKC-positive patients 
with mild pleocytosis (n =4) and elevated CSF protein (n = 2). CSF polymerase chain reaction (PCR) 
for herpes simplex virus and enterovirus was negative in all three patients tested. Serology for 
neurotropic infectious agents was negative including: mycoplasma pneumoniae (n=3), enterovirus 
(n=3), influenza (n=2), adenovirus (n=2), Epstein-Barr virus (n=2), herpes simplex virus (n=1), 
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human herpes virus 6 (n=1) and cytomegalovirus (n=1).  ANA was elevated at 1:640 in 2 patients 
(case 1 and 4) but resolved on follow-up. One patient (case 1) had hyponatremia (Na nadir 126 
mmol/L). Brain MRI showed abnormalities in 2 cases (Table 2-2). EEG showed slowing in all four 
patients, generalised in two and focal (temporal) in two. Epileptic activity or electrical seizures were 
seen in one patient and were of focal (temporal) onset. 
For comparison the 6 patients who tested negative for the VGKC Abs are presented in Table 2-3 (3 
males, age range 1-11 years, mean 6.3). Two of these patients had pre-existing mild developmental 
delay/ learning difficulty but no neurologic diagnosis. They all had convulsive status epilepticus 
which was focal in two and generalised in four. The duration of SE was 30–60 minutes in one patient, 
longer than 24 hours in 3 patients and difficult to determine in 2 patients. All 6 patients had 
encephalopathy and behavioural or cognitive alteration during the acute illness in addition to seizures. 
The 6 patients had a mean hospital admission of 17.6 days (range 6–36 days), and 5 required 
admission to intensive care for a mean of 8.3 days (range 2–25 days).  
In order to determine if there was a difference between VGKC Ab positive and negative patients, we 
compared the clinical and investigation features of the two groups. We found no significant difference 
between the positive and negative groups in terms of demographics, clinical presentations and 
investigation results, although the numbers are small (Table 2-4). It was interesting to note the 
outcome for the positive patients was poorer than for the negative ones. On follow up for an average 
of 40 months for the positive group and 11 months for the negative group, all four patients in the 
positive group had long term consequences: three had ongoing epilepsy, two had significant cognitive 
impairment, one had mild cognitive impairment and one had psychiatric disturbance. As for the 
negative group; four patients out of six showed no new deficit (two had complete recovery and two 
had no worsening of their pre-existing learning difficulty/ developmental delay, one patient had 
cognitive impairment and one patient died as a result of gastrointestinal complications (bowel 
perforation; thought to be secondary to barbiturates or ischaemia) . None of the negative patients had 
ongoing epilepsy or psychiatric disturbance. The difference in epilepsy outcome between the two 
groups was statistically significant (P value 0.03) see Table 2-4. 
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Table ‎2-2 Encephalitis and status epilepticus patients with positive VGKC Abs 
 
* Patient had mesial temporal sclerosis on follow up imaging 
** Index case 
 
 
Case 
 
Age, 
sex 
 
Predominant 
seizure type, and 
course 
 
Other clinical 
features 
 
CSF 
microscopy and 
protein 
 
EEG 
 
 
MRI 
 
 
VGKC Ab 
(pM) 
 
Outcome (length of 
follow up in months) 
1 1F 
 
Generalised 
Seizure cluster  
(5 days) 
Encephalopathy 
Behavioural alteration 
Fever 
9cells/mm
3
 
0.24 g/dl 
Left temporal slowing Normal * 
 
 
207 Temporal lobe epilepsy 
Cognitive impairment 
(66) 
2 9F Secondary 
generalised  
Seizure cluster 
(20 days) 
 
Encephalopathy 
Behaviour alteration 
Fever  
11cells/mm
3 
0.55 g/dl 
Generalised with 
dominant right 
temporal slowing 
 
Subcortical 
hyperintensities 
(bifrontal, left 
parietal) 
107 Temporal lobe epilepsy 
Cognitive impairment 
Psychiatric disorder 
(54) 
3 12M Generalised  
Seizure cluster  
(4 days) 
 
Encephalopathy 
Cognitive and 
behaviour alteration 
Vomiting 
Respiratory symptoms 
25cells/mm
3
 
0.52 g/dl 
Generalised slowing Generalised mild 
cerebral oedema 
214 Mild cognitive impairment 
(17) 
4** 14F Secondary 
generalised and 
focal 
Seizure cluster 
(16 days) 
Encephalopathy 
Cognitive and  
behaviour alteration 
Fever 
6 cells/mm
3
 
0.21g/dl 
Generalised slowing, 
bitemporal  
epileptic discharges 
and 
electrical seizures 
Normal 
 
  
640  Seizure recurrence after 2 
years seizure freedom  
(38) 
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Table ‎2-3 Encephalitis and status epilepticus patients with negative VGKC Abs 
 
  
 
Age, 
sex 
 
Predominant 
seizure type, and 
course 
 
Other clinical features 
 
CSF 
microscopy and 
protein 
 
EEG 
 
 
MRI 
 
 
Outcome ( length of 
follow up in months) 
1F 
 
Generalised, 
? Continuous 
 (24 hours?) 
Encephalopathy 
Behavioural alteration  
Fever 
0cells/mm
3
 
0.24 g/dl 
Generalised slowing, 
posterior epileptic 
discharges 
Diffusion restriction in deep WM. 
Cerebral atrophy at 2 weeks FU 
Developmental delay 
(pre-existing) 
(5) 
3F Focal  
Seizure clusters 
 (? duration) 
 
Encephalopathy 
Behaviour alteration  
Fever  
11cells/mm
3 
0.55 g/dl 
Generalised slowing, 
frontal epileptic discharges 
Normal Isolated event 
(12) 
5M Generalised, 
Seizure clusters  
(60 min) 
 
Encephalopathy 
Cognitive alteration  
Fever 
25cells/mm
3
 
0.52 g/dl 
Generalised slowing with 
right side predominance 
Diffuse leptomeningeal 
enhancement, brain oedema 
Isolated event 
(12) 
9M Generalised, 
Seizure clusters  
(? duration) 
Encephalopathy 
Cognitive and behavioural 
alteration  
Diarrhoea 
8 cells/mm
3
 
0.46g/dl 
Generalised slowing Initial: Diffuse leptomeningeal 
enhancement. Subsequent: patchy 
diffusion restriction. ? necrotising 
encephalitis 
Death  
(1) 
10F Generalised,  
Continuous 
 (? duration) 
Encephalopathy 
Fever 
6 cells/mm
3
 
0.21g/dl 
Generalised slowing 
 
left parieto-temporo-occipital 
swelling of gyri, leptomeningeal 
enhancement 
Learning difficulty 
(pre-existing) 
(20) 
11M Focal,  
Seizure clusters 
(?days) 
Encephalopathy Cognitive 
and behavioural alteration 
Fever 
46cells/mm
3
 
0.32g/dl 
Generalised slowing, left 
frontotemporal epileptic 
discharges 
 
Mild cerebral atrophy, increased 
signal in the left thalamus, mild 
meningeal enhancement 
Cognitive impairment 
(18) 
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Table ‎2-4 Comparison of VGKC Ab negative and positive encephalitis patients 
Characteristic  VGKC Ab negative 
patients n=6 (%) 
VGKC Ab positive 
patients n=4 (%) 
P value 
Mean age (y) 6.5 9 - 
Sex (F) 3/6 (50) 3/4 (75) 0.57 
Fever 5/6 (83.33) 3/4 (75) 1.0 
Seizure cluster 4/6 (66.66) 4/4 (100) 0.47 
Generalised seizures 4/6 (66.66) 2/4 (50) 1.0 
Secondary generalised 
seizures 
0/6 (0) 2/4 (50) 0.13 
Focal seizures 2/6 (33.33) 2/4 (50) 1.0 
Encephalopathy 6/6 (100) 4/4 (100) 1.0 
Cognitive or 
behavioural  alteration 
in acute illness 
5/6 (83.33) 4/4 (100) 1.0 
Length of hospital stay- 
mean (range) in days 
17.6  (6–36 ) 20  (7–28) - 
PICU admission 5/6 (83.33) 4/4 (100) 1.0 
Length of PICU stay- 
mean (range) in days 
8.3  ( 2–25) 7 ( 2–18) - 
CSF pleocytosis  5/6 (83.33) 3/4 (75) 1.0 
CSF cells mean 
(cells/mm3) 
16 12.75 - 
High protein 
(>0.40g/dl) 
3/6 (50) 2/4 (50) 1.0 
CSF protein mean (g/dl) 0.38 0.38 - 
EEG slow 6/6 (100) 4/4 (100) 1.0 
EEG epileptic 3/6 (50) 1/4 (25) 0.57 
EEG focal 4/6 (75) 
(post/frontal/frontotemporal) 
3/4 (75)                      
(temporal) 
1.0 
MRI abnormal 5/6 (83.33) 2/4 (50) 0.5 
Outcome:  
Length of follow up- 
mean (range) in months 
11.33 (1-20) 43.74 (17-66) - 
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Isolated event/complete 
recovery 
4/6 (66.66)  0/4 (0) 0.076 
Ongoing epilepsy 0/6 (0) 3/4 (75) 0.033 
Cognitive impairment 1/6 (16.66) 3/4 (75) 0.19 
Behavioural/psych 
disturbance 
0/6 (0) 1/4 (25) 0.4 
Death 1/6 (16.66) 0/4 (0) 1.0 
 
2.5.1 Case 2 presentation 
We present here the case history of another VGKC Abs positive patient (case 3 in Table 2-2) for 
comparison and to get more insight into the details of the clinical phenotype of VGKC complex Ab 
associated encephalitis in children. 
A 12 year old Caucasian male had a past medical history of repair of bilateral inguinal hernia and 
undescended testicles in the first year of life and recurrent ear infection in the first 3 years of life, but 
no other significant illnesses. He presented with a subacute illness over 7-10 days of nausea and 
vomiting initially, then rhinorrhea, sore throat and cough in addition to being irritable and not himself. 
This was followed by headache that got worse the day prior to his admission. On the morning of 
admission he was found by his mother on the floor after hearing noises. He was moaning, 
nonresponsive, had jerky movements of all limbs, stiffness all over his body and incontinent of urine. 
The duration of the seizure was unknown but longer than 20 minute. He had reduced level of 
consciousness on ambulance arrival and was irritable, however seizure activity has stopped. At the 
local hospital he was described to be irritable with reduced level of consciousness and a Glasgow 
Coma Score (GCS) of 8/15. He had no fever and no definite focal findings on neurological 
examination. He was commenced on acyclovir and cefotaxime for suspected meningoencephalitis. He 
was electively intubated due to reduced level of consciousness and in preparation for the CT scan and 
for the transfer to our tertiary hospital. A head CT scan was performed and found no abnormality. He 
was transferred to our PICU and had a low grade fever of 38 C. He became more responsive and was 
extubated.  A few hours later he had episodes of confusion and frequent jerking movements that were 
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thought to be focal seizures. He was given midazolam boluses, reintubated and commenced on 
midazolam infusion. Phenytoin was commenced. 
EEG showed diffuse slowing at 1-2 Hz with superimposed continuous fast activity of 14-16 Hz (likely 
related to benzodiazepines treatment) with no epileptic activity. A repeat CT scan of the brain showed 
poor differentiation of white and grey matter indicating cerebral oedema. MRI brain was normal. 
CSF examination revealed 5 polymorphonuclear and 20 mononuclear cells/ mm
3
, normal glucose and 
elevated protein at 0.52 g/dl. CSF PCR for herpes simplex virus and enterovirus were negative. 
Hyponatraemia was not a feature of the biochemistry. Serology for mycoplasma, cytomegalovirus, 
Epstein Barr virus, adenovirus, enterovirus and influenza were negative. Nasopharyngeal aspirate was 
negative for respiratory viruses and stool microscopy and culture was negative. 
During his four day stay in PICU he continued to have clusters of seizures that were described as 
generalised lasting 2-4 minutes each. He was maintained on phenytoin as well as on midazolam 
infusion. He also developed episodes of hypotension requiring fluid boluses, alternating with episodes 
of hypertension not requiring specific treatment. He had episodes of agitation, confusion and 
thrashing around while maintained on midazolam and morphine infusions that were treated with extra 
sedation including chloral hydrate. On day four of his admission he was discharged to the ward. He 
made slow but steady clinical improvement and was discharged on day 10.  
On review at one month and one year after his illness he was seizure free and maintained good health. 
Parents raised concerns related to some personality changes and loss of some “autobiographical” 
memories for events from childhood that he previously recalled. Formal Neuropsychological 
assessment was conducted 17 months after his illness and revealed average intellectual abilities, but 
difficulties in keeping track of mental operation and more demanding problem solving.  
2.6 Discussion  
In this retrospective study of a small cohort of children with unexplained encephalitis and status 
epilepticus we found that four out of 10 patients were positive for the VGKC-complex antibodies. 
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This suggests that VGKC Ab associated encephalitis/ encephalopathy exists in children and may be 
an important cause of paediatric encephalitis complicated by seizures, cognitive and behavioural 
alteration. 
We found no significant difference between the positive cases and the negative cases in terms of 
demographics and clinical presentation. The clinical presentation in all 10 patients was predominantly 
that of a subacute presentation of new onset seizures, status epilepticus, encephalopathy, behavioural 
and or cognitive alteration, with or without preceding infection. Seizures were generalised, focal, or 
secondary generalised. The seizure clusters occurred over days and seizures were generally 
challenging to treat. The CSF was mildly abnormal with variable degrees of pleocytosis and elevated 
protein. CSF viral PCR testing was negative when performed and serology for neurotropic agents was 
negative. MRI in all was either normal or showed non-specific abnormalities (see Tables 2-2, 2-3 
above). All patients showed a diffusely slow EEG. Interestingly for the positive patients when focal 
features were present in the EEG (focal slowing, epileptic activity or electric seizures) they were 
predominantly in the temporal region. Temporal lobe abnormalities are well described in adults with 
this syndrome (Vincent et al., 2004).  
The VGKC-complex antibody positive cases had poorer outcome compared to negative cases. All the 
positive patients had residual deficits including: ongoing epilepsy (temporal lobe epilepsy) in two, 
recurrence of seizures in one, cognitive impairment in three and psychiatric disturbance in one case. 
In comparison none of the negative patients had ongoing epilepsy or psychiatric disturbance, although 
one had residual cognitive impairment. The positive cases were followed up for a longer duration 
(mean 43.7 range 17-66 months) compared to the negative cases (mean 11.3 range 1-20 months). It 
was interesting to note that the severity of the presenting illness did not predict outcome in these 
patients. The poorer outcome in our VGKC-complex Abs positive cases might indicate that this form 
of encephalitis have a worse outcome if untreated. None of the positive cases received 
immunotherapy early and one (index case) received a short course of immunotherapy late in the 
course of her illness (15 months after onset).  It is possible that this was late and insufficient 
immunotherapy for this child as she has had recurrence of her epilepsy. 
 93 
 
Our four positive paediatric cases had similarities in their clinical presentation to adults with VGKC-
complex Ab associated LE as they had seizures, encephalopathy, behavioural and cognitive alteration. 
Our paediatric patients had worse seizures than the seizures described in adults but this may be due to 
our selection process that included patients with encephalitis and status epilepticus. The seizures 
described in our paediatric patients were not similar in semiology to the distinctive faciobrachial 
dystonic seizures described in some adults with LGI1 antibodies (Irani et al., 2011b), although video 
recording of seizures was only available for review in one of them (index case). One of our patients 
had hyponatremia which is found commonly in adult patients (Vincent et al., 2004). The CSF in our 
paediatric patients was normal or mildly abnormal. This is similar to findings in adults with VGKC-
complex associated LE (Thieben et al., 2004, Vincent et al., 2004, Jarius et al., 2008). The Brain MRI 
in our children was normal or non specific unlike adults described with the syndrome. Eight out of 10 
patients described by Vincent et al, 2004 had mesial temporal abnormalities including high signal 
initially and atrophy subsequently (Vincent et al., 2004). One of our paediatric patients had mesial 
temporal sclerosis on follow up, a finding that is similar to what has been described in a 13 year old 
girl following LE associated with VGKC Abs (Kroll-Seger et al., 2009). Our patients' EEGs and 
seizures semiology were of temporal lobe predominance. Two of our cases had ongoing temporal lobe 
epilepsy (TLE). This supports the hypothesis that VGKC-complex Ab has predilection to the temporal 
lobe structures (as part of the limbic system). The evolution from limbic encephalitis to temporal lobe 
epilepsy and mesial temporal sclerosis has been described in adults (Bien et al., 2007b). None of our 
patients had a coexisting immune disease but two had transient elevation of ANA. Elevated ANA 
have been previously described in adult patients with positive VGKC Abs (Vincent et al., 2004). 
In our patients’ sera we did not identify binding to LGI1 or CASPR 2. It is likely that these VGKC 
complex antibodies bind to other proteins in the VGKC-complex that are yet to be identified, or to the 
VGKC itself. Further studies are required to examine whether antibodies to LGI1, CASPR 2 or other 
proteins tightly complexed with the VGKC are present in children with autoimmune brain disease.  
Using the definition of positivity as per Haberlandt et al (normal <100pM), low positive (100–150 
pM), positive (150–400 pM) and high positive (>400 pM) (Haberlandt et al., 2011) one of our four 
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positive cases (case 2, Table 2-2) had a low positive titre of VGKC antibodies (107 pM). Lower titres 
might be associated with lower certainty about the significance of these antibodies and their 
pathologic role. Positive antibodies might be a secondary phenomenon in these patients. 
One of our paediatric control cases was positive for VGKC- complex Abs and this patient had the 
clinical features of NMDAR encephalitis and refractory seizures. This patient was positive for both 
VGKC and NMDAR antibodies. The finding of more than one autoantibody type has been described 
in adult patient with autoimmune limbic encephalitis (Pellkofer et al., 2010), and is also now 
increasingly recognised (Irani et al., 2010a, Haberlandt et al., 2011).  
The VGKC-complex Ab LE in adults is thought to be immune-responsive and have a better outcome 
when compared to the para-neoplastic form of LE. While this comparison is difficult to conduct in 
children as para-neoplastic LE is rare in children, our cohort showed that VGKC-complex Ab 
associated encephalitis in children generally has a poor outcome. This could be due to the fact that the 
diagnoses were made retrospectively and none of the patients received early adequate 
immunotherapy. In adults the syndrome is now well recognised and appropriate treatment regimens 
are still under evaluation. In children the situation is different and treatment is likely to be delayed as 
this form of encephalitis is not well recognised. Testing for VGKC-complex Abs is only done in a few 
specialised laboratories in the world and this can delay the results. However commercial companies 
are now producing kits that might be used locally and reduce the diagnostic delay. 
The findings in our study and in the other reports from paediatric cases (Dhamija et al., 2011, 
Haberlandt et al., 2011) have helped change our clinical practice. At present in our hospital we try to 
identify the patients with autoimmune encephalitis early. We send their sera for testing however we 
commence immunotherapy while results are still pending. As there are no guidelines available for 
children we have adopted an intensive treatment regimen consisting of intravenous methyl 
prednisolone at 30mg/kg/day for 3 days, as well as intravenous immunoglobulin of 2 g/kg, followed 
by oral prednisolone tapering treatment over weeks or months depending on severity. The intravenous 
treatment with immunoglobulin and/or methyl prednisolone can be repeated after a few weeks if 
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adequate improvement is not achieved. Alternatively plasma exchange can be considered or second 
line therapy (discussed later, see Chapter 4). There is no consistent protocol and decision-making is 
left to the discretion of the involved clinician. We suspect that early and adequate treatment is 
necessary to achieve the best possible outcome. Any delay in treatment may result in irreversible 
damage. 
We conclude that VGKC-complex Ab associated encephalopathy exists in children as it does in adults 
and may be an important cause for new onset seizures, encephalopathy, behavioural and cognitive 
alteration, psychiatric disturbance, temporal lobe epilepsy and mesial temporal sclerosis. We 
recognise the need for larger studies in children to help further understand the role of VGKC-complex 
antibodies in children. 
 
  
 96 
 
Chapter 3 Neuronal antibodies in children with new onset 
seizures classified according to the revised ILAE 
classification 2010 
Acknowledgment 
This chapter is a detailed and a slightly modified version of the published paper (Suleiman et 
al., 2013b) , see Appendix 6. 
3.1 Introduction 
The role of autoantibodies has been increasingly recognised in the pathogenesis of epilepsy. This 
includes antibodies against neuronal surface antigens such as VGKC-complex, LGI1, CASPR2, 
NMDAR, GABABR, and AMPAR as well as intracellular antigens such as GAD. The association 
between these antibodies and seizures is best described in patients with limbic encephalitis who often 
have temporal lobe seizures. However epilepsies of autoimmune basis have been described in the 
absence of limbic encephalitis (Peltola et al., 2000, McKnight et al., 2005, Majoie et al., 2006, Irani et 
al., 2008, Niehusmann et al., 2009, Barajas et al., 2010, Quek et al., 2012). Currently “autoimmune 
epilepsy” is becoming a recognised term that is used in patients with epilepsy who have positive 
neuronal antibodies (Irani et al., 2011a, Vincent et al., 2011b, Quek et al., 2012).  
Mcknight et al found positive VGKC antibodies in 16 out of 139 patients with epilepsy that they 
studied (11%) and high level GAD antibodies (defined as more than 1000 U) in three out of the 139 
patients (2.1%) (McKnight et al., 2005). VGKC antibody positive patients were older at age of seizure 
onset and often had accompanying acute or subacute encephalopathy, whereas GAD antibodies 
positive patients were younger at age of seizure onset and had chronic drug-resistant epilepsy. 
Faciobrachial dystonic seizures (FBDS) are seizures with distinctive semiology that has been 
described in patients with LGI1 antibodies that sometimes precedes limbic encephalitis (Irani et al., 
2008, Irani et al., 2011b). These are frequent, brief dystonic seizures that predominantly affected the 
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arm and ipsilateral face. It is thought that recognizing and treating these seizures with immunotherapy 
might prevent progression to encephalopathy and cognitive impairment.  
A recent study found neuronal antibodies in 11% of two adult patients cohorts with new and 
established epilepsy including VGKC complex proteins (5%), glycine receptor (3%), GAD (1.7) and 
NMDA receptor (1.7%) (Brenner et al., 2013). There was no significant difference between patients 
with newly diagnosed and established epilepsy. However positive antibody were found more in 
patients with focal epilepsy of unknown cause than in those with structural/metabolic focal epilepsy 
(14.8% vs. 6.3%; p < 0.02). 
In children fewer reports are available regarding the association of neuronal antibodies and epilepsy. 
NMDAR encephalitis occurs in children and focal or generalised seizures are an important feature. 
VGKC-complex antibodies have been reported in children with limbic encephalitis (Kroll-Seger et al., 
2009, Haberlandt et al., 2011) and in some children with status epilepticus in the context of 
unexplained encephalitis (Suleiman et al., 2011a). There are a few recent paediatric reports that 
describe VGKC antibodies in children with epilepsy in the absence of encephalitis including a child 
with epileptic encephalopathy and epileptic spasms (Suleiman et al., 2011b) and two children with 
symptomatic generalised epilepsy (Dhamija et al., 2011).  
Seizures and epilepsy have many types and causes and accurate description and classification is 
important on clinical and research levels.  The ILAE classification system is widely used and has been 
revised a few times since its implementation in 1969 to meet the ongoing developments in the 
understanding of epilepsy and its causes. The classification of seizures and epilepsies involves three 
major areas or "axes" including seizure type and semiology, epilepsy syndrome and epilepsy 
aetiology (Engel, 2001).  The latest ILAE report in 2010 presented a revision of terminology and 
concepts and approaches for classification of seizures, epilepsy syndromes and epilepsy aetiology 
(Berg et al., 2010). The new report proposed using a simplified meaningful approach and suggested 
changing a few existing terms including the replacement of the terms “idiopathic, symptomatic, 
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and cryptogenic” with “genetic, structural/metabolic and unknown cause” when describing 
aetiology (Berg et al., 2010). 
3.2 Hypothesis and aims 
There have been no large paediatric cohort studies to examine the role of neuronal antibodies in 
children with epilepsy. We suspect that a proportion of children with epilepsy have an autoimmune 
cause of their epilepsy. In these patients early immune therapy might improve their outcome. 
We aimed to prospectively recruit children with new onset seizures, record their demographic and 
clinical features, classify their seizures and epilepsies according to the ILAE classification system and 
test them for neuronal antibodies. This study aimed to determine the proportion of epilepsy with a 
putative autoimmune aetiology. In addition, this study examined the utility of the new ILAE 
classification. 
3.3 Methods 
This was a prospective study that recruited children with new onset seizures presenting to the 
Children’s Hospital at Westmead from September 2009 to November 2011.  
3.1.1 Power calculation and sample size 
Based upon the results of the McKnight study where 11% of adult patients were positive for VGKC 
antibodies we assumed that 11% of our patients would be positive. 
We performed a power calculation assuming that 11% of patients and 1% of controls will have 
autoantibodies. We expected to be able to recruit more patients than controls. Using significance of 
p<0.05, and power of 80% (standard), the number of patients required was 115 and the number of 
controls was 58.  
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3.3.2 Ethics approval  
Ethics approval from the Ethics Committee at the Children Hospital at Westmead was sought. The 
process included filling an online application form with detailed information about the study and its 
methodology. This was reviewed and approval was obtained in August 2009 (for ethics application 
and associated information see Appendix 3). 
In addition clinicians involved in the management of patients with new onset seizures were informed 
about the study including paediatric neurologists and general paediatricians at the hospital who agreed 
to recruit their consenting patients. 
3.3.3 Patient recruitment 
We recruited consenting patients with the following inclusion criteria: 
 Age 2 months to 16 years 
 New onset seizures of any types or aetiology (except those excluded, see below) 
 Serum collected within six months after seizure onset. We think that testing for antibodies 
around the time of onset of seizures provides the best chance to understand the relevance of 
these antibodies 
 Patients were inpatients or outpatients at The Children's Hospital at Westmead 
A seizure was defined based on the clinical history of an episode that was suggestive of a seizure. 
A clinical seizure was defined as per by ILAE Guidelines: “the clinical manifestation consists of 
sudden and transitory abnormal phenomena which may include alterations of consciousness, 
motor, sensory, autonomic, or psychic events, perceived by the patient or an observer” 
(Commission On et al., 1993). Patients were included if they had a single or multiple seizures as 
determined by the treating clinician. This included patients with febrile seizures.  
The following patients were excluded from the study: 
 100 
 
 Neonates (0-60 days) as many of the causes for their seizures are age specific and have 
different aetiological factors. 
 Patients who had a clear cause for their seizures at onset including bacterial meningitis, 
strokes, traumatic brain injury and brain tumors. Patients with malformation of cortical 
development or neurocutaneous syndromes were not excluded as dual pathology is possible 
and recognised. For example, cortical dysplasia has been described in patients with 
Rasmussen encephalitis, which is thought to be immune mediated (Palmer et al., 1999). 
 Patients whose serum sample was collected more than 6 months from onset of first seizure. 
 Patients with non epileptic paroxysmal events. Distinguishing seizures and epileptic events 
from non epileptic events including pseudo-seizures, syncope, sleep disorders and others was 
based on the clinical manifestations. Patients who had clinical events suggestive of seizures 
but when captured on EEG were consistent with alternate diagnosis (such as non epileptic 
events) were excluded. 
Patients were identified by the primary investigator (JS) through reviewing the inpatient list on a daily 
basis, and collaboration with medical staff in the medical and neurology teams at the hospital. The 
recruited patients were from a tertiary referral hospital, which might have caused bias in the types and 
severity of the patients’ epilepsies. Patients were more likely to be seen and recruited by the primary 
investigator if they were inpatients rather than outpatients, and if they had a longer hospital admission. 
Patient recruitment took place over 2 years. 114 patients were recruited of whom 104 patients were 
seen by a paediatric neurologist during the course of their illness either as primary physician or 
consultant. The remaining 10 patients were managed by a general paediatrician. 16 patients were 
transferred from another hospital to our hospital for tertiary care. 
3.3.4 Consenting process 
Information sheets about the study were created for both parents and young patients and approved by 
the Ethics Committee at the Children's Hospital at Westmead (see Appendix 3). These letters 
explained background information as well as the purpose of the study in lay terms and also explained 
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the requirement of blood collection for the study. Patients and families were informed that they have 
the full choice to enroll in the study and that the results of this study were not going to change their 
current management.  
The ethics committee approved consent forms were signed by the parents and patients who were older 
than 14 years (see Appendix 3).  
Most patients were approached while in the hospital (wards or clinics) and given information sheets 
and consent forms. Signed consents were then either collected in person or posted back to the 
investigators. Patients who were referred by other medical staff and were not seen by the primary 
investigator were sent information sheets and consent forms by mail with reply paid envelopes to be 
returned (free of charge) to the investigators.  
3.3.5 Serum collection 
A serum sample was collected for all consenting patients. The serum was collected either for a 
clinically indicated test that required a serum sample (for example serology for suspected infective 
agents), or collected in conjunction with other indicated tests such as drug levels. None of the children 
enrolled in this study were exposed to blood sampling merely to collect serum for this study.  
The serum sample had to be collected within 6 months of the onset of seizures. Patients who had 
serum collected outside this time window were excluded. Most sera were collected during the acute 
admission associated with the first seizure. If an acute admission sample was not possible, then a 
blood form was given to the parents to collect serum along with the next blood test required for 
clinical care (for example at the time of liver function testing after starting sodium valproate). Getting 
a serum sample within the indicated window (6 months) was a major determinant factor for enrolling 
patients. Many patients were identified then excluded as a result of being unable to obtain a serum 
sample, particularly outpatients who were not hospitalized for their seizures. The serum samples were 
saved in the hospital laboratory. At the end of recruitment phase the serum samples were retrieved, 
 102 
 
coded and dispatched to our collaborators Beth Lang and Angela Vincent at John Radcliffe Hospital, 
Oxford to be tested for neuronal antibodies as below. 
3.3.5.1 Serum samples of the cohort  
Serum sample date and serum sample timing in relation to onset of epilepsy (in days) were reported 
for each of the 114 patients. 
The date of onset of seizures was easy to ascertain if the patient presented to the hospital acutely. In 
some patients where seizures were more subtle or less severe the seizures might have been occurring 
for a period of time prior to presentation. The date of onset was determined as best as could be 
recalled by the parents or carer. 
Serum samples were all collected within 6 months (180 days) of seizure onset as per inclusion criteria. 
Serum collection time range was 0-180 days with a mean of 38.35 and a median of 15.5 days after the 
first seizure (see Figure 3.1). Sixty seven patients (57.7%) had their serum collected within 1 month 
and 86 (75.4%) within 2 months (see Figure 3.1).  
 
 Figure ‎3.1 Serum sample collection timing for total cohort (n=114)  
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3.3.6 VGKC- complex and other neuronal antibodies assays 
The following antibodies were tested in the 114 patients: VGKC-complex (n=114), NMDAR (n=114), 
LGI1 (n=113), CASPR2 (n=113), GAD (n=113), Glycine R (n=112), AMPAR (n=112) and contactin-
2 (n=112). The minor incomplete testing was due to some samples becoming exhausted. The methods 
of testing were the same as described in Chapter 2. The antibodies to VGKC-complex and GAD were 
tested by radioimmunoassay (RIA). VGKC Abs and GAD levels greater than 100 pM and 100 U/ml 
respectively were considered positive. All other neuronal antibodies were tested by cell based assays 
(CBA). The CBA were scored on a visual scale 0 (no binding)-4 (strong binding to all transfected 
cells) by 2 independent observers. Results were considered positive if scoring >1 in NMDAR, LGI1, 
and CASPR2 assays and >2 in the Gly-R assay. Assays were performed and read by Sukhvir Wright 
(Oxford) who was blinded to the clinical data, and re-scored by an additional reader. 
3.3.7 Data Collection 
The prospective nature of the study was mainly to ensure that serum was collected within the window 
period of 6 months from seizure onset. However the investigators did not perform a separate clinical 
assessment for the patients unless they were responsible for their care. Hence patients’ information 
was recorded by reviewing the hospital electronic medical recording system including clinical notes 
from presentation to emergency and admission to hospital, referral letters from other hospitals, 
hospital discharge summary and clinic letters. Data collected included demographics, previous 
medical and neurologic history, family history of epilepsy, seizure onset and type, the presence of 
status, associated clinical features (including encephalopathy, movement disorder, cognitive 
impairment or inter-current illness), hospital and intensive care admission, investigations including 
EEG, imaging and CSF, seizure and epilepsy treatments including the use of steroids and/or 
immunoglobulins, outcome including ongoing epilepsy, drug resistance, developmental delay, 
cognitive or psychiatric impairment and others (see Appendix 5). 
The data collection was performed and completed by the primary investigator (JS) with complete 
blinding to the result of antibody testing. 
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3.3.7.1 Demographic features of the cohort (n=114) 
A total of 114 patients with new onset seizures were included in this study (58 females, mean age at 
onset 4.39 years (median 2.55 and range 0.13-15.25 years). 51 patients (44.7%) were younger than 2 
years (see figure 3.2). This mainly reflects the fact that younger children and infants were more likely 
to be admitted to the hospital and investigated after their first seizure and therefore more likely to be 
recruited for this study. 
 
Figure ‎3.2 Distribution of cohort according to their age (n=114) 
3.3.7.2 Hospital admission and intensive care treatment 
Hospital admission and length of stay as well as admission to the intensive care unit and length of 
admission were reported as ‘surrogate markers’ of the severity of illness.  
101 out of the 114 patients were admitted to the hospital during their initial presentation or during the 
first six months after seizure onset. The first hospital stay was used for reporting of duration of 
hospital admission and intensive care treatment. The mean length of hospital stay was 13.36 days 
(median 4.5 days, range 1 to 360 days). 18 patients were admitted to the intensive care unit during 
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their initial presentation or hospitalization. The mean length of intensive care admission was 8.15 
days (median 2 days, range 0.8 to 64 days). 
3.3.7.3 Clinical features of the cohort  
3.3.7.3.1 Past neurological and medical history 
During data retrieval we recorded the presence of pre-existing: 
1. Developmental delay including speech, language, gross or fine motor delay in the young 
children or learning difficulties in older children. 
2. Behavioural or psychiatric impairment including anxiety, depression, attention deficit and 
hyperactivity. 
3.  Motor deficits such as hypotonia, spasticity, hemiplegia or other deficits. 
These features were considered to be present if they were formally diagnosed previously or 
reported by the parent or carer, or if they were evident to the treating clinician at the time of 
assessment for the new onset seizures and known to be longstanding.  
Other neurologic or medical diagnoses including that of autoimmune diseases were also reported. 
None of the recruited 114 patients had preceding seizures or epilepsy; however on further review of 
clinical data three patients had possible febrile seizures when younger (9, 6 and 5 years earlier than 
their current presentation) - we nominated to keep these patients in the cohort.  
78 patients had no preexisting neurological or developmental abnormality and 36 had one or more 
preexisting developmental, motor or psychiatric abnormality including 33 with developmental delay 
and /or learning difficulty, 14 with motor deficits and four with behavioral or psychiatric disturbance. 
22 patients had one or more of the following neurologic diagnoses including: visual or hearing 
impairment (n=5), chromosomal abnormalities (Trisomy 21, 14q21 deletion, tetrasomy 15q11.2-
q13.1, chromosome 7 inversion) (n=5), cerebral palsy (n=3), dysmorphic features and undiagnosed 
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syndromes (n=2), microcephaly (n=2), microform holoprosencephaly (n=1), neurofibromatosis type 
1(n=1), congenital myopathy (n=1), congenital nystagmus (n=1) and propionic acidaemia (n=1). 
41 patients had one or more preexisting medical condition, as follows: 
 Congenital malformations (n=10): including congenital cataract, choanal atresia, 
laryngomalacia, trachea-oesophageal fistula, congenital cardiac disease, diaphragmatic hernia, 
vesicoureteric reflux, undescended testicles, hip dysplasia and skin haemangioma. 
 Atopy (n=10): including asthma, eczema, hey fever and food allergies. 
 Gastrointestinal (n=5): including Crohn’s disease, Hirschsprung disease, chronic constipation, 
feeding difficulties and celiac disease. 
 Autoimmune disorders (n=4): including type 1 diabetes mellitus, Henoch-Schonlein purpura 
and autoimmune chorioretinitis. 
 Premature delivery (n=3). 
 Obesity (n=2). 
 Endocrine disorders (n=2), including diabetes insipidus and hyperinsulinism. 
 Short stature (n=1). 
 Recurrent bronchiolitis (n=1). 
 Juvenile Myelocytic Leukemia (n=1). 
3.3.7.3.2 Family history 
A family history of epilepsy or seizures in first-degree relatives was reported. This was determined by 
reviewing medical records and reported as present when clearly mentioned in the clinical history. 
However under reporting is a possibility as this study was not designed to study the genetics of 
epilepsy.  
There was a family history of seizures or epilepsy (including febrile seizures) in first degree relatives 
in 19 patients.  
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3.3.7.3.3 Presenting seizure characteristics 
The seizure semiology at onset was determined from the description available in the medical records, 
and as reported by the parent, carer or witnesses from clinical staff including nursing and medical 
staff. The classification system for seizures is evolving and changing hence we used the latest ILAE 
classification (Berg et al., 2010), in addition to previous ILAE classification reports (Bancaud et al., 
1981, Engel, 2001, Engel, 2006).  Seizures were classified as follows:  
1. Focal when the initial semiology of the seizure was consistent with initial activation of only 
part of one cerebral hemisphere (ICES 1981) (Bancaud et al., 1981). This includes: 
a. Focal motor, autonomic or sensory (without impairment of consciousness). 
b. Focal dyscognitive was defined as a focal seizure that was associated with 
impairment of consciousness or awareness (Engel, 2006, Berg et al., 2010). 
c. Focal evolving to a bilateral convulsive seizure (including tonic, clonic or tonic 
clonic), which was recommended to replace the previous similar term “secondarily 
generalised seizure” (Berg et al., 2010). 
2. Generalised was used when the initial semiology was consistent with involvement of both 
cerebral hemispheres (ICES 1981). 
3. Spasms: Epileptic spasms have been classified as “unknown” in the latest ILAE classification 
(Berg et al., 2010), hence we kept them in a separate category. 
When possible, further characterization of seizure semiology was performed as per the ILAE 
commission report: Glossary of Descriptive Terminology for Ictal Semiology (Blume et al., 2001), 
see Table 3-1.   
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Table ‎3-1 Seizure types at presentation: definitions used in the cohort 
(generated from glossary of descriptive terminology for ictal semiology, Blume 2001) 
Focal “A seizure whose initial semiology is consistent with initial 
activation of only part of one cerebral hemisphere” 
Generalised “A seizure whose initial semiology is consistent with more 
than minimal involvement of both cerebral hemispheres” 
 
Motor 
Tonic Sustained contraction in the muscles lasting a few seconds to 
minutes 
Epileptic spasms A sudden flexion or extension or combination of both and 
mainly involving proximal and truncal muscles that is more 
sustained than a myoclonic jerk but less than a tonic seizure 
(i.e about 1 second). Limited forms may occur such as head 
nodding and grimacing. Epileptic spasms often occur in 
clusters 
Versive A sustained forced conjugate ocular, cephalic and/or truncal 
rotation or deviation from midline 
Myoclonic Sudden, brief, non sustained involuntary single or multiple 
contractions of muscles or group of muscles (axial, proximal 
limb, distal limb) 
Clonic Myoclonus that is regularly repetitive and involves small 
muscle groups at 2-3 contractions per second (rythmic 
myoclonus) 
Tonic clonic A sequence consisting of tonic followed by clonic phase 
Generalised tonic clonic Bilateral symmetric tonic contractions then bilateral clonic 
contractions of muscles 
Atonic Sudden loss (or diminution) of muscle tone without apparent 
preceding myoclonic or tonic even, involving head, trunk, jaw 
or limb muscles. 
Astatic (drop attack) Loss of erect posture that result from atonic, myoclonic or 
tonic mechanism 
Automatism Repetitive motor activity usually occurring when cognition is 
impaired 
 
Sensory 
Somatosensory Tingling, numbness, electric shock feeling, pain, sense of 
movement or desire to move 
Visual Flashing or flickering lights, spots, simple patterns, scotomas 
or amaurosis 
Auditory Buzzing, drumming sounds or single tones 
Autonomic A sensation consistent with involvement of the autonomic 
nervous system including cardiovascular, gastrointestinal, 
vasomotor and thermoregulatory function 
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The presenting seizure(s) in the 114 patients were classified into focal (n=56), generalised (n=42) and 
spasms (n=16) and are presented in Table 3-2. Impairment of consciousness was determined from 
commentary made by a witness including parent, carer or clinician, or when other terms which imply 
impairment of consciousness were used such as “unresponsive”, “confused”, “vague” etc. Sensory 
phenomena and auras are likely to be under reported in this cohort given the young age of the patients 
who are unable to describe their auras and seizures. A proportion of generalised and focal seizures 
were not further classified, as detailed descriptions of seizure semiology were inadequate to 
characterize them, and we used the term “unclassified” for those seizures. 
3.3.7.3.4 Status epilepticus (n=21)  
Status epilepticus was defined as a single seizure lasting more than 30 minutes or a series of seizures 
without recovery in between the ictal events over a period of at least 30 minutes (Commission On et 
al., 1993). Twenty one patients had status epilepticus as their initial presentation and all were admitted 
to the hospital including nine who were admitted to the intensive care unit. 
3.3.7.3.5 Early seizure recurrence (n=77) 
Early recurrence of seizures, occurring within 48 hours of first seizure onset occurred in 77 out of the 
114 patients.  
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Table ‎3-2 Seizure types at onset for the total cohort (n=114) 
(classified as per Berg 2010 and Blume 2001) 
Seizure type  Patients (number) 
Focal (n=56) 
 Focal motor   
 Tonic 2 
 Clonic  2 
 Myoclonic  2 
 Versive  2 
 Automatism 2 
 Tonic clonic 1 
 Other focal motor 6 
 Focal dyscognitive  12 
 Focal evolving to bilateral convulsive  8 
 Focal sensory   
 Visual  3 
 Somatosensory  2 
 Auditory 1 
 Autonomic  1 
 Focal unclassified  10 
Generalised (n=42) 
 Tonic clonic 28 
 Absence 3 
 Myoclonic 2 
 Clonic 2 
 Tonic 3 
 Myoclonic atonic 1 
 Generalised unclassified 3 
Unknown (n=16) 
 Spasms 16 
Total   114 
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3.3.7.3.6 Other features at presentation 
Inter-current illness, infection or vaccination (n=41) occurring in the preceding seven days was 
considered significant. The following intercurrent illnesses were documented:  
 Infections (n=32) which included upper respiratory tract infections (URTI) (n=13), 
gastroenteritis (n= 7), fever and no other symptoms (n=6), fever and rash (n= 2), fever and 
headache (n=2), and fever and other nonspecific symptoms (n=2). 21 out of these 32 
patients had a documented temperature of 37.8 C◦ or higher (axillary) at the time of the 
presenting seizure. 37.8 C is the temperature used to define febrile seizures (Berg 1992 Feb 
seizures)). 
 Other intercurrent illnesses (n=3) included asthma exacerbation (n=1), cardiac surgery (n=1), 
and elevated blood pressure (n=1). 
 History of vaccination in the preceding week (n=5). 
 Infliximab infusion in the preceding week (n=1). 
Other neurological and neuro-psychiatric features (n=48) were recorded when they occurred 
within the first week of seizure presentation, including one or more of the following features: 
 Encephalopathy (n=33) was defined by the presence of lethargy, drowsiness, reduced 
responsiveness or altered level of consciousness (reported by the carer or clinician) that lasted 
more than 24 hours and was not attributed to the post ictal state (Glaser 2003). 
 Behavioural or psychiatric alteration (n=27) was defined by the presence of agitation, 
emotional lability, irritability, or other changes from normal behaviour as reported by the 
carer or clinicians. Behavioural alteration occurred mostly in patients who also had 
encephalopathy (above). 
 Motor impairment (n=17) of new onset and not attributed to drug side effects included 
ataxia, limb weakness (including Todd's paresis), swallowing difficulties, slurred speech or 
hypotonia reported in association with seizure onset. 
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 Cognitive alteration (n=12) was difficult to ascertain particularly for young children and 
infants and was defined by the presence of memory or intellectual concerns reported in the 
clinical record, from parental concerns, clinical assessment or standardised testing when 
performed.  
 Movement disorder (n=5) was reported occasionally including tremor in three, dystonia in 
one and dyskinesia in three (more than one movement disorder reported in some individuals). 
3.3.7.4 Investigations of the cohort 
The investigation was requested by the attending clinician as clinically indicated for the individual 
case. No further investigations were performed for the purpose of this study apart from neuronal 
antibody assays. The following investigations were performed for the 114 patients:  
3.3.7.4.1 EEG/Video EEG 
An EEG was done in 113 out of the 114 patients and was abnormal in 86 out of the 113 done (76.1%). 
A degree of slowing (focal, diffuse, continuous or intermittent) was found in 62 patients (54.9%). 
Epileptic activity was found in 58 patients (51.3%). Clinical or electrical seizures were recorded in 27 
patients (23.9%). In 22 patients the EEG findings contributed significantly to the diagnosis including: 
hypsarrythmia, burst suppression, epileptic encephalopathy, abnormalities supportive of 
electroclinical syndromes (West syndrome, Childhood absence epilepsy, Benign epilepsy with 
centrotemporal spikes) and abnormalities suggestive of focal epilepsy due to a possible structural 
cause. 
3.3.7.4.2 Brain MRI 
MRI scan of the brain was done in 105 out of the 114 patients (92.1%) and showed an abnormality in 
52 patients out of the 105 done (49.5%). MRI was diagnostic or suggestive of a cause of the epilepsy 
in 30 patients (28.6%), including malformation of cortical development (n=12), encephalitis (n=5), 
encephalomalacia (n=4), neurocutaneous syndrome (n=3), occipital gliosis suggestive of neonatal 
hypoglycemia (n=2), metabolic disorders (n=2, Mitochondrial encephalomyopathy, lactic acidosis, 
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and stroke-like episodes- MELAS and propionic academia), Rasmussen encephalitis (n=1) and 
posterior reversible encephalopathy syndrome (PRES) (n=1). 
3.3.7.4.3 CSF 
CSF analysis was performed in 66 out of the 114 patients (57.9%) and showed the following 
abnormalities: pleocytosis (defined as white cells in excess of 5/mm
3
) (n=7), elevated neopterin 
suggestive of inflammation (>30 nmol/L) (n=22, 55 tested), abnormal oligoclonal bands (n=2, 41 
tested) (with mirrored serum bands in one and intrathecal bands in one). CSF viral PCRs were 
performed as follows: Herpes Simplex Virus (HSV) (n=27, all negative), enterovirus (n=26, two 
positive), Varicella Zoster Virus (VZV) (n=4, all negative), Human Herpes Virus 6 (HHV6) (n=3, one 
positive) and Cytomegalovirus (CMV) (n=1, negative). 
3.3.7.4.4 Other Investigations 
Other investigations were performed including metabolic, imaging, genetic, infectious and 
immunologic investigations were recorded when performed. In six patients these investigations 
helped establish a diagnosis, including the metabolic disorders congenital glycosylation disorder 
(CGD) (n=2) and MELAS (n=1). In addition, genetic abnormalities were found in three including 
genetic mutations or abnormalities as follows: PCDH19 (n=1), SCN1A (n=1) and deletion of 22q11.2 
(n=1). 
3.3.7.5 Treatment  
This study was not designed to study acute or long term treatment of seizures. Treatment received was 
recorded by listing the antiepileptic medications used (acutely or on long term). The use of steroids 
and/ or IVIG was recorded as well as the response of seizures. 
Forty-six patients received acute seizure treatment including a single medication or combination of 
the following: midazolam (buccal/nasal or intravenous) (n=30), phenytoin (n=27), phenobarbitone 
(n=6), clobazam (oral) (n=4), pyridoxine (intravenous) (n=3), levetiracetam ((intravenous) (n=1) and 
thiopentone (n=1). 
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Twenty-nine patients received no long term antiepileptic treatment, defined as more than seven days. 
85 patients received long term antiepileptic drugs (AEDs) including one AED (n=38), two AEDs 
(n=18) and three or more AEDs (n=29) (as single agents or in combination) during the period of 
follow up. 
Twenty-three out of 114 received variable regimens of steroids, including steroids alone (oral 
prednisolone and intravenous methyl prednisolone) in 18 and steroids and intravenous 
immunoglobulins (IVIG) in five. A positive response to steroids given alone was reported in 14 
patients, including West syndrome (n=6), epilepsy of unknown cause (n=4), Lennox Gastaut 
syndrome (n=2), epilepsy attributed to malformation of cortical development (n=1) and epilepsy 
attributed to perinatal insult (encephalomalacia, n=1). A positive response to steroids given in 
combination with IVIG was reported in 2 patients including Rasmussen encephalitis (n=1) and basal 
ganglia encephalitis (n=1).  
3.3.7.6 Outcome 
The outcome was studied by reviewing the last follow up recorded on the electronic recording system, 
either through attending outpatient clinic or hospital emergency, hospital admission or through follow 
up phone calls made by the caring teams. 10 patients (8.8 %) had no follow up information available. 
For the remaining 104 patients, the mean length of follow up (from seizure onset) was 11.7 months 
(median 11 months, range 1-36 months).  
The following outcome measures were used: 
3.3.7.6.1 Epilepsy outcome 
The seizure or epilepsy outcome was recorded for the 104 patients with natural follow up as follows: 
1. Isolated event (n=20) where the patient had no further seizures during follow-up. For 
example a patient with encephalitis who had seizures on presentation with the encephalitis 
illness (single or multiple) but had no further seizures on follow up (without being on long 
term antiepileptic medications) was considered to have an isolated event. 
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2. Ongoing epilepsy (n=84) was recorded if the patient had further seizures beyond the acute 
presenting seizures. This includes those who have achieved seizure control on one or more 
antiepileptic medications. Of the 84 patients with ongoing epilepsy, 23 (27.3%) had drug 
resistant (refractory epilepsy) which was defined by as per ILAE special report 2010 as 
“failure of adequate trials of two tolerated, appropriately chosen and used antiepileptic drugs 
(as monotherapy or in combination) to achieve sustained seizure freedom” (Kwan et al., 
2010).  
3.3.7.6.2 Other outcome measures 
A new deficit (other than epilepsy) was present in 32 patients, this included developmental delay/ 
learning difficulties/ cognitive impairment, behavioural/ psychiatric impairment or motor impairment 
that were not present prior to the onset of seizures.  
The following new deficits were recorded at follow up:  
a. Development delay/ cognitive impairment (n=24) as reported by family or treating clinician 
was defined as failure to achieve age appropriate developmental milestones (in young 
children) or learning difficulties and concerns regarding cognitive function (in older children), 
or when these were evident on standardized testing. 
b. Behavioral/ psychiatric disturbance (n=18) were recorded such as anxiety, emotional 
lability, depression, aggressive behavior and attention deficit hyperactivity disorder. 
c. Motor or focal deficits (n=13) were recorded such as hypotonia, spasticity, ataxia, weakness, 
sensory deficits, visual impairment and slurred speech. 
3.3.8 ILAE classification of epilepsy syndromes and epilepsy aetiology 
Classifications of patients’ seizures, epilepsy type, electroclinical syndrome and aetiology was 
performed by the primary investigator (JS) and cross checked by an associate supervisor who is a 
Paediatric Neurologist and Epileptologist (DG). Both the primary investigator and the associate 
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supervisor were blinded to the results of the antibody testing at the time of performing the 
classification.  
Classification of patients into an epilepsy syndrome was made by reviewing the child’s age, 
neurological and developmental state, seizure semiology (at onset and on follow up), EEG, imaging 
and other relevant investigations findings.  
The latest proposed ILAE classification was used for this purpose (Berg et al., 2010). The major 
difference of the latest ILAE 2010 report to previous reports was the replacement of the previous 
terms “idiopathic” with “genetic”, “symptomatic” with “structural-metabolic”, and “cryptogenic” with 
“unknown” (see Chapter 1). 
The following categories were used for the patients’ classification: 
3.3.8.1 Electroclinical Syndromes (n=33) 
Patients who had an electroclinical syndrome “as described in ILAE classifications (Engel, 2001, 
Berg et al., 2010)” were classified as such irrespective of the aetiology of their epilepsy and its 
syndrome. For example patients with epileptic spasms and hypsarrythmic EEG were classified as 
West syndrome despite some of these patients having a known structural or metabolic cause. The 
syndromes were described according to the patient age as per ILAE classifications. 
In addition to the electroclinical syndromes described in the latest ILAE classification we found that 
some of our patients had generalised seizures with no underlying structural brain lesion or other 
neurological signs or symptoms. These patients do fit into the old classification “idiopathic 
generalised epilepsy” which is presumed to be genetic (Engel, 2001). The term “idiopathic” is not 
recommended by the new ILAE classification by Berg et al; however we used it to classify these 
patients as we did find it useful in this setting- these patients were classified as “idiopathic generalised 
epilepsy not otherwise specified”, see Table 3-3. 
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3.3.8.2 Epilepsy attributed to structural-metabolic causes (n=33) 
Patients who did not fit into any electroclinical syndrome were classified (as per the ILAE 2010 
recommendation) on the basis of presence of metabolic diseases or structural abnormalities of the 
brain such as malformation of cortical development, neurocutaneous syndromes, infections and other 
structural or metabolic causes, see Table 3-3 and 3-4. 
3.3.8.3 Epilepsy of unknown cause (n=30) 
The term “epilepsy of unknown cause” was used to classify other patients who do not fit into an 
electroclinical syndrome and who have no known structural, metabolic or genetic cause for their 
epilepsy. These patients were further sub-classified according to whether the seizures were focal, 
generalised or spasms. In some patients it was difficult to determine whether their epilepsy was focal 
or generalised as they had both focal and general seizures and EEG was normal or showed both focal 
and generalised abnormalities, and the term “undetermined” was used in these cases as per the 
previous ILAE commission report (Roger et al., 1989). 
3.3.8.4 Seizures that are traditionally not diagnosed as a form of epilepsy (n=18) 
Patients with epileptic seizures that are not traditionally diagnosed as a form of epilepsy were kept in 
a separate group. This included the following groups: 
1. Febrile seizures (n=7) were defined as seizures occurring in previously normal children aged 
6 months-5 years, who had a documented temperature of 37.8 C
◦
 (axillary) or 38.5 C
◦
 (rectal) 
or higher at the time of the presenting seizure (Berg et al., 1992) in the absence of CNS 
infection or inflammation or another cause for the seizures. Upon follow-up these children 
either developed no further seizures or had further febrile seizures and developed no 
neurological or developmental abnormalities. Children who presented with febrile seizures 
but developed afebrile or unprovoked seizures later on (particularly if they had family history 
of epilepsy) were classified as febrile seizure plus (FS+). Children who continued to have 
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febrile seizures with significant neuro-developmental deterioration were classified as Dravet 
Syndrome, if the other clinical and age characteristics were consistent with Dravet syndrome. 
2. Acute symptomatic (provoked) seizure (n=9) was the term used for children who had 
systemic insults at the time of presentation, including systemic infections (without fulfilling 
the above criteria for febrile seizures), or other acute CNS insult (Beghi et al., 2010, Beleza, 
2012). We did not include patients with encephalitis here as some patients with encephalitis 
developed long term epilepsy. Instead we classified the encephalitis patients in the subgroup 
attributed to structural metabolic causes (see Table 3-3). Patients who had encephalitis are 
described in more details at the end of this section. 
3. Unprovoked seizure (n=2) was the term used to describe a single seizure occurring in the 
absence of any identified systemic or CNS insult. Patients with unprovoked seizures are 
thought to have a different risk of seizure recurrence (Beghi et al., 2010). 
The ILAE classification and electroclinical syndromes of the 114 patients are presented in Table 3-3. 
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Table ‎3-3 Epilepsy ILAE classification/electro-clinical syndromes and others  
 (as per the recommended structure by Berg et al 2010) 
ILAE classification/ electro-clinical syndrome  
 
Patients 
(number) 
Electroclinical syndrome (n=33)
 a
 
Infancy    
 West syndrome 9
 b
 
 Benign infantile epilepsy 3 
 Dravet Syndrome 3 
 Myoclonic epilepsy in infancy (MEI) 1 
Childhood    
 Lennox Gastaut Syndrome (LGS) 4
 c
 
 Febrile seizures plus (FS+) 2 
 Panayiotopoulos syndrome 2 
 Epilepsy with myoclonic atonic seizures 2 
 Benign epilepsy with centrotemporal spikes 
(BECTS) 
1 
 Childhood absence epilepsy (CAE) 1 
 Late onset Childhood occipital epilepsy 
(Gastaut type) 
1 
Adolescence    
 Autosomal dominant epilepsy with auditory 
features (ADEAF) 
1 
Idiopathic generalised epilepsy 
(not otherwise specified) 
d
 
 3 
Epilepsy attributed to structural-metabolic causes (n= 33) 
 Infections/inflammation   
 Encephalitis  11
 e
 
 Rasmussen Syndrome 1 
 Malformation of cortical development (MCD) 10 
 Perinatal insults 5 
 Metabolic  3
 f
 
 Neurocutaneous syndrome 3 
Epilepsies of unknown cause (n=30) 
 Focal  16 
 Generalised 7 
 Spasms  4 
 Undetermined   3 
Conditions with epileptic seizures that are traditionally not diagnosed as a form of epilepsy (n=18) 
 Febrile seizures  7 
 Acute symptomatic (provoked seizures)   
 Infection mediated 7
 g
 
 Posterior reversible encephalopathy 
syndrome (PRES) secondary to 
hypertension 
1 
 Asthma 1 
 Single unprovoked seizure  2 
Total  114 
 
 120 
 
 
a
  "The arrangement of electroclinical syndromes does not reflect etiology" (Berg 2010) 
b
  3 genetic, 2 metabolic (Congenital glycosylation disorder), 1 structural (perinatal insult), 3 unknown 
c
  2 structural (malformation of cortical development, holoprosencephaly), 2 unknown 
d 
 "Idiopathic generalised epilepsy" was used here though not part of the new classification, as the investigators 
found it useful for these patients 
e
  Encephalitis patients include the following: five with potential infectious aetiology, one with dopamine 
receptor 2 encephalitis, and five not otherwise specified. 
f 
 MELAS, Propionic acidemia, Ornithine transcarbamylase deficiency 
g
 These patients had a systemic infection that was presumed to have provoked the seizure, but no evidence of 
CNS infection or inflammation, and either had no fever or were outside the age definition for febrile seizures. 
The precipitating infections were gastroenteritis (n=3), URTI (n=2), H1N1 influenza (n=1), fever alone (n=1). 
 
3.3.8.5 ILAE aetiology classification  
A second level of classification was performed according to the aetiology of epilepsy regardless of the 
epilepsy syndrome classification- this was performed by the primary investigator (JS) blinded to the 
results on antibody studies.  
96 out of the 114 patients had epilepsy and were classified according to the aetiology of their epilepsy 
irrespective of their epilepsy syndrome into structural-metabolic (n=36), genetic (or presumed 
genetic) (n=25), and unknown (n=35), see Table 3-4. The remaining 18 patients had conditions with 
epileptic seizures that are traditionally not diagnosed as a form of epilepsy and were not included in 
this aetiology classification, although they are included in Table 3-4 for completeness. Patients with 
these conditions are generally thought to have a genetic predisposition for their seizures. 
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Table ‎3-4 Epilepsy aetiology classification for patient cohort as per Berg 2010 
Aetiology  Patients 
(number) 
Structural- metabolic (n=36) 
Infection/inflammation (n=12)   
 Encephalitis 11 
 Rasmussen Syndrome  1 
Malformation of cortical 
development (MCD) (n=12) 
  
 Focal cortical dysplasia (FCD) 5* 
 Polymicrogyria  3 
 Subcortical band heterotopias  1 
 Periventricular nodular heterotopia 1 
 Pachygyria 1 
 Holoprosencephaly 1 
Metabolic (n=5)   
 Congenital Disorders of Glycosylation  2 
 Ornithine transcarbamylase deficiency  1 
 Propionic acidemia   1 
 MELAS 1 
Perinatal insult (n=6)   
 Occipital gliosis secondary to neonatal 
hypoglycaemia 
2 
 Cerebral atrophy secondary to old ischaemic 
infarctions 
2 
 Encephalomalacia secondary to intraventricular 
hemorrhage (prematurity) 
2 
Neurocutaneous syndrome (n=3)   
 Tuberous sclerosis 1 
 Neurofibromatosis type 1 1 
 Sturge Weber Syndrome 1 
Genetic (n=25) 
Presumed genetic (n=20)  20 
Chromosomal (n=3)   
 Trisomy 21 2 
 Tetrasomy 15 1 
Monogenic (n=2)   
 SCN1A  1 
 PCDH19 1 
Unknown (n=35) 
Conditions with epileptic seizures that are traditionally not diagnosed as a form of epilepsy (n=18) 
Febrile seizures (n=7)  7 
Acute symptomatic seizures 
(provoked) (n=9) 
  
 Systemic infection  (n=7)   
 Gastroenteritis  3 
 URTI  2 
 H1N1 influenza 1 
 Fever  1 
 Posterior reversible encephalopathy syndrome 
(PRES) secondary to hypertension  
1 
 Asthma  1 
Unprovoked seizures (n=2)  2 
Total   114 
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*one patient had FCD presumed secondary to genetic abnormality (14q21deletion), we elected to keep in 
structural metabolic group rather than genetic. 
 
Encephalitis (n=11) 
Eleven patients had encephalitis as per Tables 3-3 and 3-4. All patients fulfilled criteria of 
encephalitis as per Granerod (Granerod et al., 2010). As this group was heterogeneous in aetiology we 
describe these patients in more details here. A potential infectious cause was found in five patients 
including: a virus isolated from CSF (n=2) (enterovirus and human herpes simplex virus 6), positive 
serology (n=2) (mycoplasma pneumoniae and adenovirus) and positive nasopharyngeal aspirate (n=1) 
(influenza B virus). One patient had basal ganglia encephalitis and was dopamine receptor 2 positive 
(Dale et al., 2012). Five patients had no aetiology found. Two patients had clinical and radiographic 
features of limbic encephalitis (one with positive human herpes simplex virus 6 and one with no 
aetiology found).  
3.3.9 Controls 
The control group used in this study is different to that used in Chapter 2. This control group consisted 
of hospital patients who had serum collected as part of their routine investigations (for infectious or 
immunological tests) during the year 2007. This group included 65 control patients (27 females, mean 
age 9 years, median 9.14 years, range: 1-16 years). The underlying medical problems were 
immunologic/ inflammatory or allergic (n=28), haematologic/oncologic (n=20) or other medical 
condition (n=14), see Table 3-5. 
The 65 control patients were tested at the same time as the patients for the following antibodies: 
LGI1, CASPR2, contactin-2, NMDAR, GAD, Gly R (n=65) and VGKC-complex (n=62, due to run 
out of samples for three controls).  
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Table ‎3-5 Classification of control group (n=65) 
Group Subgroup Patients 
(number) 
Immune/allergic/inflammatory (n=28) 
 Type 1 diabetes mellitus 8 
 Asthma/food allergies 5 
 Crohn disease/ulcerative colitis 4 
 Familial periodic fever 3 
 Systemic lupus erythematosis 3 
 Immunodeficiency 2 
 Arthritis (post streptococcal) 1 
 Uveitis  1 
 Idiopathic thrombocytopaenia purpura 1 
Hematologic/oncologic (n=21) 
 Acute leukemia 9 
 Neuroblastoma 3 
 Fanconi Anaemia 2 
 Wiscott Aldrich Syndrome 2 
 Familial platelet disorder 2 
 Hemophagocytic lymphohistiocytosis 1 
 Osteosarcoma 1 
 Bone marrow transplant (for Adrenal 
Leukodystrophy) 
1 
Other  medical (n=16) 
 Respiratory (Cystic fibrosis, 
bronchopulmonary dysplasia) 
3 
 Nutritional  and growth (poor weight gain, 
growth delay) 
3 
 Endocrine (Thyroid dysgenesis, multiple 
endocrinopathies) 
2 
 Recurrent infections (no immunodeficiency) 2 
 Cardiac (cardiomyopathy) 1 
 Gastrointestinal (chronic diarrhea) 1 
 Acute infection 1 
 Post viral fatigue and positive ANA 1 
 Tic disorder, Tourette syndrome 1 
 Prader Willi syndrome 1 
Total   65 
 
3.3.10 Statistics 
Fisher exact test was used to calculate the P value and analyse 2x2 contingency tables for categorical 
data, while Mann-Whitney test was used to compare continuous data. 
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3.4 Results of neuronal antibodies 
3.4.1 Results of patients (n=114) 
11 out of 114 (9.65%) patients with seizures were positive for one or more of the tested antibodies, 
VGKC-complex (n=6), NMDAR (n=4) and CASPR2 (n=3). Two patients were double positive for 
VGKC-complex and NMDAR Abs. None of the patients was positive for LGI1 or GAD antibodies. 
3.4.1.1 Clinical features of positive patients (n=11) 
The 11 positive patients (4 females) had a mean age of 4.4 years (median 3.4, age range 0.5-10 years). 
The positive cases are presented in Table 3-6. 
All 11 patients had new onset seizures; however on further review one patient (case 11) had a possible 
febrile seizure at the age of 23 months. Nine patients had no preexisting neurologic abnormality and 
two had pre-existing developmental delay, which was severe in one. These two patients with 
preceding neurological abnormalities had underlying neurologic conditions including microform 
holoprosencephaly in one, and dysmorphic features and possible undiagnosed syndrome in the other. 
Four patients had medical conditions including Diabetes Insipidus (n=1), Crohn’s disease (n=1), short 
stature (n=1) and hip dysplasia (n=1). There was family history of epilepsy in one patient and of 
febrile seizures in a further patient.  
The presenting seizure was focal in six, generalised in 4 and focal with secondary generalisation in 
one. The presenting seizure was associated with fever in one patient (case 6). One patient had status 
epilepticus at presentation of 45 minutes duration (case 8). Early seizure recurrence in the first 48 
hours of presentation occurred in seven out of the 11 patients. 
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Table ‎3-6 Demographic, clinical, electrographic and imaging features of positive patients (n=11) 
No. Age 
and 
sex 
Seizure type at 
onset/early 
seizure 
recurrence 
Associated 
features 
EEG * MRI Seizure type on 
follow up 
 
Number 
of AED on 
follow up 
(months) 
ILAE classification Ab positivity $ 
1 2.5M Focal 
dyscognitive/+ 
Nil Epileptic: left fronto-
temporal 
Seizure: left temporal  
Normal Focal dyscognitive, 
atypical absence 
1 (11) 
 
Epilepsy of unknown 
cause (focal-temporal 
lobe) 
VGKC (293) 
2 4.9M Focal versive/- Nil  Epileptic: generalised 
with bifrontal lead  
Normal Generalised tonic 
clonic 
1 (6) Epilepsy of unknown 
cause (undetermined) 
VGKC (193) 
3 3.4M Generalised 
tonic clonic/+ 
Nil  Slowing: right 
posterior 
Normal Generalised tonic 
clonic, atonic 
2 (6) Epilepsy of unknown 
cause (generalised) 
VGKC (182) 
4 1.5F Focal 
dyscognitive/+ 
Motor deficit 
(ataxia) 
Normal  Normal Focal dyscognitive, 
atypical absence 
1 (17) Epilepsy of unknown 
cause (focal) 
VGKC (133) 
5 0.5F Focal tonic with 
secondary 
generalisation/+ 
Intercurrent 
infection 
Slowing: right 
temporal  
Epileptic: central 
Normal Focal tonic with 
secondary 
generalisation 
1 (11) Epilepsy of unknown 
cause (focal) 
CASPR2 (2) 
6 7M Focal tonic 
clonic/- 
Intercurrent 
infection 
Fever 
Not done Not done No follow up - Acute symptomatic 
(provoked) seizure 
CASPR2 (1) 
7 10M Focal 
myoclonic/+ 
Encephalopathy 
Motor deficit 
(hemiparesis) 
Slowing: generalised 
Epileptic: left 
parietal. 
 
Left parietal 
hyperintensity 
Focal  2 (13) Epilepsy attributed to 
metabolic cause 
(MELAS) 
CASPR2 (2.5) 
8 4.5M Focal 
dyscognitive/- 
Nil  Slowing: right 
occipital.  
Normal No follow up - Epilepsy of unknown 
cause (focal-
occipital) 
NMDAR (1.5) 
9 3M Generalised 
Myoclonic /+ 
Encephalopathy 
Behavioural 
alteration 
Slowing: generalised 
Epileptic: right 
frontal. 
Corpus callosal 
dygenesis, 
frontal 
heterotopia  
Mixed (myoclonic, 
tonic, atonic) 
4 (12) Lennox- Gastaut 
syndrome 
NMDAR (1.5) 
10 8F Generalised 
tonic/- 
Preceding 
infliximab 
infusion 
High voltage 
generalised spike and 
slow wave 
Generous 
ventricles 
Tonic, myoclonic 1 (10) Epilepsy of unknown 
cause (generalised) 
VGKC (368) 
NMDAR (1.5) 
11 3F Generalised 
tonic clonic/+ 
Intercurrent 
infection 
Normal Asymmetric 
hippocampi 
Generalised tonic 
clonic  
2 (7) Febrile seizure plus 
(FS+) 
VGKC (233) 
NMDAR (1.5) 
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* EEG abnormal findings described in the following order when present: slowing and location, epileptic activity and location, seizure and onset. + present, - Absent 
 
$ VGKC Abs >100pM are considered positive, CASPR2 score of more than 1 and NMDAR score of more than 1.5 are considered positive (0 no binding- 4 strong binding)
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The associated features on presentation included: intercurrent infection (n=3), encephalopathy 
(n=2), motor impairment (n=2) (ataxia and right hemiparesis), behavioural alteration (n=1) 
and fever (n=1). One patient had infliximab infusion one day prior to seizures onset for the 
treatment of her Crohn’s disease (case 10). 
All 11 patients were admitted to hospital with a mean duration of hospital stay of 3.72 days 
(median 3 days, range 2-11 days). None of the 11 patients required admission to the intensive 
care unit.  
3.4.1.2 Investigations of positive patients  
An EEG was done in 10 out of the 11 positive patients and was abnormal in eight. Slowing 
was present in five cases (focal in four and generalised in one) and epileptic discharges were 
present in six cases (focal in four and generalised in two). A tonic seizure with left temporal 
onset was recorded in one patient (case 1). 
MRI brain was done in 10 out of 11 patients and was abnormal in four. One had a known 
preexisting structural abnormality. The abnormalities found include generous CSF spaces 
(n=1), asymmetry in hippocampi without abnormal signal (n=1), corpus callosum dysgenesis 
and periventricular heterotopia (n=1) and focal cortical hyperintensity suggestive of MELAS 
(n=1). MRI was diagnostic in two cases (MELAS and heterotopia). 
CSF analysis was performed in four cases. The following CSF indices were negative or 
normal in tested patients: cell count (n=4), protein (n=3), oligoclonal bands (n=3), culture 
(n=4) and PCR for HSV (n=1) and enterovirus (n=1). CSF neopterin was elevated in one out 
of three tested at 68 nmol/L (normal <30) (case1). 
Other positive investigations performed for the patients include low serum sodium 128 (case 
6), elevated serum lactate (3.6 mmol/L, normal <2.0) and positive m.3243A>G mutation 
suggestive of MELAS (case 7), parainfluenza virus detected in nasopharyngeal aspirate (case 
5), and duplication of chromosome 7 found on array-comparative genomic hybridization (a-
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CGH) (case 1). This duplication involved a segment of 0.24 Mb in bands q22.3 to q31.1 and 
contained 7 known genes, two of which are associated with OMIM-listed disease (SLC26A4 
& SLC26A3) but none of these genes have been associated with seizures. The same 
duplication was found in his mother who is healthy. It was concluded that the duplication is a 
familial variant and of no clinical significance. 
3.4.1.3 Treatment of positive patients 
Four patients out of the 11 positive patients received acute treatment for their first seizure 
including phenytoin (n=3) and midazolam (n=1). Nine patients received long term 
antiepileptic drugs (AED). None of the 11 positive patients received steroids or IVIG at any 
stage. 
3.4.1.4 Outcome of positive patients  
Two cases were lost to follow up (cases 6 and 8). The mean length of follow up for the 
remaining nine cases was 10.33 months (median 11 months, range 6-11 months). 
All of the nine patients with follow up had ongoing epilepsy and one had drug resistant 
epilepsy (case 9). At the time of follow up five patients were on one AED, three were on two 
AEDs and one was on four AEDs. Two patients had a new neurologic or developmental 
deficit (other than epilepsy) including speech impairment and hyperactivity (case 3), and 
motor deficit and behavioural alteration (case 5). 
3.4.1.5 ILAE Classifications of positive patients 
The 11 Ab positive patients had the following ILAE epilepsy classifications: electroclinical 
syndrome (n=2), epilepsy attributed to structural metabolic causes (n=1) and epilepsy of 
unknown cause (n=7). The 11th patient had an acute symptomatic seizure (which is not 
considered a form of epilepsy). 
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The positive patients in different categories of ILAE classifications are presented in Figure 
3.3 as a percentage of the total patients in each group. Only 2/ 33 patients with an 
electroclinical syndrome (6.1%) had positive antibodies (cases 9 and 11), which was not 
significantly different to the positive Abs in the control group, see below (3/65, 4.6%). Case 9 
had Lennox Gastaut Syndrome (LGS) and antibodies to NMDAR, and case 11 had febrile 
seizures plus with antibodies to both the NMDAR and VGKC-complex.  
Only 1/ 33 patients with epilepsy attributed to a structural-metabolic cause (3%) had positive 
antibodies (case 7) which was not significantly different to the controls. Case 7 had MELAS 
and was positive for CASPR2 antibodies.  
In comparison, 7/30 of patients with epilepsy of unknown cause (23.3%) had positive 
antibodies, which was significantly different to the controls (4.6%, p=0.01, Fisher’s exact). Of 
these seven antibody positive patients with epilepsy of unknown cause, four had VGKC-
antibodies only (cases 1-4), three of whom presented with focal seizures, and three had early 
seizure recurrence (cases 1, 3 and 4). Case 5 had CASPR2 antibodies, presented with focal 
tonic/clonic seizures and had intercurrent infections. Case 8 was positive for NMDAR-Abs 
and had focal dyscognitive seizures and focal status epilepticus on presentation. Case 10 was 
double positive for NMDAR and VGKC-complex and had a number of co-morbidities 
including developmental delay and treatment resistant Crohn’s disease; she presented with 
seizures following an infliximab infusion, a monoclonal antibody used to treat autoimmune 
diseases which has been previously associated with seizures (Brigo et al., 2011). 
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Figure ‎3.3 ILAE classifications of patients positive for one or more antibodies 
 (expressed as percentage of total). 
 
3.4.1.6 Comparison between positive and negative patients with seizures 
There was no difference in the demographic features of positive and negative patients. There 
were seven males out of the 11 positive patients (63.63%) compared to 49 males out of the 
103 negative patients (47.57%) ( p=0.36, Fisher's exact test). The age mean was 4.39 years for 
both positive and negative patients (p value 0.42, Mann-Whitney test). The median age for 
positive patients was 3.4 years and that for the negative patients was 2 years. The mean for 
serum sample collection time (from seizure onset) was 17.55 days for the positive patients 
and 40 days for the negative patients (P=0.16, Mann-Whitney test). The median time for 
serum sample timing was 4 days for positive patients and 20 days for negative patients. 
There was no significant difference between the positive and negative seizure patients in 
clinical characteristics including past medical history, presenting seizure type, associated 
features or outcome, see Table 3-7. 
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There was a statistically significant difference in the classification of epilepsy between 
positive and negative patients. The proportion of antibody positive patients in the epilepsy of 
unknown cause category (7/11; 63%) was significantly higher compared to the remaining 
antibody negative patients  (23/103; 22 %; p=0.007, Fisher’s exact test). Moreover, in the 
antibody positive patient group, 4 out of 11 had focal epilepsy of unknown cause (36.4%) 
compared with only 12 of the 103 antibody-negative patients  (11.7%; p=0.047, not corrected 
for multiple comparisons), see Table 3-7. 
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Table ‎3-7 Comparison of features of positive and negative cases by ILAE Classification and 
clinical characteristics 
Characteristic Presence of 
characteristic in Ab 
positive patients 
(%) n=11 
Presence of 
characteristic in Ab 
negative patients 
(%) n=103 
P value 
Past medical history 
Previously normal (n=78) 9 (81.81) 69 (66.99) 0.50 
    
First Seizure  
Focal  7 (63.63) 49 (47.57) 0.36 
Generalised  4 (36.36) 38 (36.89) 1.00 
Status epilepticus 1 (9.09) 20 (19.41) 0.69 
Early seizure recurrence 7 (63.63) 70 (67.96) 1.00 
    
Hospitalisation (n=101) 11 (100.00) 90 (87.38) 0.36 
Intensive care (n=18) 0 (0.0) 18 (17.48) 0.21 
    
Associated features 
Fever  1 (9.09) 20 (19.41)  0.69 
Infection   3 (27.27) 28 (27.18) 1.00 
Encephalopathy  2 (18.18) 31 (30.08) 0.51 
Movement disorder 0 (0.0) 5/ (4.85) 1.00 
Behavioural abnormality 1 (9.09) 26 (25.24) 0.45 
Cognitive abnormality 0 (0.0) 12 (11.65) 0.60 
Motor deficit 2 (18.18) 15 (14.56) 0.67 
    
Outcome 
Ongoing epilepsy 9 (81.81) 75 (72.82) 0.72 
New deficit 2 (18.18) 30 (29.13) 0.73 
Developmental delay  0 (0.0) 16 (15.53) 0.36 
Behavioural /psych 
impairment 
2 (18.18) 16 (15.53) 0.68 
Cognitive impairment 0 (0.0) 17 (16.50) 0.36 
    
ILAE Classification 
Electroclinical syndrome (n=33) 2 (18.18) 31 (30.1) 0.51 
Epilepsy attributed to structural-
metabolic causes (n=33) 
1 (9.09) 31 (30.1) 0.18 
Epilepsy of unknown cause 
(n=30) 
7 (63.64) 23 (22.33) 0.007 
Epilepsy of unknown 
cause (focal) 
4 (36.36) 12 (11.65) 0. 047 
Epilepsy of unknown 
cause (generalised) 
2 (18.18) 5 (4.85) 0.14 
Epilepsy of unknown 
cause (spasms) 
0 (0.0) 4 (3.88) 1.00 
Epilepsy of unknown 
cause (undetermined) 
1 (9.09) 2 (1.94) 0.26 
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3.4.2 Results of controls (n=65) 
Three out of 65 controls (4.61%) were positive for any of the tested antibodies including 
VGKC-complex Abs (n=2) and NMDAR Abs (n=1). None of the controls tested positive for 
CASPR2, LGI1 or GAD Abs.  
3.4.2.1 Clinical features of the positive controls (n=3) 
The three positive controls were as follows: 
1. Control 1 (VGKC 497pM): a 3 year old male with type 1 diabetes mellitus and no 
neurologic condition on four years follow up. 
2. Control 2 (VGKC 200pM): a 2 year old male with vomiting illness and poor weight 
gain with no neurologic abnormality. He had no natural follow up recorded. 
3. Control 3 (NMDAR score 2) : a 8 year old male with relapsed acute lymphocytic 
leukemia treated with bone marrow transplant which was complicated by chronic 
graft versus host disease. He had no neurological abnormality on four years follow 
up. 
3.4.3 Comparison between positive seizure patients and positive controls 
11 out of 114 patients (9.65%) and 3 out of 65 controls (4.62%) were positive for any of the 
tested antibodies with no statistical significance (p=0.26 Fisher's exact test). There was also 
no significant difference for the individual antibodies between patients and controls; see 
Table 3-8.  
However when positive patients in the epilepsy of unknown cause category are compared to 
controls there is a significant difference (see section 3.4.1.5 above). 
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Table ‎3-8 Comparison of the results of individual antibodies testing for patients and 
controls 
Antibody Definition of 
positivity 
Patients 
positive 
Controls 
positive 
P value 
VGKC >100 pM 6/114 2/62* 0.71 
LGI1 >1.0 0/114 0/65 1.0 
CASPR2 >1.0 3/114 0/65 0.55 
NMDAR >1.0 4/114 1/65 0.65 
GAD >100U/ml 0/114 0/65 1.0 
Gly R >2.0 0/114 0/65 1.0 
*62 tested for VGKC Abs due to samples exhaustion 
3.5 Discussion  
3.5.1 Methods and characteristics of cohort 
This study represents a cohort of children presenting with new onset seizures at a tertiary 
children hospital in Sydney, Australia. The cohort consists of a heterogeneous group of 
patients with epilepsy and epileptic seizures with a wide spectrum of severity and aetiology, 
including febrile seizures, acute symptomatic seizures due to various infectious and metabolic 
causes, epilepsies within the spectrum of defined electroclinical syndromes, epilepsies due to 
structural and metabolic causes, epilepsies caused by genetic defects and epilepsies of 
unknown cause. The patients were not selected according to the possibility of an autoimmune 
cause for their seizures (see inclusion criteria). Many patients in the cohort were young and 
complex, required intensive acute treatment or had ongoing refractory epilepsy as they 
represent an inpatient sample rather than a community outpatient sample. 
The cohort description and classification represented a challenging exercise particularly at a 
time where the ILAE classification and terminology is evolving. The investigator(s) found the 
revised ILAE 2010 classification easy to use however in a few patients I needed to revisit the 
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previous classifications, such as for patients with "idiopathic generalised epilepsy". The 
investigator(s) performed the classification blinded to the results of antibody testing. 
3.5.2 Results 
3.5.2.1 Patients results 
The positive patients among the whole cohort were 11 out of 114 (9.65%), which is not 
different to adult studies examining epilepsy cohorts (McKnight et al., 2005, Brenner et al., 
2013). However when the patients in our study were separated according to their epilepsy 
classification seven out of the 30 patients with epilepsy of unknown cause (23.3%) and four 
out of 16 patients with focal epilepsy of unknown cause (25%) were positive for neuronal 
antibodies. 
The four patients with positive VGKC-complex Abs were negative for LGI and CASPR2, a 
finding that is similar to children previously reported with positive antibodies against VGKC-
complex (Dhamija et al., 2011, Illingworth et al., 2011, Suleiman et al., 2011a) and different 
to adults where the target antigens in most patients with VGKC-complex antibodies were 
found to be LGI1, CASPR2 or contactin 2 (Irani et al., 2010a, Lai et al., 2010). It is likely that 
the VGKC-complex antibodies in children bind to other antigenic targets that are yet to be 
found or to the potassium channel itself. The four patients with positive VGKC-complex 
antibodies had epilepsy of unknown cause, and three had focal seizures at onset. The seizures 
were of temporal lobe onset in at least one patient (case 1). 
In this cohort three patients tested positive for CASPR2 antibodies, which have not been 
identified in children before, however these patients tested negative for the VGKC complex 
antibodies in the radioimmunoassay and would have been missed with standard VGKC 
complex-Ab screening. The three patients with positive CASPR2 antibodies had focal 
seizures at presentation, with secondary generalisation in one.  
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None of the VGKC-complex or CASPR2 antibodies positive patients had a phenotype typical 
of limbic encephalitis, suggesting that neuronal antibodies can be present beyond the 
spectrum of these recognised syndromes, especially in children.  
The two patients with positive NMDAR Abs had epilepsy in the absence of classic 
autoimmune NMDAR encephalitis. One patient with NMDAR Abs presented with focal 
dyscognitive seizures likely of occipital lobe origin, and one patient had a mixed seizure 
disorder and structural brain malformation. This is similar to adult cases described with new 
onset epilepsy associated with NMDAR Abs who also predominantly had extratemporal 
seizures (Niehusmann et al., 2009). Additionally, two patients, both presenting with 
generalised seizures, were positive for both NMDAR and VGKC-complex Abs; the finding of 
two or more neuronal Abs is well recognised (Pellkofer et al., 2010, Haberlandt et al., 2011, 
Irani et al., 2011b) and may reflect a wider activation of the immune system, likely by 
infections or possibly as a secondary response to neuronal damage. 
The significance of the finding of two positive patients with known structural or metabolic 
cause for their epilepsy (case 7: MELAS and case 9: holoprosencephaly) is unclear and the 
antibody findings in these patients are likely to be either clinically irrelevant, or represent dual 
pathology. An association of neuronal surface (NMDAR) Abs has previously been reported in 
MELAS (Finke et al., 2012). 
The investigations performed for the positive patients including CSF studies and brain 
imaging were unremarkable, a finding that is not uncommon in children with neuronal 
antibodies (Suleiman et al., 2011a). Only one patient out of four who had CSF studies had 
evidence of CNS inflammation evident by raised CSF neopterin (case 1). It is also interesting 
to note that 22 out of 55 patients tested had elevated CSF neopterin, a marker of CNS 
inflammation (Dale et al., 2009a). While some of those patients with positive neopterin had 
an inflammatory cause for their seizures (encephalitis or systemic infection), the others had 
different aetiologies and syndromes such as Dravet and West Syndromes and myoclonic 
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astatic epilepsy. It is possible that inflammation may play a role in a number of epilepsy 
syndromes, either as a primary phenomenon (such as autoimmunity), or as a secondary 
phenomenon (such as in neurodegeneration).  
Nine of the 11 positive patients with recorded follow up had ongoing epilepsy but 
unfortunately, none of the 11 positive patients received immunotherapy. These patients did 
not develop long term cognitive or behavioural impairment although the follow-up was short 
and detailed neuropsychology was not done. This is in contrast to our previously described 
patients with VGKC-complex Abs who had poor outcome (Suleiman et al., 2011a). This may 
indicate that a wider range of seizure phenotypes is associated with neuronal antibodies 
including milder forms of epilepsy. One could hypothesise that immunotherapy, if given, 
might have improved the epilepsy outcome in these patients. 
3.5.2.2 Control results 
The control group consisted of children with various immunological, oncological and medical 
conditions and three controls out of 69 were positive for one of the tested antibodies although 
they did not have apparent neurological symptoms. This level of positivity is higher than in 
adult control cohorts (McKnight et al., 2005, Brenner et al., 2013). The ability to develop 
antibodies in response to circulating pathogens or environmental factors may be higher in 
children, particularly in those who are already unwell. It is possible that these positive 
controls could be at risk of future neurological dysfunction if the antibodies remain sustained, 
for instance during disruption of the blood brain barrier secondary to infection for example.  
Two of the positive controls had conditions that can potentially result in immune disturbances 
namely type 1 diabetes mellitus (control1) and bone marrow transplant and 
immunosuppressant drugs (control 3). It is also possible that the presence of neuronal 
antibodies in these controls is an epiphenomenon or secondary to structural damage or 
immune activation, therefore results should be interpreted in the clinical context of the 
individual patient.   
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3.5.3 Limitations of the study and future directions 
This cohort represents a hospitalised, severe, young and co-morbid sample rather than a 
community or outpatient sample. The cohort would probably have been more antibody-
positive if patients with a known cause for their epilepsy (such as structural and genetic) had 
been excluded, and if patients with other autoimmune diseases or patients with evidence of 
CNS inflammation had been positively selected (Suleiman et al., 2013a).  
The significance of positive serum antibodies in the controls, and in some patients with a 
known alternate aetiology for their epilepsy is uncertain and raises some questions about the 
specificity of these serum antibodies in patients with seizures. CSF testing could possibly 
improve the sensitivity and meaning of the positive results (particularly for NMDAR) 
(Lancaster and Dalmau, 2012), however CSF testing was not performed in this study due to 
limited sample availability. 
Further studies targeting patients with focal seizures of unknown cause might shed more light 
into the importance of these antibodies in this subgroup of patients with epilepsy. CSF testing 
of selected patients might help in understanding the significance of positive results. Future 
studies should also examine the effects of immune therapies in these patients.  
It is important to note that finding a cause for epilepsy depends on how much investigations 
are performed and classifying patients into "epilepsy of unknown cause" category can be 
inaccurate particularly if investigations are incomplete or inadequate. Moreover epilepsy can 
be multifactorial and genetic defects can be associated with structural abnormalities (Shorvon, 
2011).  
3.6 Conclusions 
This study is the first to examine a relatively large cohort of children with new onset seizures 
and apply the latest ILAE classification and test them for neuronal antibodies. 
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The findings in this study suggest that a proportion of children with epilepsy of unknown 
cause might have neuronal antibodies as a cause for their epilepsy, in particular those with 
focal epilepsies. We suggest that antibody testing be part of the extended work up of these 
patients, in addition to other tests that are usually performed in this setting including high 
resolution imaging, genetic and metabolic studies. The current ILAE classification does not 
incorporate ‘autoimmunity’ in the aetiology or epilepsy classification. We suggest that an 
"immune or autoimmune" category is added to the list of structural metabolic causes in the 
epilepsy classification. Alternatively an additional aetiological category of "immune" or " 
inflammatory" may be added to the current list of genetic, structural metabolic and unknown 
causes. The fact that the role of these antibodies in the associated seizure and epilepsy  
syndromes in not fully understood and a whether the immune system plays a primary or 
secondary role here might make the addition of this category a bit complicated. 
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Chapter 4 Case Series and Proposed Guidelines for the 
Identification of Autoimmune Seizures in Children 
Acknowledgment 
This chapter is a slightly modified version of the published work in paper 3 in Appendix 
6 (Suleiman et al., 2013a). 
4.1 Introduction 
The association between autoantibodies and central nervous system (CNS) disease is 
increasingly recognised. Serum and CSF antibodies that bind to neuronal cell surface proteins 
including channels and receptors have the potential to be pathogenic and cause CNS disease. 
By contrast onconeuronal antibodies are typically targeted against intracellular antigens and 
not thought to be directly pathogenic (Vincent et al., 2011a, Bien et al., 2012). Recently 
antibodies that bind extracellularly and are associated with CNS disorders have been called 
“neuronal surface antibodies” (NSAbs) and the disorders associated with these NSAbs are 
called “neuronal surface antibody syndromes” (NSAS) (Zuliani et al., 2012). There are well 
defined CNS syndromes associated with NSAbs where seizures are an important feature. 
Examples include NMDAR encephalitis in which 76 to 83 % of patients will have focal, focal 
dyscognitive or generalised seizures (Dalmau et al., 2007, Dalmau et al., 2008, Irani et al., 
2010b, Dalmau et al., 2011, Irani and Vincent, 2011), and VGKC-complex antibody 
associated autoimmune limbic encephalitis (including LGI1 and CASPR2 antibodies) in 
which patients often have temporal lobe seizures (Irani et al., 2010a, Lai et al., 2010).  In 
addition, faciobrachial dystonic seizures are seen in adults in association with LGI1 
antibodies and often precede the onset of the limbic encephalitis (Irani et al., 2011b). Other 
NSAbs less frequently found in adults with limbic encephalitis are AMPA and GABAB 
receptor antibodies (Lai et al., 2009, Lancaster et al., 2010, Boronat et al., 2011). Antibodies 
to GAD have been associated with limbic encephalitis (Malter et al., 2010).  Although GAD 
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is an intracellular antigen and therefore GAD Abs themselves may not be pathogenic, it is 
possible that unrecognised NSAbs may coexist with GAD Abs (Zuliani et al., 2012). 
Zuliani et al proposed guidelines for the recognition, testing and treatment of suspected 
autoimmune CNS disorders. They used clinical criteria, supportive features, neuronal 
antibody testing and the response to immune therapy to classify patients into categories of 
definite, probable and possible NSAS, see Tables 4-1 and 4-2 (Zuliani et al., 2012).  
Lancaster and Dalmau have proposed an alternative laboratory based algorithm for 
identification and assessment of antibodies to neuronal cell-surface antigens using cell based 
assays as well as rat brain immunohistochemistry and cultures of neurons for serum and CSF 
antibody binding (Lancaster and Dalmau, 2012). 
Table ‎4-1 Criteria and supportive features used in the work up for suspected NSAS 
(Zuliani et al., 2012). 
 
 
 
 
 
 
 
 
 
 
NSAbs: neuronal surface antibodies. 
The following three clinical criteria are used to suggest a possible immune mediated 
cause associated with NSAbs 
1. Acute or subacute (<12 weeks) onset of symptoms. 
2. CNS inflammation manifested by at least one of: 
a. CSF pleocytosis, oligoclonal bands or elevated IgG index; 
b. MRI abnormality including increased signal in the mesiotemporal lobe 
(LE- like syndrome) and cerebellar enhancement (cerebellitis) or 
functional imaging abnormalities including hypermetabolism on 
positron emission tomography or hyperperfusion on single proton 
computed tomography; 
c. inflammatory neuropathology on biopsy. 
3. Exclusion of other causes (infection, trauma, toxic, metabolic, tumour, previous 
CNS disease). 
The following supportive features would strengthen the suspicion for a suspected NSAS: 
1. History of other antibody mediated condition (e.g  myasthenia gravis) or organ 
specific autoimmunity. 
2. Preceding infection, febrile illness or viral disease-like prodromes. 
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Table ‎4-2 Classification diagnosis of suspected NSAS 
 (Zuliani et al., 2012) 
 
 
 
 
 
 
 
 
 
 
 
In children, NMDAR encephalitis is well described (Florance et al., 2009), whilst limbic 
encephalitis has been described in association with a number of different autoantibodies 
including VGKC-complex Abs (Haberlandt et al., 2011, Suleiman et al., 2011a).  In children 
there are other epileptic conditions where immune-mediated mechanisms are suspected such 
as Febrile-Infection Related Epilepsy Syndrome (van Baalen et al., 2010) or Fever-Induced 
Refractory Epileptic Encephalopathy in School-aged children (Nabbout et al., 2010, Nabbout 
et al., 2011), both called FIRES. Previous terms used to describe similar syndromes include 
Devastating Epileptic Encephalopathy in School-aged Children (DESC) (Mikaeloff et al., 
2006) and Acute Encephalitis with Refractory Repetitive Partial Seizures (AERRPS)  
(Sakuma, 2009). These conditions are characterised by new onset refractory focal status 
A diagnosis of definite, probable or possible NSAS is based on clinical presentation, 
NSABs testing and the response to immunotherapy, as follows: 
A diagnosis of definite NSAS can be made if: 
 known NSAbs are present in serum or CSF  
 AND there is response to immunotherapy.  
A diagnosis of probable NSAS can be made if: 
 known NSAbs are present,  
 OR there are other neuronal Ab markers (GAD, unknown neuronal 
surface or neuropil antibodies), or at least one of the supportive features 
above (history of other Ab mediated disorder or preceding 
fever/infection) are present AND there is a response to immunotherapy. 
A diagnosis of possible NSAS can be made if clinical criteria are suggestive and 
no known NSABs are found, if: 
 other neuronal Ab markers are present (GAD, unknown neuronal 
surface or neuropil),  
 OR at least one of the above supportive features are present,  
 OR there is a response to immunotherapy.  
 
 143 
 
epilepticus, preceded by fever or infection in previously normal children, followed by a 
chronic phase of refractory focal epilepsy and severe neurologic impairment (Sakuma et al., 
2010). The cause of these conditions is unknown and underlying immune mechanisms have 
been proposed (Sakuma et al., 2010, Specchio et al., 2010, Nabbout et al., 2011).  
Here we present a representative case series of 13 children suspected to have an autoimmune 
basis for their epilepsies. We propose modified guidelines for the recognition of autoimmune 
epilepsy and apply these guidelines to the 13 children with suspected autoimmune epilepsy to 
test their utility. 
4.2 Methods 
4.2.1 Cases identification 
Through our clinical practice at The Children's Hospital at Westmead (CHW) we identified 
cases with seizures that may have an autoimmune aetiology. The neurology department at 
CHW is a busy tertiary children's hospital, which sees 300-400 children with new onset 
seizures per year, as well as other acute and chronic neurological diseases in children. The 
patients presented in this cohort were discussed in detail by JS and RCD as they were 
suspected to have an autoimmune cause of their epilepsy (as defined below), and were 
investigated for neuronal surface antibodies. This cohort does not represent all children with 
encephalitis (of all aetiologies) seen during this time (n=33) which are currently being studied 
in a separate research study. 
It is also likely that other autoimmune epilepsies were missed by the investigating team and 
were not tested for antibodies. Instead this cohort should be considered a representative 
sample of children with suspected autoimmune epilepsy, which were used to test the utility of 
the modified guidelines. 
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We suspected autoimmune epilepsy in children with acute or subacute onset of seizures once 
other causes (infection, structural, metabolic or genetic) were excluded, and when any of the 
features described in Table 4-3 were present. 
Here we describe 13 representative patients seen over a three and a half year period (late 2008 
to mid 2012), who we suspected may have an autoimmune cause for their epilepsy, and who 
had serum available for testing for neuronal antibodies. No patients have been previously 
reported except case 5 (Suleiman et al., 2011a) and this case was included to test the utility of 
the guidelines. This study was approved by the hospital ethics committee. 
10 patients had serum testing in the acute phase of their illness while in three the serum was 
from the chronic symptomatic phase. All samples were taken before immune therapy, if 
given. Antibody assays were all performed in Oxford UK using previously published methods 
(Irani et al., 2010a) apart from case 3, which was performed in National NMDAR antibody 
referral laboratory (Brisbane, Australia). 
4.2.2 Proposed modified guidelines 
In order to improve recognition and diagnosis of children with suspected autoimmune 
epilepsy, we modified the guidelines proposed by Zuliani et al for identification of children 
with neuronal surface antibodies syndromes (Table 4-3). Then, based on antibody testing and 
the response to immunotherapy (when given), we proposed five categories for classification 
(in descending order of likelihood of autoimmune epilepsy) including definite, probable, 
possible, unlikely or unknown autoimmune epilepsy (Table 4-4, Figure 4.1). We applied the 
modified guidelines to our 13 cases to test their usefulness (Table 4-5).  
The main differences to the Zuliani et al guidelines for adults include the following: 
 In children a paraneoplastic cause of epilepsy is very rare and testing for onconeural 
antibodies is rarely necessary. However; girls with positive NMDAR Abs should be 
screened for ovarian teratomas. 
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 In children fever and intercurrent infections are common and less likely to be a 
supportive feature for an autoimmune process as has been proposed in adults, so this 
was not used as one of the supportive features (Zuliani et al., 2012).    
 We used elevated CSF neopterin as an additional marker of CNS inflammation (Dale 
et al., 2009a). 
 In Zuliani et al., abnormalities on functional imaging including hypermetabolism on 
positron emission tomography or hyperperfusion on single proton computed 
tomography were used as features to suggest CNS inflammation. However there is 
inadequate research to demonstrate their ability to discriminate epilepsy aetiologies in 
children and therefore we did not include these features. 
 Antibodies included in the guidelines are those available at international laboratories 
including antibodies against VGKC-complex proteins, LGI1 and CASPR2, NMDAR 
and GAD. Positive GAD antibodies in neurological disease is defined as >1000IU/ml. 
We did not include neuronal binding or neuropil antibody testing (using 
immunohistochemistry or immunofluorescence on rat brain tissue) for recognisable 
staining patterns (Lancaster and Dalmau, 2012) as these are done in research settings 
and are less available to clinicians routinely.  
 Response to immunotherapy was defined as significant clinical improvement of 
encephalopathy or reduction of seizures as judged by the treating clinicians. We 
accept the subjective nature of this, and the fact that there are a number of 
confounders that could be responsible for improvements such as the concomitant 
change in anti-epileptic drugs. 
 We incorporated patients who did not receive immunotherapy into the classification 
either because an immune mediated mechanism was not initially suspected or because 
of spontaneous improvement. 
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Table ‎4-3 Criteria and supportive features to suspect autoimmune epilepsy  
(modified from Zuliani et al.2012) 
 
 
 
 
 
 
 
 
 
 
 * Criteria and supportive features are for guidance purpose only; to suggest potenti 
 
 
* It is recognised that epilepsy is more common in many autoimmune disorders including multiple 
sclerosis, systemic lupus erythematosus (SLE), type 1diabetes mellitus (T1DM), coeliac disease and 
autoimmune thyroid disease (Vincent and Crino, 2011). 
NSAbs: neuronal surface antibodies. 
 
  
The following two clinical criteria are used to suspect autoimmune epilepsy associated 
with NSAbs (both are needed) 
4. Acute or subacute (<12 weeks) onset of symptoms. 
5. Exclusion of other causes (CNS infection, trauma, toxic, tumour, metabolic, 
previous CNS disease). 
The following supportive features would strengthen the suspicion of autoimmune 
epilepsy (patients should have at least 1 of the following): 
a. The presence of a well defined clinical syndrome such as NMDAR or limbic 
encephalitis 
b. CNS inflammation manifested by at least one of: 
i. CSF pleocytosis (defined as >5 white cells/mm3) or presence of 
oligoclonal bands, elevated IgG index or elevated neopterin (defined as 
>30 nmol/L) 
ii. MRI abnormality compatible with an inflammatory or autoimmune 
encephalitis including increased signal in the mesiotemporal lobe (LE- 
like syndrome) 
iii. Inflammatory neuropathology on biopsy 
c. History of other antibody mediated condition (e.g. myasthenia gravis), organ 
specific autoimmunity or other autoimmune disorders.* 
d. Improvement in clinical state after immunotherapy  
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Table ‎4-4 Classification categories of suspected autoimmune epilepsy in children 
(identified using the criteria and supportive features in Table 4-3, modified from Zuliani et 
al). 
 
 
 
 
 
 
 
 
 
 
 
 
 
* Patients in this category may move to a different category if they receive immunotherapy, such as 
“possible” if they respond or “unlikely” if they did not respond to immunotherapy. 
 
 
 
 
 
 
Classification categories expressing the likelihood of autoimmune epilepsy based on the 
presence of NSAbs and GAD Abs and the response to immunotherapy (see also Figure 
4.1): 
Definite autoimmune epilepsy is present if: 
 known NSAbs are present in serum or CSF  
 AND there is response to immunotherapy 
Probable autoimmune epilepsy is present if: 
 known NSAbs are present and no immunotherapy responsiveness 
demonstrated (immunotherapy unsuccessful or not given) 
 OR GAD antibodies are present AND there is response to 
immunotherapy 
Possible autoimmune epilepsy is present if known NSAbs are negative and: 
 GAD antibodies are present and no immunotherapy responsiveness 
demonstrated (unsuccessful or not given) 
 OR GAD antibodies are negative and there is a response to 
immunotherapy 
Unlikely autoimmune epilepsy is present if: 
 known NSAbs and GAD are negative and there is no response to 
immunotherapy 
Unknown autoimmune epilepsy* is present if: 
 known NSAbs and GAD are negative and immunotherapy is not given 
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Figure ‎4.1 Flow chart for approach to children with seizures of suspected autoimmune aetiology 
 
OCB: oligoclonal bands, *: onconeuroral Abs testing is rarely necessary in children, #: if NMDAR look for ovarian teratoma in females, @: GAD positivity is 
defined as >1000u/ml. Immunotherapy refers to high dose steroids and/or intravenous immunoglobulins. (Flow chart modified from Zuliani et al., 2012).
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Table ‎4-5 Patients with suspected autoimmune epilepsy: clinical criteria, supportive features and classification 
(as per guidelines, see Figure 4.1) 
Case  Age 
(years
)/sex 
Epilepsy 
diagnosis 
Acute 
or sub 
acute 
onset 
Seizure type Associated 
features 
CSF 
inflammat
ion 
(pleocyto
sis/ OCB/ 
neopterin) 
MRI 
inflammator
y changes 
Presence  of 
autoimmune
/ Ab 
mediated 
disease 
NSAbs/ 
GAD 
Abs 
Response to 
immune 
therapy 
Outcome Guidelines 
classification 
1 3/F NMDAR 
encephalitis 
+ Focal 
dyscognitive 
Encephalopathy, 
aphasia, 
dystonia, 
emotional 
lability, relapse 
-/+/+ - - NMDAR 
CSF and 
serum 
+ (steroid, 
IVIG, 
mycophenolate
) 
Relapse, 
normal in 
between 
Definite  
2 6/M NMDAR 
encephalitis 
+ Focal 
dyscognitive 
Encephalopathy, 
agitation, 
chorea, dystonia 
+/-/+ - - NMDAR 
CSF and 
serum 
+ (steroid and 
IVIG) 
Recovery Definite  
3 7/F NMDAR 
encephalitis 
+ Focal 
dyscognitive 
Encephalopathy, 
agitation, 
irritability, 
dyskinesia, 
fever 
+/- /ND + - NMDAR 
CSF and 
serum 
+ (steroids, 
IVIG) 
Recovery  Definite  
4 1/F 
 
VGKC 
encephalitis 
+ Focal 
dyscognitive
, focal 
motor with 
automatism 
Encephalopathy, 
fever, 
respiratory 
infection 
+/ND/+ + - VGKC 
serum 
(421 pM) 
Not given Recovery  Probable  
5 15/F VGKC 
encephalitis 
+ Focal, 
secondary 
generalised  
tonic clonic, 
SE  
Encephalopathy,  
memory deficit, 
fever  
+/-/+ - - VGKC 
serum 
(640 pM) 
+ (steroids, 
IVIG) 
Relapse, 
normal in 
between 
Definite 
6 12/F 
 
Limbic 
encephalitis 
+ Focal 
dyscognitive 
Encephalopathy, 
lethargy, 
behavioural 
alteration 
ND + +/- (ANA) negative Not given Cognitive, 
psychiatric 
impairment 
Unknown  
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7 15/F Limbic 
encephalitis 
+ Focal 
dyscognitive
, secondary 
generalised 
tonic clonic 
Encephalopathy, 
cognitive 
deficits, fever 
+/-/+ - - negative + (steroid) Recovery  Possible 
8 
 
3/M 
 
FIRES + Focal, status 
epilepticus 
Encephalopathy, 
irritability, 
fever, rash,  
-/-/+ - - negative -  (steroids, 
IVIG, 
rituximab) 
Severe 
neurologic 
disability, 
refractory 
epilepsy 
Unlikely  
9 8/F 
 
FIRES + Focal, 
secondary 
generalised 
Encephalopathy, 
headache, 
confusion, fever 
+/-/+ +/- - negative -  (steroids) Severe 
neurologic 
disability, 
refractory 
epilepsy 
Unlikely  
10 1/F 
 
Epileptic 
encephalopat
hy 
+ Epileptic 
spasms 
Encephalopathy, 
developmental 
delay 
-/+/+ - - VGKC 
serum 
(201 pM) 
+ (steroids) Developmen
tal delay 
Definite  
11 13/F 
 
Suspected 
autoimmune 
epilepsy 
(JME) 
+ Myoclonic, 
generalised 
tonic clonic  
Hyperthyroidis
m  
ND - + (Grave’s 
disease and 
T1DM) 
negative Not given Ongoing 
epilepsy  
Unknown  
12 3/F Suspected 
autoimmune 
epilepsy 
+ Focal 
dyscognitive 
 Myasthenia  ND - + 
(MG) 
negative + (steroids) Steroid 
dependent 
myasthenia 
Possible  
13 4/F Suspected 
autoimmune 
epilepsy 
+ Absence  Ataxia  -/ND/ND No + (T1DM) GAD 
(3000U/
ml) 
Not given Cognitive 
impairment, 
ongoing 
epilepsy 
Possible  
 
Definitions: FIRES: Fever-Induced Refractory Epileptic Encephalopathy in School-aged children, SE: status epilepticus, JME: Juvenile Myoclonic Epilepsy, OCB: 
oligoclonal bands, ND: not done, T1DM: type 1 diabetes mellitus, MG: myasthenia gravis, NSAb: neuronal surface antibody, Encephalopathy is defined by the presence of 
acquired reduction in consciousness, cognitive dysfunction or behavioural change lasting more than 24 hours, and not related to the post-ictal state 
 +: present or positive, -: absent or negative 
Abnormal ranges: Pleocytosis: CSF white blood cells > 5cells/mm
3
, Neopterin elevated >30 nmol/L, VGKC serum >100pM, High titre cut-off for GAD antibodies in 
neurological disease is 1000U/ml. 
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4.3 Results 
The 13 patients with seizures of suspected autoimmune origin (11 females, age range 1-13 years, 
mean 6 years) are presented in Table 4-5. All patients had other potential causes for their seizures 
excluded. All 13 patients had new onset seizures and at least one supportive feature of CNS 
inflammation or the presence of other autoimmune diseases (Table 4-3 and 4-4). Three patients had 
the clinical characteristics of NMDAR encephalitis (all with CSF and serum NMDAR antibodies), 
two had encephalitis associated with VGKC-complex antibodies, two had features suggestive of 
limbic encephalitis (with negative antibodies), three had epilepsy in association with other 
autoimmune diseases (one with GAD antibodies), two had FIRES, and one had epileptic 
encephalopathy with CNS inflammation (VGKC antibody positive).  
Seven patients out of the 13 (53.9%) were positive for one of the tested antibodies including NMDAR 
(n=3), VGKC-complex (n=3) and GAD (n=1). Immunotherapy was given in nine patients, five with 
positive neuronal antibodies, and four negative. The immune therapy was steroids alone (n=4), 
steroids and IVIG (n=3), steroids, IVIG and mycophenolate (n=1) and steroids, IVIG and rituximab 
(n=1). All five patients with positive neuronal antibodies who received any immune therapy improved 
after receiving therapy, whereas only 2 of 4 with negative neuronal antibodies improved after 
receiving therapy.  Three out of the four patients who did not receive immunotherapy had poor 
outcome including ongoing epilepsy, cognitive and psychiatric impairment (Table 4-5).  
Patients were classified according to the proposed modified guidelines (Table 4-4, figure 4.1) and 
their classification is presented in Table 4-5. Five patients had definite, one had probable, three had 
possible, two had unlikely and two had unknown autoimmune epilepsy. 
We present the case histories for nine of the 13 patients in detail below as representative examples. 
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4.5 Case histories 
1) Case 3: NMDAR encephalitis 
A previously well seven year old girl had a prodromal illness of headache, fevers, vomiting and 
abdominal pain followed by right leg pain and difficulties with fine motor skills. Memory impairment 
and cognitive decline followed. Three weeks into her illness she developed an absence-like seizure 
with unresponsiveness and salivary drooling that lasted for 10 minutes. She had more episodes 
suggestive of focal dyscognitive seizures and was admitted to hospital, and treated with phenytoin and 
levetiracetam. She developed abnormal movements in the form of orobuccal dyskinesia, excessive 
blinking, non purposeful limb movements and excessive thrashing movements in her bed. Her 
behaviour was altered with agitation, irritability, inappropriate affect and mood swings. She had 
slurred and reduced speech and became confused and disoriented.  
Neuropsychological assessment showed significant impairment in language and verbal intellect as 
well as mild impairment in processing speed and fluctuation in attention. EEG showed left temporal 
slowing and no epileptiform activity. CSF analysis revealed 15white cells/mm
3
 and MRI revealed 
hyperintensities in the right frontal, left temporal and insular cortex. Ovarian ultrasound was normal. 
NMDAR Abs were positive in serum and CSF and VGKC-complex Abs were negative. 
She was treated with intravenous pulse 30 mg/kg/day methylprednisolone for five days followed by 
oral prednisolone weaning regimen over four weeks in addition to intravenous immunoglobulin at a 
dose of 2g/kg. Three weeks later she was reported by her family to be 90% back to normal and had no 
ongoing seizures or abnormal movements. Further doses of monthly IVIG over 3 months were given 
and associated with a full recovery. 
This patient had positive NMDAR antibodies and positive response to immunotherapy and applying 
the guidelines’ classification she has “definite” autoimmune epilepsy.  
2) Case 4: VGKC-complex Abs associated encephalitis  
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A previously well 15 month old girl presented after an upper respiratory tract infection with a 30 
minute new onset focal seizure involving the left side of the face and the left arm. At the hospital she 
had a low grade fever and was floppy, unresponsive and staring into space. She had more episodes of 
focal seizures consisting of facial twitching, staring and lip smacking. Seizures were treated with 
phenytoin, phenobarbitone and midazolam and stopped within five days of onset. Encephalopathy, 
cognitive or behavioural alterations were not prominent features of her illness once the seizures were 
controlled.  
EEG showed diffuse slowing of the background with superimposed fast activity and no epileptiform 
activity. CSF analysis revealed 6 white cells/mm
3 
and raised neopterin of 205 nmol/L (normal <30). 
CSF culture and viral PCR were negative. Mycoplasma IgM was positive using complement fixation 
test and there was no hyponatremia. MRI of the brain revealed T2 high signal in right basal ganglia, 
both temporal lobes and in the right parietal lobe. Testing of her serum from the acute illness revealed 
positive VGKC-complex Abs at 421 pM (normal <100pM) but negative antibodies against CASPR2, 
LGI1, NMDAR and GAD. 
Four months following her illness she was back to normal and continued to achieve developmental 
milestones appropriate to her age. She had no further seizures and her anti-epileptic drugs (AEDs) 
have been withdrawn. 
This patient was positive for a known NSAb (VGKC-complex Ab) but did not receive 
immunotherapy therefore she has “probable” autoimmune epilepsy. 
3) Case 6: Limbic encephalitis with negative NSAbs 
A previously well 12 year old girl presented to the local hospital with frequent “funny episodes” over 
six week period. The episodes started with nausea followed by confusion and disorientation, and 
lasted 60-90 seconds. She had lethargy, intermittent headache and behaviour alteration with episodes 
of agitation, screaming and confusion. The episodes were initially thought to be psychological until an 
EEG performed four weeks after discharge showed epileptiform activity in the right temporal region 
and MRI brain then showed swelling in the right hippocampus . She was commenced on 
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carbamazepine and referred to our hospital. She had ongoing temporal lobe seizures when she was 
reviewed at our hospital a few months after her acute illness. Repeated MRI scan at this time showed 
resolution of the right temporal lobe swelling and it was concluded that she had limbic encephalitis. 
Academic decline and emotional and behavioural abnormalities were reported, and 
neuropsychological testing showed difficulties in higher level thinking skills, attention, behaviour and 
emotional function.  
Three years following her acute illness the seizures have settled and carbamazepine was stopped. 
Repeat neuropsychological assessment showed persistent cognitive impairment. Autoimmune screen 
showed very high ANA titres at 1: 2560 (normal <1:40) with a strong centromere staining pattern, 
although further immunological investigations and clinical assessments failed to confirm a diagnosis 
of systemic autoimmune disease. Antibodies against VGKC-complex, NMDAR and GAD tested on 
serum collected three years after onset of her seizures were negative. 
This patient illness is consistent with autoimmune limbic encephalitis based on clinical presentation, 
MRI abnormality, and the associated high titre of ANA which supported an autoimmune tendency.  
Despite the clinical suspicion of limbic encephalitis, using the classification she has “unknown” 
autoimmune epilepsy as she was NSAbs and GAD Abs negative and received no immunotherapy. 
4) Case 8: Fever-Infection Related Epilepsy Syndrome- FIRES 
A previously well three year old boy presented with fever and blanching rash for a few days followed 
by irritability and reduced level of consciousness. He was semi-comatose on presentation to hospital 
and required intubation and ventilation. He had status epilepticus with frequent and prolonged focal   
seizures which were refractory to AEDs.  
CSF analysis revealed 4 white cells/mm3 and elevated neopterin at 264 nmol/L (normal <30). 
Extensive serological, microbial, metabolic and genetic testing did not reveal aetiology. EEG showed 
diffusely slow background with quasiperiodic multifocal high voltage epileptiform activity followed 
by periods of electrical attenuation and frequent multi-focal electrical and clinical seizures. MRI was 
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normal apart from nonspecific signal abnormality in the white matter of the frontal and occipital 
lobes. Subsequent MRI showed loss of white matter volume and increased signal in the 
periventricular areas. Antibodies against VGKC-complex, LGI1, CASPR2, NMDAR and GAD were 
negative. 
Intensive care treatment with multiple antiepileptic drugs and barbiturate induced coma as well as 
ketogenic diet did not help control his seizures. Early immunotherapy in the form of high dose 
intravenous pulse methylprednisolone at 30 mg/kg/day for three days followed by oral prednisolone 
for eight weeks and adjunctive intravenous immunoglobulin 2 g/kg followed by anti-CD20 antibody 
rituximab had no effect. 
After 64 days in intensive care he was discharged to the ward, and continued to have refractory focal 
seizures and significant neurological impairment. He was discharged home after eight months. 
Sixteen months later he had severe cognitive and developmental impairment, refractory focal epilepsy 
on six AEDs and prolonged hypogammaglobulinemia presumed secondary to rituximab treatment and 
requiring IVIG replacement. 
5) Case 9: FIRES 
A previously well eight year old girl presented with high fever, headache and lethargy, confusion with 
altered level of consciousness and proceeded to have frequent focal seizures which evolved into 
generalised seizures requiring intubation and ventilation. 
CSF analysis revealed 5 white cells/mm3 and elevated neopterin at 296 nmol/l (normal <30) but 
negative oligoclonal bands, viral PCRs and bacterial cultures. Extensive work up for infectious 
agents, immune screen and metabolic investigations were negative. Initial EEG showed diffuse high-
voltage slowing consistent with encephalopathic process. Subsequent EEGs showed burst 
suppression, multifocal epileptiform activity and focal electrical seizures alternating from both 
hemispheres. Initial MRI was normal and subsequent acute MRIs revealed meningeal enhancement, 
patchy areas of cerebral oedema and high signal in bilateral thalami and hippocampi. Subsequent MRI 
showed global cerebral and cerebellar atrophy and periventricular white matter high signal.  
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Intensive care treatment with mechanical ventilation, thiopentone and multiple antiepileptic drugs did 
not control her seizures. She received ketogenic diet and electroconvulsive treatment (ECT) without 
effect. She was given high dose intravenous methylprednisolone 30 mg/kg/day over 3 days with 
negative response. No other forms of immunotherapy were given.  
After eight months in intensive care she was discharged to the ward where she continued to have 
multiple daily focal seizures. She was discharged home after 20 months in hospital in vegetative state. 
Four years after her illness she remained in “minimally conscious state” with refractory focal seizures 
on multiple AEDs.  
Retrospective testing of serum stored form the acute illness for antibodies against VGKC-complex, 
LGI1, CASPR2, NMDAR and GAD were negative. 
Using the classification these two cases with FIRES have “unlikely” autoimmune epilepsy as they are 
negative for known NSAbs and GAD Abs and were unresponsive to immune therapy.  
6) Case 10: Epileptic encephalopathy with evidence of CNS inflammation 
This case was reported and published (Suleiman et al., 2011b), see Appendix 6, here we present a 
summary of her case history to apply the guidelines. 
A 13 month old girl was referred to our hospital with epileptic spasms with onset at four months of 
age and significant developmental delay. EEG showed slow background with high amplitude multi-
focal spike and slow-wave complexes compatible with “modified hypsarrhythmia” and consistent 
with epileptic encephalopathy. Brain MRI showed mild diffuse cerebral atrophy and mild delay in 
white matter myelination. Extensive metabolic testing was negative. CSF had no cells, but CSF 
neopterin was mildly elevated at 33.3nmol ⁄L (normal<28) and mirrored oligoclonal bands (OCBs) 
were detected in CSF and serum. 
Treatment with vigabatrin, pyridoxine, biotin and levetiracetam had minimal or no benefit. Over the 
next few months, the patient had no obvious clinical seizures; however, she made no progress in her 
development. She lived internationally and was two years old at the time of reassessment. Her EEG 
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remained encephalopathic with a modified hypsarrhythmic pattern; therefore oral prednisolone at 
40mg daily was started and was followed by improvement in the encephalopathic state with improved 
awareness and interactions noted by the family. Repeat EEG eight days after starting steroids showed 
improvement in hypsarrythmia.  
Retrospective testing of serum taken at 13 months of age was positive for VGKC-complex (201pmol ⁄ 
L, normal< 100pmol ⁄ L), but negative for LGI1, and CASPR2, NMDAR and GAD antibodies. 
This patient had positive VGKC-complex Abs and positive response to immunotherapy therefore she 
has “definite” autoimmune epilepsy. 
7) Case 11: Epilepsy, type 1 diabetes mellitus (T1DM) and autoimmune thyroid disease 
A 13 year old girl with well controlled T1DM presented with early morning episodes of shaking 
lasting a few minutes and often followed by confusion and fatigue. She developed early morning 
myoclonic jerks in the absence of hypoglycaemia and some of the episodes were associated with loss 
of consciousness. At this time she was noted to have recent loss of weight and had tachycardia, 
hypertension and goitre on examination. 
Thyroid function tests were consistent with hyperthyroidism. Thyroid antibodies were elevated 
including anti thyroglobulin antibodies 1314 U/ml (<60), anti thyroid peroxidase antibodies 105 U/ml 
(<35) and anti thyrotropin receptor antibodies 35.7 U/L (0 – 2). EEG showed generalised spike and 
wave discharges suggestive of idiopathic generalised epilepsy but MRI brain was normal. 
She was diagnosed with Graves’ disease and juvenile myoclonic epilepsy (JME), commenced on 
carbimazole for the treatment of thyrotoxicosis and her epilepsy was successfully treated with AEDs.  
Retrospective testing of her serum collected at the time of seizure onset was negative for VGKC-
complex, LGI1, CASPR2, NMDAR and GAD antibodies. 
This child had negative NSAbs and GAD Abs and received no immunotherapy and applying the 
guidelines she has “unknown” autoimmune epilepsy. 
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8) Case 12: Anti MuSK myasthenia gravis and epilepsy 
A previously healthy three year old girl presented with a four month history of ptosis and non-
conjugate eye movements with diurnal variation. Examination confirmed a fatigable ptosis and 
variable ophthalmoplegia, but no generalised muscle weakness. Mestinon test was associated with 
clinical improvement confirming the diagnosis of myasthenia. Serum AChR antibodies were negative 
however MuSK antibodies were positive with a titre of 0.87 nmol/L (normal <0.09). At the same time 
as the myasthenia she started to have staring episodes, occurring multiple times per day. Her EEG 
showed bilateral occipital epileptiform discharges (L>R) without photosensitivity consistent with a 
focal epilepsy. Her MRI brain was normal and autoimmune screen was negative. Antibodies against 
VGKC-complex, NMDAR and GAD were negative. 
 She was treated with carbamazepine and low dose oral prednisolone at 5 mg daily for four weeks 
with partial improvement then increased to 2 mg/kg/day with complete resolution of myasthenic and 
epileptic symptoms. Initial attempt to wean off steroid was associated with recurrence of ocular 
symptoms as well as seizures while she remained on AED thus steroids were maintained. After 17 
months of disease, she is steroid dependent despite adding azathioprine, but her ocular myasthenia 
gravis and seizures are in remission. Long term steroid treatment was associated with behavioural 
adverse side effects. 
Both the patient’s epilepsy and myasthenia gravis responded to immunotherapy particularly steroids. 
She was negative for NSAbs and GAD Abs and applying the guidelines to this case she has “possible” 
autoimmune epilepsy. 
9) Case 13 T1DM, Epilepsy, ataxia and high titre GAD antibodies 
A 4 year old girl with chronic ear infection, grommets, hearing impairment and speech delay 
presented with acute unsteadiness of gait, lethargy and irritability. She was febrile and had a rash 
thought to be consistent with a viral exanthem. She had difficulty obeying commands, was ataxic and 
had mild hand tremor; but no other focal neurologic findings.  
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MRI brain was normal and EEG showed paroxysmal epileptic discharges during sleep. CSF analysis 
showed no cells, normal glucose, protein and lactate and negative culture. Her symptoms recovered 
during her hospital stay over 5 days however she was noted to have infrequent staring episodes at the 
time of discharge. Her illness was thought to be consistent with an immune mediated ataxia with 
complete recovery. 
Five years following her acute ataxia she presented with new onset T1DM. She was reassessed by her 
neurologist for concerns about ongoing absence episodes that were associated with eye deviation, and 
thought to be consistent with focal seizures. However, the events were infrequent and required no 
treatment. The child had cognitive impairment and was attending a support class at school. EEG was 
normal and Video EEG was not performed. Testing of serum collected at the time of onset of DM 
showed highly elevated GAD antibody titre at 3000 U/mL and negative antibodies against VGKC-
complex, LGI1, CASPR2 and NMDAR. 
Applying the guidelines this patient has “possible” autoimmune epilepsy as she was negative for 
NSAbs but positive for GAD Abs and received no immunotherapy. 
4.6 Discussion  
The recognition of immune mechanisms in neurological disorders is important as this can prompt 
early treatment and may lead to better outcomes. The identification of specific and potentially 
pathogenic NSAbs is increasing and the spectrum of the clinical syndromes associated with NSAbs is 
widening (Zuliani et al., 2012). Recently guidelines have been developed to help in the diagnosis and 
management of adults with suspected NSAS (Zuliani et al., 2012). In children the lack of large studies 
regarding NSAbs and their related syndromes makes it harder to identify these cases, therefore 
guidelines may help in the identification of NSAS particularly when seizures are an important feature.  
In this study, we describe 13 representative patients with seizures of suspected autoimmune aetiology 
and we propose features for identification of these paediatric patients, and a classification system 
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testing the strength of evidence of autoimmune epilepsy based on the presence of neuronal antibodies 
and response to immunotherapy.  
There were some general features common to the cohort. Females were over-represented in this 
cohort, as is often described in autoimmune disorders in general. The seizures were often focal, and 
generally occurred in association with encephalopathy or other features of CNS dysfunction. 
Three cases had typical features of NMDAR encephalitis in children, as represented by case 3 
description. The NMDAR encephalitis patients generally had focal epilepsy, and the presence of 
psychiatric manifestations, behaviour alteration and movement disorder were strong indicators of 
NMDAR encephalitis. However it is possible that NMDAR Abs are present in children with epilepsy 
in the absence of the classic phenotype as has been described in adults (Niehusmann et al., 2009), and 
therefore testing for NMDAR Abs in children with suspected autoimmune seizures may provide 
further information about the spectrum of NMDAR antibody associated disease.  
Two cases had VGKC-complex Ab associated encephalitis, characterised by fever associated focal 
seizures and status epilepticus, one was previously reported in chapter 2 (case 5) and the clinical 
phenotype of the second newly reported case (case 4) was similar to our previously reported 
paediatric patients with VGKC-complex Abs associated encephalitis (Suleiman et al., 2011a). The 
seizure semiology was suggestive of temporal lobe onset, a finding that is commonly seen in both 
adults and children with this syndrome (Vincent et al., 2004, Suleiman et al., 2011a). In Case 4, 
Mycoplasma IgM was positive and was consistent with acute infection. Mycoplasma infection has 
been described in association with NMDAR encephalitis in children and may be a trigger of 
autoimmune CNS disorders (Florance et al., 2009). However, mycoplasma pneumoniae is a common 
cause of respiratory infections in children and positive mycoplasma serology may therefore be 
incidental in some patients (Waites and Talkington, 2004). Antibodies against LGI1 or CASPR2 
which have been identified as the target of VGKC-complex Abs in adults were negative in this case, a 
finding that is common in children with positive VGKC-complex Abs. It is possible that in children 
VGKC-complex Abs are targeted against other antigens in the VGKC-complex that are yet to be 
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identified. Patients with VGKC-complex Ab associated encephalitis often respond to immune therapy 
but spontaneous improvement can also occur (Irani et al., 2010a) as was the case in this patient.  
Case 6 had a syndrome of limbic encephalitis however NSAbs and GAD Abs were negative possibly 
due to late testing and the patient received no immunotherapy, her classification is "unknown". Early 
recognition, testing and treatment might have improved her outcome. Case 7 had a limbic encephalitis 
syndrome and was negative for NSAbs but responded to immune therapy and her classification is 
"possible".  Antibodies against AMPAR and GABABR (not tested) or other unrecognised NSAbs 
could be the cause of limbic encephalitis in these patients. The diagnosis of limbic encephalitis can be 
challenging in children, where its existence is reported but probably under-recognised (Haberlandt et 
al., 2011). The diagnosis of limbic encephalitis is partly clinical with new onset temporal lobe 
seizures and cognitive disturbance, sometimes associated with radiological mesial temporal or 
hippocampal changes. As hippocampal signal change is described in a proportion of children with 
febrile status epilepticus (Shinnar et al., 2012), it is difficult to discriminate radiologically seizure 
induced hippocampal swelling from limbic encephalitis. 
Cases 8 and 9 were typical of “FIRES” (van Baalen et al., 2010, Nabbout et al., 2011). Neuronal 
antibodies were negative and there was no response to immunotherapy in both patients. The absence 
of antibodies and the negative response to immune therapy make an autoimmune aetiology 
“unlikely”. Negative response to immunotherapy has been reported in a series of seven cases of 
FIRES, and NSAbs were negative in the tested patients (three tested for VGKC-complex Abs and one 
for NMDAR Abs) (Howell et al., 2012). In addition a series of 12 children with FIRES were negative 
for neuronal surface antibodies and GAD (van Baalen et al., 2012). There is one report of a boy with 
positive VGKC antibodies associated with FIRES who benefited from immunotherapy (Illingworth et 
al., 2011), however this case did not have a typical course of FIRES and it is possible that the case had 
VGKC-complex antibody associated encephalitis instead. The markers of CNS inflammation seen in 
our two cases (8 and 9) have been reported in the acute phase of FIRES, and may be explained by the 
extremely high seizure load, seizure-related neuronal injury or cytokine release (Howell et al., 2012). 
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Rather than an autoimmune epilepsy syndrome, FIRES may be a genetic channelopathy or a chronic 
epilepsy syndrome with explosive onset (Ismail and Kossoff, 2011, Howell et al., 2012).  
Case 10 had epileptic encephalopathy and epileptic spasms. This patient had positive VGKC-complex 
Abs and positive response to immunotherapy and “definite” autoimmune epilepsy when we applied 
the guidelines. However steroid responsiveness exists in patients with epileptic spasms even in the 
absence of antibodies or immune mediated aetiologies. 
Three of our cases had epilepsy in association with other autoimmune diseases including Type 1 
diabetes mellitus (T1DM) and autoimmune thyroid disease (case 11), anti MuSK myasthenia gravis 
(case 12), and T1DM and possible autoimmune ataxia (case 13). T1DM is a T cell mediated 
autoimmune disorder and there is an increased prevalence of epilepsy in children with this disease 
(Schober et al., 2012). Seizures can occur in Hashimoto’s encephalopathy, which is a rare association 
of autoimmune Hashimoto’s thyroiditis associated with Abs against thyroid peroxidase and 
thyroglobulin (Castillo et al., 2006). Patients described with Hashimoto encephalopathy present with 
broad clinical manifestations and are classically reported to be steroid responsive. The role of thyroid 
antibodies in Hashimoto encephalopathy is uncertain and the term “Steroid responsive 
encephalopathy associated with autoimmune thyroiditis” (SREAT) has been used to reflect the 
hypothesis that Hashimoto encephalopathy may be caused by unidentified neuronal autoantibodies 
(Castillo et al., 2002, Schauble et al., 2003). 
 Graves’ disease is an antibody mediated autoimmune disorder and JME has been previously 
associated with Grave’s disease, and may be due to thyroxine causing a lower seizure threshold (Su et 
al., 1993). Our case 11 was diagnosed to have juvenile myoclonic epilepsy (JME) based on her age, 
seizure phenotype and EEG abnormality. JME is considered to be a genetic epilepsy, and indeed in 
this case there was limited evidence that the epilepsy was autoimmune despite the presence of other 
autoimmune diseases, and her classification was “unknown” as she was negative for NSAbs and 
received no immunotherapy.  
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Seizures in association with anti MuSK Ab myasthenia gravis are rare but have been reported in an 
adult patient (Bhagavati et al., 2007) . Case 12 had anti-MuSK Ab associated myasthenia gravis and 
concurrent focal epilepsy. Her seizures did not respond to carbamazepine but improved when high 
dose steroids were used to treat her myasthenia gravis. It is possible that myasthenia gravis and 
epilepsy in our patient is a chance association, although both clinical entities presented, remitted and 
relapsed concurrently.  
Case 13 had seizures in the context of T1DM. This patient had an acute transient ataxia followed by 
chronic epilepsy, with very high GAD antibodies. GAD antibodies are associated with a variety of 
CNS syndromes including stiff person syndrome, immune ataxia, epilepsy and limbic encephalitis 
(Honnorat et al., 2001, Saiz et al., 2008, Malter et al., 2010). In our patient the immune mediated 
ataxia, cognitive impairment, focal epilepsy and high GAD antibodies were supportive of the 
autoimmune epilepsy hypothesis.  
Patients with epilepsy and other systemic autoimmune diseases may have other as-yet-unidentified 
NSAbs. However other explanations for increased epilepsy incidence in systemic autoimmune 
disorders include incidental coexistence, a common genetic predisposition, or secondary effects of the 
primary disease (Vincent and Crino, 2011).  
One important feature of the adult guidelines is that response to immunotherapy is used as a 
retrospective feature to help with classification. In other words the “guideline classification” cannot 
be completed until immunotherapy is used. Our modified guidelines partly address this issue and 
incorporate patients who did not receive immunotherapy. In our case series some patients did not 
receive immunotherapy either because an autoimmune aetiology was not initially suspected at 
presentation or due to spontaneous improvement without the need for immunotherapy. A positive 
response to immunotherapy was more common in patients who had positive NSAb (five out of five 
given immunotherapy) compared to those who were NSAb negative (two out of four). However, in a 
recent study of 48 children with suspected autoimmune encephalitis, only 21 had specific antibodies 
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detected, and beneficial treatment responses were seen in both antibody positive and negative groups 
(Hacohen Y, 2013). 
In our clinical practise over the last few years we have been increasingly using immunotherapy 
empirically once an underlying immune-mediated disorder is suspected whilst awaiting the specific 
investigations. Children suspected of potential autoimmune epilepsy undergo investigations to 
exclude infectious, toxic, metabolic or genetic causes, and neuronal surface and GAD antibodies are 
requested. Whilst awaiting the results of the neuronal antibodies, empiric immunotherapy may be 
commenced if the clinical syndrome is severe and impairing. We suggest that immunotherapy be used 
early in the disease course to optimise its potential effect. The regimen we have been using includes 
intravenous pulse methylprednisolone at 30 mg/kg/day for three days followed by a tapering course of 
oral prednisolone (variable duration of weeks to months according to the disorder), often in 
conjunction with intravenous immunoglobulins at 2 g/kg given over two days. Patients with partial 
response or no response after one to three weeks may receive further doses of intravenous 
immunoglobulins or plasma exchange if the condition is severe and concerning, and the autoimmune 
hypothesis remains possible. Patients who fail to respond or who have a partial response may be 
considered for second line therapy, such as rituximab or cyclophosphamide. However the side effect 
profile of these drugs is more concerning so a “risk versus benefit” assessment is necessary. In our 
case series immunotherapy was generally tolerated well particularly when given short term (such as 
the NMDAR encephalitis cases). Two patients developed significant side effects attributed to 
immunotherapy including behavioural alteration with prolonged steroid use (case 12) and prolonged 
hypogammaglobulinemia requiring IVIG replacement presumed to be secondary to rituximab (case 
8), a finding that has been previously described (Makatsori et al., 2012). Some patients with seizures 
of autoimmune aetiology can have complete recovery without immunotherapy (similar to case 4); 
however it is hard to predict which cases will spontaneously recover and therefore early 
immunotherapy is suggested when the patient is severely impaired. Similar treatment regimens have 
been used in adults with VGKC Ab positive encephalitis with good effect (Reid et al., 2009, Wong et 
al., 2010).  Although plasma exchange is used commonly in adults, the use of plasma exchange in 
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children as a modality of immune therapy is limited due to its invasiveness, the need for intensive care 
treatment and potential side effects. 
Although a positive response to immunotherapy supports immune mediated mechanisms, steroids 
(and IVIG to a lesser extent) are used in the treatment of refractory and severe epilepsies that are not 
proven to be autoimmune.  
In conclusion autoimmune mechanisms play an important role in a proportion of children presenting 
with seizures. We propose guidelines that may help clinicians in the approach to identify children 
with suspected autoimmune seizures. Although helpful, the guidelines are not perfect and only 
represent an attempt to identify and classify these patients. These guidelines do not predict treatment 
responsiveness or outcome. Future studies may improve the understanding of clinical phenotypes of 
autoimmune epilepsy in children and help further develop syndrome-specific and treatment oriented 
guidelines. 
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Chapter 5 Conclusions and Future Directions 
Here I summarise the findings in each of the studies and discuss the limitations of these studies as 
well as the potential directions for future research targeting autoimmune seizures in children. 
5.1 Autoimmune VGKC encephalitis 
The first study (see Chapter 2) aimed to investigate neuronal antibodies in children presenting with 
status epilepticus in the context of unexplained encephalitis, a presentation that is not uncommon in 
children. This study demonstrated that VGKC Abs are potentially an important cause for encephalitis 
with severe seizures in children. The affected children in our study had features similar to those 
described in adults with VGKC Ab encephalitis (Vincent et al., 2004), including encephalopathy, 
temporal lobe seizures and mild CSF abnormalities. However Brain MRI showed non-specific or 
minimal abnormalities in our patients, unlike adult patients who often have mesial temporal lobe 
signal abnormalities. The children who were positive for VGKC Abs in our study had poor outcome 
including ongoing epilepsy and cognitive impairment, although none of them received early immune 
therapy.  
This study was limited by its retrospective nature, the small number of patients, and the lack of acute 
immune therapy. Future studies need to examine larger cohorts of children with unexplained 
encephalitis where seizures are an important presenting feature and test them for the different known 
neuronal Abs, as well as other Abs that may become evident in the future. Studying the role of 
immunotherapy in these children and its effect on their neurological outcome is also important. A 
separate encephalitis study is being conducted at the same time at this hospital aiming to study 
children with different types of encephalitis, and test them for neuronal Abs. 
5.2 New onset seizures 
The second study (see Chapter 3) aim was to test a large cohort of children with new onset seizures 
for neuronal antibodies to examine their potential role in paediatric epilepsy. The patients' sera were 
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examined within six months of seizure onset (within two months in 75% of the cohort). We believe 
this is a relative strength of the study, as antibody testing in chronic epilepsy patients could possibly 
be associated with secondary immune abnormalities (i.e. epiphenomena). The study applied the latest 
version of the ILAE classification (Berg et al., 2010) at a time where the ILAE classification is 
evolving, which we consider a relative strength of this study. 9.7 % of tested children were positive 
for neuronal Abs including VGKC, CASPR 2 and NMDAR Abs. This study is the first to describe 
serum CASPR2 Abs in children with epilepsy. Seven out of the 11 antibody-positive patients (64%) 
had focal epilepsy of unknown cause and none of the positive patients had encephalitis.  The results of 
this study suggest that neuronal antibodies are present beyond the spectrum of encephalitis and may 
be an important cause of focal epilepsy of unknown cause in children. Focal seizures are also typical 
in adults with neuronal Abs (Quek et al., 2012). Many of the affected antibody-positive children in 
our study had ongoing epilepsy, although none of them received immune therapy.  
While this study is important and novel there are many limitations. The new onset seizure study tested 
a heterogeneous group of patients presenting to a tertiary hospital. The patients had a wide spectrum 
of seizures and epilepsies, including some with structural and metabolic causes. The yield of this 
antibody study might have been higher if the patients were selected on the basis of suspicion of 
autoimmune seizures (see Chapter 4), or if the patients with a known cause for their epilepsies were 
excluded.  
As this study found that neuronal Abs were more common in patients with focal epilepsy of unknown 
cause, we suggest that future studies target patients with focal epilepsy. Positive neuronal Abs were 
also found in some patients with a known structural or metabolic causes, as well as in some controls. 
The significance of this finding in not clear and studying larger cohorts of children with epilepsy and 
healthy controls are needed to help understand the specificity of neuronal Abs in these cases. It is 
likely that serum antibodies are not 100% specific, and therefore the results of Ab testing need to be 
interpreted in the clinical context. However as a screening investigation, one might accept a lower 
specificity for a higher sensitivity so no patient is missed. CSF testing for neuronal Abs might be 
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more specific than serum testing however this was not performed in our study due to sample 
limitation.  
We found neuronal antibodies in patients with epilepsy of unknown cause, and as these patients now 
have a "known" cause for their epilepsy, namely immune, we suggest that an "immune" category is 
added to the current ILAE classification to incorporate these patients. 
In this study none of the positive patients received immunotherapy, and future studies need to 
examine the role of immune therapy and the effect on epilepsy and neurological outcomes in these 
patients.  
5.3 Diagnostic guidelines study 
We studied a miscellaneous group of children presenting with seizures that were suspected to be of 
autoimmune origin, based on the presence of suggestive features such as CNS inflammation and the 
presence of other autoimmune disorders (Chapter 4). A proportion of these children were positive for 
neuronal antibodies, however we think that negative antibody testing does not fully exclude an 
autoimmune cause, as it is likely that there are as-yet-unidentified anti-neuronal antibodies. We 
proposed guidelines that might help clinicians in the identification and work up of children with 
suspected autoimmune seizures. We applied the proposed guidelines to the miscellaneous group of 
patients with seizures of suspected autoimmune origin, to test their usefulness. We think these 
guidelines are a starting point to approach these children while our understanding of autoimmune 
epilepsies in children continues to evolve. Evaluation of these guidelines applicability in larger, 
prospective cohorts will help validate their usefulness. 
These guidelines are clinically oriented, whereas a different laboratory based guideline has been 
recently proposed by Lancaster et al to identify autoimmune encephalopathy (Lancaster and Dalmau, 
2012).  These laboratory based guidelines used cell based assays as well as rat brain 
immunohistochemistry and cultures of neurons for serum and CSF antibody binding; however these 
methods are not readily available for clinicians but are important for research purposes. 
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Our proposed guidelines for identification of autoimmune seizures are limited by the lack of 
understanding of the phenotypic spectrum of autoimmune epilepsy in children. The guidelines 
represent a broad starting point. Future studies examining larger cohort of patients with suspected 
autoimmune seizures will help improve clinical and treatment specific guidelines. 
5.4 Other insights and future directions 
Children with VGKC complex Abs in our studies (in total 12 patients) were negative for LGI1, 
CASPR2 and contactin2, which were frequently found to be the targets of VGKC-complex Abs in 
adults. This suggests that VGKC-complex Abs in children are different to adults and might have other 
antigenic targets. Future directions should aim at identifying VGKC complex antigen(s) involved in 
antibody binding in children. Although we found CASPR2 Abs in some of our patients with new 
onset epilepsy (three cases) we have found no LGI1 antibodies in any of our patients, and it is 
possible that LGI1 Abs are restricted to adults with autoimmune encephalopathy. 
Many neuronal Abs are now known to be associated with epilepsy and seizures; however it is likely 
that many more are yet to be discovered. We think that some of the patients that are currently negative 
for the known neuronal Abs might be positive for other unidentified Abs, which means there are 
unidentified patients with autoimmune epilepsy. Future studies should aim at identifying other 
autoantigens involved in autoimmune epilepsy.  
The "pathogenicity" of these neuronal antibodies is an important area that needs further study. While 
the research so far indicates that some of these antibodies are pathogenic, it is possible that some of 
these Abs are secondary to cell damage (an epiphenomenon). 
Finally this thesis explores a possible epileptogenic cause, namely auto immune. It is hoped that early 
identification and intervention, in the form of immune therapy could improve outcomes. Early 
intervention treatment trials in children with suspected autoimmune epilepsy, particularly previously 
unknown focal epilepsy, are warranted. 
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6. APPENDICES 
Appendix 1 ILAE classification tables  
Tables 1 to 4 text is from Engel 2001 (Engel, 2001), Table 5 text is from Berg et al 2010 (Berg et al., 
2010). 
Table 1 Proposed diagnostic scheme for people with epileptic seizures and with epilepsy (Engel 
2001). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Epileptic seizures and epilepsy syndromes are to be described and categorized according to a system 
that uses standardized terminology, and that is sufficiently flexible to take into account the 
following practical and dynamic aspects of epilepsy diagnosis: 
1. Some patients cannot be given a recognized syndromic diagnosis. 
2. Seizure types and syndromes change as new information is obtained. 
3. Complete and detailed descriptions of ictal phenomenology are not always necessary. 
4. Multiple classification schemes can, and should, be designed for specific purposes (e.g., 
communication and teaching; therapeutic trials; epidemiologic investigations; selection of surgical 
candidates; basic research; genetic characterizations). 
This diagnostic scheme is divided into five parts, or Axes, organized to facilitate a logical clinical 
approach to the development of hypotheses necessary to determine the diagnostic studies and 
therapeutic strategies to be undertaken in individual patients: 
Axis 1: Ictal phenomenology, from the Glossary of Descriptive Ictal Terminology, can be used to 
describe ictal events with any degree of detail needed. 
Axis 2: Seizure type, from the List of Epileptic Seizures. 
Localization within the brain and precipitating stimuli for reflex seizures should be specified when 
appropriate. 
Axis 3: Syndrome, from the List of Epilepsy Syndromes, with the understanding that a syndromic 
diagnosis may not always be possible. 
Axis 4: Etiology, from a Classification of Diseases Frequently Associated with Epileptic Seizures or 
Epilepsy Syndromes when possible, genetic defects, or specific pathologic substrates for 
symptomatic focal epilepsies. 
Axis 5: Impairment, this optional, but often useful, additional diagnostic parameter can be derived 
from an impairment. 
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Table 2 Definitions of key terms (Engel 2001). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Epileptic seizure type: An ictal event believed to represent a unique pathophysiologic mechanism 
and anatomic substrate. This is a diagnostic entity with etiologic, therapeutic, and prognostic 
implications. (new concept) 
Epilepsy syndrome: A complex of signs and symptoms that define a unique epilepsy condition. This 
must involve more than just the seizure type: thus frontal lobe seizures per se, for instance, do not 
constitute a syndrome. (changed concept). 
Epileptic disease: A pathologic condition with a single specific, well-defined etiology. Thus 
progressive myoclonus epilepsy is a syndrome, but Unverricht–Lundborg is a disease. (new concept) 
Epileptic encephalopathy: A condition in which the epileptiform abnormalities themselves are 
believed to contribute to the progressive disturbance in cerebral function. (new concept) 
Benign epilepsy syndrome: A syndrome characterized by epileptic seizures that are easily treated, or 
require no treatment, and remit without sequelae. (clarified concept) 
Reflex epilepsy syndrome: A syndrome in which all epileptic seizures are precipitated by sensory 
stimuli. Reflex seizures that occur in focal and generalized epilepsy syndromes that also are 
associated with spontaneous seizures are listed as seizure types. Isolated reflex seizures also can 
occur in situations that do not necessarily require a diagnosis of epilepsy. Seizures precipitated by 
other special circumstances, such as fever or alcohol withdrawal, are not reflex seizures. (changed 
concept) 
Focal seizures and syndromes: Replaces the terms partial seizures and localization-related 
syndromes. (changed terms) 
Simple and complex partial epileptic seizures: These terms are no longer recommended, nor will 
they be replaced. Ictal impairment of consciousness will be described when appropriate for 
individual seizures, but will not be used to classify specific seizure types. (new concept) 
Idiopathic epilepsy syndrome: A syndrome that is only epilepsy, with no underlying structural brain 
lesion or other neurologic signs or symptoms. These are presumed to be genetic and are usually age 
dependent. (unchanged term) 
Symptomatic epilepsy syndrome: A syndrome in which the epileptic seizures are the result of one or 
more identifiable structural lesions of the brain. (unchanged term) 
Probably symptomatic epilepsy syndrome: Synonymous with, but preferred to, the term cryptogenic, 
used to define syndromes that are believed to be symptomatic, but no etiology has been identified. 
(new term) 
 172 
 
Table 3 Epileptic seizure types and precipitating stimuli for reflex seizures (Engel 2001). 
 
Self-limited seizure types 
Generalized seizures 
Tonic–clonic seizures (includes variations beginning with a 
clonic or myoclonic phase) 
Clonic seizures 
Without tonic features 
With tonic features 
Typical absence seizures 
Atypical absence seizures 
Myoclonic absence seizures 
Tonic seizures 
Spasms 
Myoclonic seizures 
Eyelid myoclonia 
Without absences 
With absences 
Myoclonic atonic seizures 
Negative myoclonus 
Atonic seizures 
Reflex seizures in generalized epilepsy syndromes 
Focal seizures 
Focal sensory seizures 
With elementary sensory symptoms (e.g., occipital and parietal lobe seizures) 
With experiential sensory symptoms (e.g., temporoparietooccipital junction 
seizures) 
Focal motor seizures 
With elementary clonic motor signs 
With asymmetric tonic motor seizures (e.g., supplementary motor seizures) 
With typical (temporal lobe) automatisms (e.g., mesial temporal lobe 
seizures) 
With hyperkinetic automatisms 
With focal negative myoclonus 
With inhibitory motor seizures 
Gelastic seizures 
Hemiclonic seizures 
Secondarily generalized seizures 
Reflex seizures in focal epilepsy syndromes 
Continuous seizure types 
Generalized status epilepticus 
Generalized tonic–clonic status epilepticus 
Clonic status epilepticus 
Absence status epilepticus 
Tonic status epilepticus 
Myoclonic status epilepticus 
Focal status epilepticus 
Epilepsia partialis continua of Kojevnikov 
Aura continua 
Limbic status epilepticus (psychomotor status) 
Hemiconvulsive status with hemiparesis 
Precipitating stimuli for reflex seizures 
Visual stimuli 
Flickering light: color to be specified when possible 
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Patterns 
Other visual stimuli 
Thinking 
Music 
Eating 
Praxis 
Somatosensory 
Proprioceptive 
Reading 
Hot water 
Startle 
 
Table 4 Epilepsy syndromes and related conditions (Engel 2001). 
 
Benign familial neonatal seizures 
Early myoclonic encephalopathy 
Ohtahara syndrome 
Migrating partial seizures of infancy 
West syndrome 
Benign myoclonic epilepsy in infancy 
Benign familial infantile seizures 
Benign infantile seizures (nonfamilial) 
Dravet’s syndrome 
HH syndrome 
aMyoclonic status in nonprogressive encephalopathies 
Benign childhood epilepsy with centrotemporal spikes 
Early-onset benign childhood occipital epilepsy (Panayiotopoulos type) 
Late-onset childhood occipital epilepsy (Gastaut type) 
Epilepsy with myoclonic absences 
Epilepsy with myoclonic–astatic seizures 
Lennox–Gastaut syndrome 
Landau–Kleffner syndrome (LKS) 
Epilepsy with continuous spike-and-waves during slow-wave sleep (other than LKS) 
Childhood absence epilepsy 
Progressive myoclonus epilepsies 
Idiopathic generalized epilepsies with variable phenotypes 
Juvenile absence epilepsy 
Juvenile myoclonic epilepsy 
Epilepsy with generalized tonic–clonic seizures only 
Reflex epilepsies 
Idiopathic photosensitive occipital lobe epilepsy 
Other visual sensitive epilepsies 
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Primary reading epilepsy 
Startle epilepsy 
Autosomal dominant nocturnal frontal lobe epilepsy 
Familial temporal lobe epilepsies 
Generalized epilepsies with febrile seizures plus 
Familial focal epilepsy with variable foci 
Symptomatic (or probably symptomatic) focal epilepsies 
Limbic epilepsies 
Mesial temporal lobe epilepsy with hippocampal sclerosis 
Mesial temporal lobe epilepsy defined by specific etiologies 
Other types defined by location and etiology 
Neocortical epilepsies 
Rasmussen syndrome 
Other types defined by location and etiology 
Conditions with epileptic seizures that do not require a diagnosis of epilepsy 
Benign neonatal seizures 
Febrile seizures 
Reflex seizures 
Alcohol-withdrawal seizures 
Drug or other chemically induced seizures 
Immediate and early posttraumatic seizures 
Single seizures or isolated clusters of seizures 
Rarely repeated seizures (oligoepilepsy) 
 
 
Table 5 Electroclinical syndromes and other epilepsies (Berg et al 2010). 
 
Electroclinical syndromes arranged by age at onset 
a
 
Neonatal period 
Benign familial neonatal epilepsy (BFNE) 
Early myoclonic encephalopathy (EME) 
Ohtahara syndrome 
Infancy 
Epilepsy of infancy with migrating focal seizures 
West syndrome 
Myoclonic epilepsy in infancy (MEI) 
Benign infantile epilepsy 
Benign familial infantile epilepsy 
Dravet syndrome 
 175 
 
Myoclonic encephalopathy in nonprogressive disorders 
Childhood 
Febrile seizures plus (FS+) (can start in infancy) 
Panayiotopoulos syndrome 
Epilepsy with myoclonic atonic (previously astatic) seizures 
Benign epilepsy with centrotemporal spikes (BECTS) 
Autosomal-dominant nocturnal frontal lobe epilepsy (ADNFLE) 
Late onset childhood occipital epilepsy (Gastaut type) 
Epilepsy with myoclonic absences 
Lennox-Gastaut syndrome 
Epileptic encephalopathy with continuous spike-and-wave 
during sleep (CSWS)b 
Landau-Kleffner syndrome (LKS) 
Childhood absence epilepsy (CAE) 
Adolescence – Adult 
Juvenile absence epilepsy (JAE) 
Juvenile myoclonic epilepsy (JME) 
Epilepsy with generalized tonic–clonic seizures alone 
Progressive myoclonus epilepsies (PME) 
Autosomal dominant epilepsy with auditory features (ADEAF) 
Other familial temporal lobe epilepsies 
Less specific age relationship 
Familial focal epilepsy with variable foci (childhood to adult) 
Reflex epilepsies 
Distinctive constellations 
Mesial temporal lobe epilepsy with hippocampal sclerosis (MTLE with HS) 
Rasmussen syndrome 
Gelastic seizures with hypothalamic hamartoma 
Hemiconvulsion–hemiplegia–epilepsy 
Epilepsies that do not fit into any of these diagnostic categories can be distinguished first on the basis 
of the presence or absence of a known structural or metabolic condition (presumed cause) and then on 
the basis of the primary mode of seizure onset (generalized vs. focal) 
Epilepsies attributed to and organized by structural-metabolic causes 
Malformations of cortical development (hemimegalencephaly, 
heterotopias, etc.) 
Neurocutaneous syndromes (tuberous sclerosis complex, 
Sturge-Weber, etc.) 
Tumor 
Infection 
Trauma 
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Angioma 
Perinatal insults 
Stroke 
Etc. 
Epilepsies of unknown cause 
Conditions with epileptic seizures that are traditionally not diagnosed as a form of epilepsy per se 
Benign neonatal seizures (BNS) 
Febrile seizures (FS) 
 
a
  The arrangement of electroclinical syndromes does not reflect etiology. 
b
 Sometime referred to as Electrical Status Epilepticus during Slow Sleep (ESES). 
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Appendix 2 Glossary of Descriptive Terminology for Ictal Semiology (Blume 
et al., 2001) 
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INTRODUCTION 
 
This glossary intends to provide a standard terminol- 
ogy for health care workers to communicate what is ob- 
served and what a patient reports during a seizure. As 
this terminology is descriptive and phenomenologic, its 
use would not imply or require knowledge of ictal patho- 
physiology, any pathological substrate, or etiology. 
Many terms are adjectives modifying “seizure,” which 
itself is defined under “general terms.” This pertains to 
seizures with single or multiple components. 
Terms in this glossary (e.g., “seizure,” “ictus,” which 
have widespread applicability in other fields of clinical 
neuroscience) are herein defined according to their ref- 
erences to epilepsy. 
Some terms of this glossary are “fundamental” (i.e., 
they encompass other more precise words). These can be 
used as the sole descriptor when data to characterize a 
phenomenon more precisely are not available. Such in- 
clude aura, automatism, experiential, motor, and sensory. 
A seizure will often consist of two or more phenomena 
occurring simultaneously or sequentially and should be 
described accordingly. 
Quantitative terms, such as duration of motor events, 
are not intended as immutable confines, but as clarifying 
guides to describe clinically observed events. 
Scientific progress dictates an evolution of terms to 
retain their relevance. However, needs of communication 
in everyday life require that changes be gradual and evo- 
lutionary rather than abrupt and revolutionary. The use of 
synonyms in this glossary reflects incidents in which 
gradual changes are likely. 
Terminology in some areas remains unresolved. 
Therefore we view this glossary as a dynamic process for 
which feedback will be welcomed. 
 
 
PRINCIPLES FOR TERMS AND DEFINITIONS 
 
In developing the “lexique” of this report, we adopted 
and applied the following principles. 
Terms and definitions should 
 
1. Contain features that distinguish or modify seizure 
entities. 
2. Be descriptive of the phenomena involved. 
3. Comply with terminology of clinical neuroscience. 
4. Use current terminology and definitions wherever 
possible. 
5. Contain new terms only if necessary. 
6. Be easily translatable to other languages. 
7. Be readily understood and used by potential users. 
 
 
I GENERAL TERMS 
 
1.0 SEMIOLOGY 
That branch of linguistics concerned with signs and 
symptoms. 
 
2.0 EPILEPTIC SEIZURE 
Manifestation(s) of epileptic (excessive and/or hyper- 
synchronous), usually self-limited activity of neurons in 
the brain. 
 
3.0 ICTUS 
A sudden neurologic occurrence such as a stroke or an 
epileptic seizure. 
 
4.0 EPILEPSY 
 
a) Epileptic Disorder: A chronic neurologic condition 
characterized by recurrent epileptic seizures. 
b) Epilepsies: Those conditions involving chronic re- 
current epileptic seizures that can be considered 
epileptic disorders. 
 
5.0 FOCAL (syn. partial) 
A seizure whose initial semiology indicates, or is con- 
sistent with, initial activation of only part of one cerebral 
hemisphere. 
 
6.0 GENERALIZED (syn. bilateral) 
A seizure whose initial semiology indicates, or is con- 
sistent with, more than minimal involvement of both ce- 
rebral hemispheres. 
 
7.0 CONVULSION 
Primarily a lay term. Episodes of excessive, abnormal 
muscle contractions, usually bilateral, which may be sus- 
tained or interrupted. 
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II TERMS DESCRIBING EPILEPTIC 
SEIZURE SEMIOLOGY 
 
These are descriptors of seizures unless specified oth- 
erwise. 
 
1.0 MOTOR 
Involves musculature in any form. The motor event 
could consist of an increase (positive) or decrease (nega- 
tive) in muscle contraction to produce a movement. 
Unless noted, the following terms are adjectives modi- 
fying “motor seizure” or “seizure” (e.g., “tonic motor 
seizure or dystonic seizure”), and whose definitions can 
usually be understood as prefaced by “refers to . . .”. 
 
1.1 ELEMENTARY MOTOR 
A single type of contraction of a muscle or group of 
muscles that is usually stereotyped and not decompos- 
able into phases. (However, see tonic–clonic, an elemen- 
tary motor sequence). 
 
1.1.1 TONIC 
A sustained increase in muscle contraction lasting a 
few seconds to minutes. 
 
1.1.1.1 EPILEPTIC SPASM (Formerly 
Infantile Spasm) 
Noun: A sudden flexion, extension, or mixed exten- 
sion–flexion of  predominantly proximal and  truncal 
muscles that is usually more sustained than a myoclonic 
movement but not so sustained as a tonic seizure (i.e.,   1 
s). Limited forms may occur: grimacing, head nodding. 
Epileptic spasms frequently occur in clusters. 
 
1.1.1.2 POSTURAL 
Adoption of a posture that may be bilaterally symmet- 
ric or asymmetric (as in a “fencing posture”). 
 
1.1.1.2.1 VERSIVE 
A sustained, forced conjugate ocular, cephalic, and/or 
truncal rotation or lateral deviation from the midline. 
 
1.1.1.2.2 DYSTONIC 
Sustained contractions of both agonist and antagonist 
muscles  producing athetoid  or  twisting  movements, 
which, when prolonged, may produce abnormal postures. 
 
1.1.2 MYOCLONIC (adjective); 
MYOCLONUS (noun) 
Sudden, brief (<100 ms) involuntary single or multiple 
contraction(s) of muscles(s) or muscle groups of variable 
topography (axial, proximal limb, distal). 
 
1.1.2.1 NEGATIVE MYOCLONIC 
Interruption of tonic muscular activity for <500 ms 
without evidence of preceding myoclonia. 
1.1.2.2 CLONIC 
Myoclonus that is regularly repetitive, involves the 
same muscle groups, at a frequency of   2–3 c/s, and is 
prolonged. Synonym: rhythmic myoclonus. 
 
1.1.2.2.1 JACKSONIAN MARCH 
Noun: Traditional term indicating spread of clonic 
movements through contiguous body parts unilaterally. 
 
1.1.3 TONIC–CLONIC 
A sequence consisting of a tonic followed by a clonic 
phase. Variants such as clonic–tonic–clonic may be seen. 
 
1.1.3.1 GENERALIZED TONIC–CLONIC 
SEIZURE (syn. bilateral tonic–clonic seizure) 
(Formerly “Grand Mal” Seizure) 
Noun: Bilateral symmetric tonic contraction and then 
bilateral clonic contractions of somatic muscles, usually 
associated with autonomic phenomena. 
 
1.1.4 ATONIC 
Sudden loss or diminution of muscle tone without ap- 
parent preceding myoclonic or tonic event lasting $1 to 
2 s, involving head, trunk, jaw, or limb musculature. 
 
1.1.5 ASTATIC 
Loss of erect posture that results from an atonic, myo- 
clonic, or tonic mechanism. Synonym: drop attack. 
 
1.1.6 SYNCHRONOUS (Asynchronous) 
Motor events occurring (not) at the same time or at the 
same rate in sets of body parts. 
 
1.2 AUTOMATISM 
Noun: A more or less coordinated, repetitive, motor 
activity usually occurring when cognition is impaired 
and for which the subject is usually amnesic afterward. 
This often resembles a voluntary movement and may 
consist  of  an  inappropriate continuation of  ongoing 
preictal motor activity. 
The  following adjectives are  usually employed to 
modify “automatism.” 
 
1.2.1 OROALIMENTARY 
Lip smacking, lip pursing, chewing, licking, tooth 
grinding, or swallowing. 
 
1.2.2 MIMETIC 
Facial expression suggesting an emotional state, often 
fear. 
 
1.2.3 MANUAL OR PEDAL 
 
1. Indicates principally distal components, bilateral or 
unilateral. 
2. Fumbling, tapping, manipulating movements. 
 
1.2.4 GESTURAL 
Often unilateral. 
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1. Fumbling or exploratory movements with the hand, 
directed toward self or environment. 
2. Movements resembling those intended to lend fur- 
ther emotional tone to speech. 
 
1.2.5 HYPERKINETIC 
 
1.  Involves predominantly proximal limb  or  axial 
muscles producing irregular sequential ballistic 
movements, such  as  pedaling, pelvic  thrusting, 
thrashing, rocking movements. 
2. Increase in rate of ongoing movements or inappro- 
priately rapid performance of a movement. 
 
1.2.6 HYPOKINETIC 
A decrease in amplitude and/or rate or arrest of ongo- 
ing motor activity. 
 
1.2.7 DYSPHASIC 
Impaired communication involving language without 
dysfunction of relevant primary motor or sensory path- 
ways, manifested as impaired comprehension, anomia, 
paraphasic errors, or a combination of these. 
 
1.2.8 DYSPRAXIC 
Inability to perform learned movements spontaneously 
or on command or imitation despite intact relevant motor 
and sensory systems and adequate comprehension and 
cooperation. 
 
1.2.9 GELASTIC 
Bursts of laughter or giggling, usually without an ap- 
propriate affective tone. 
 
1.2.10 DACRYSTIC 
Bursts of crying. 
 
1.2.11 VOCAL 
Single or repetitive utterances consisting of sounds 
such as grunts or shrieks. 
 
1.2.12 VERBAL 
Single or repetitive utterances consisting of words, 
phrases, or brief sentences. 
 
1.2.13 SPONTANEOUS 
Stereotyped, involve only self, virtually independent 
of environmental influences. 
 
1.2.14 INTERACTIVE 
Not stereotyped, involve more than self, environmen- 
tally influenced. 
 
2.0 NONMOTOR 
 
2.1 AURA 
Noun: A subjective ictal phenomenon that, in a given 
patient, may precede an observable seizure; if alone, con- 
stitutes a sensory seizure. 
2.2 SENSORY 
A perceptual experience not caused by appropriate 
stimuli in  the  external world. Modifies “seizure” or 
“aura.” 
 
2.2.1 ELEMENTARY 
A single, unformed phenomenon involving one pri- 
mary sensory modality (e.g., somatosensory, visual, au- 
ditory, olfactory, gustatory, epigastric, or cephalic). 
 
2.2.1.1 SOMATOSENSORY 
Tingling, numbness, electric-shock sensation, pain, 
sense of movement, or desire to move. 
 
2.2.1.2 VISUAL 
Flashing or flickering lights, spots, simple patterns, 
scotomata, or amaurosis. 
 
2.2.1.3 AUDITORY 
Buzzing, drumming sounds or single tones. 
 
2.2.1.4 OLFACTORY 
Odor, usually disagreeable. 
 
2.2.1.5 GUSTATORY 
Taste sensations including acidic, bitter, salty, sweet, 
or metallic. 
 
2.2.1.6 EPIGASTRIC 
Abdominal discomfort including nausea, emptiness, 
tightness, churning, butterflies, malaise, pain, and hun- 
ger; sensation may rise to chest or throat. Some phenom- 
ena may reflect ictal autonomic dysfunction. 
 
2.2.1.7 CEPHALIC 
Sensation in the head such as light-headedness, tin- 
gling or headache. 
 
2.2.1.8 AUTONOMIC 
A sensation consistent with involvement of the auto- 
nomic nervous system, including cardiovascular, gastro- 
intestinal, sudomotor, vasomotor, and thermoregulatory 
functions. (Thus “autonomic aura”; cf. “autonomic 
events” 3.0). 
 
2.2.2 EXPERIENTIAL 
Affective, mnemonic, or composite perceptual phe- 
nomena including illusory or composite hallucinatory 
events; these may appear alone or in combination. In- 
cluded are feelings of depersonalization. These phenom- 
ena have subjective qualities similar to those experienced 
in life but are recognized by the subject as occurring 
outside of actual context. 
 
2.2.2.1 AFFECTIVE 
Components include fear, depression, joy, and (rarely) 
anger. 
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2.2.2.2 MNEMONIC 
Components that reflect ictal dysmnesia such as feel- 
ings of familiarity (de´ja`-vu) and unfamiliarity (jamais- 
vu). 
 
2.2.2.3 HALLUCINATORY 
A creation of composite perceptions without corre- 
sponding external stimuli involving visual, auditory, so- 
matosensory, olfactory, and/or gustatory phenomena. 
Example: “hearing” and “seeing” people talking. 
 
2.2.2.4 ILLUSORY 
An alteration of actual percepts involving the visual, 
auditory, somatosensory, olfactory, or gustatory systems. 
 
2.3 DYSCOGNITIVE 
The term describes events in which (1) disturbance of 
cognition is the predominant or most apparent feature, 
and (2a) two or more of the following components are 
involved, or (2b) involvement of such components re- 
mains undetermined. Otherwise, use the more specific 
term (e.g., “mnemonic experiential seizure” or “halluci- 
natory experiential seizure”). 
Components of cognition: 
 
•  perception: symbolic conception of sensory infor- 
mation 
• attention: appropriate selection of a principal per- 
ception or task 
• emotion: appropriate affective significance of a per- 
ception 
•  memory: ability to store and retrieve percepts or 
concepts 
• executive function: anticipation, selection, monitor- 
ing of consequences, and initiation of motor activity 
including praxis, speech 
 
3.0 AUTONOMIC EVENTS 
 
3.1 AUTONOMIC AURA 
A sensation consistent with involvement of the auto- 
nomic nervous system, including cardiovascular, gastro- 
intestinal, sudomotor, vasomotor, and thermoregulatory 
functions (see 2.2.1.8). 
 
3.2 AUTONOMIC SEIZURE 
An objectively documented and distinct alteration of 
autonomic nervous system function involving cardiovas- 
cular, pupillary, gastrointestinal, sudomotor, vasomotor, 
and thermoregularity functions. 
 
4.0 SOMATOTOPIC MODIFIERS 
 
4.1 LATERALITY 
 
4.1.1 UNILATERAL 
Exclusive or virtually exclusive involvement of one 
side as a motor, sensory, or autonomic phenomenon. 
4.1.1.1 HEMI- 
A prefix to other descriptors (e.g., hemiclonic). 
 
4.1.2 GENERALIZED (syn. “bilateral”) 
More than minimal involvement of each side as a mo- 
tor, elementary sensory, or autonomic phenomenon. 
Motor component: further modified as 
 
4.1.2.1 ASYMMETRIC 
Clear distinction in quantity and/or distribution of be- 
havior on the two sides. 
 
4.1.2.2 SYMMETRIC 
Virtual bilateral equality in these respects. 
 
4.2 BODY PART 
Refers to area involved (i.e., arm, leg, face, trunk, and 
other). 
 
4.3 CENTRICITY 
Modifier describes proximity to the body axis. 
 
4.3.1 AXIAL 
Involves trunk, including neck. 
 
4.3.2 PROXIMAL LIMB 
Signifies involvement from shoulders to wrist, hip to 
ankle. 
 
4.3.3 DISTAL LIMB 
Indicates involvement of fingers, hands, toes, and/or 
feet. 
 
5.0 MODIFIERS AND DESCRIPTORS OF 
SEIZURE TIMING 
The following terms are listed in the form (adjective, 
noun, verb) according to principal usage; as adjective 
unless specified. 
 
5.1 INCIDENCE 
Noun:  Refers to the number of epileptic seizures 
within a time period or the number of seizure 
days per unit of time. 
 
5.1.1 REGULAR, IRREGULAR 
Consistent (inconsistent) or  predictable (unpredict- 
able, chaotic) intervals between such events. 
 
5.1.2 CLUSTER 
 
1. Noun:   Incidence of seizures within a given period 
(usually one or a few days) that exceeds 
the average incidence over a longer period 
for the patient. 
2. Verb:   To vary in incidence as above. 
 
5.1.3 PROVOCATIVE FACTOR 
Noun:   Transient and sporadic endogenous or exog- 
enous element capable of augmenting seizure 
incidence in persons with chronic epilepsy 
and evoking seizures in susceptible individu- 
als without epilepsy. 
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5.1.3.1 REACTIVE 
Occurring in association with transient systemic per- 
turbation such as intercurrent illness, sleep loss, or emo- 
tional stress. 
 
5.1.3.2 REFLEX 
Objectively and consistently demonstrated to be 
evoked by a specific afferent stimulus or by activity of 
the patient. Afferent stimuli can be elementary [i.e., un- 
structured (light flashes, startle, a monotone)] or elabo- 
rate [i.e., structured, (a symphony)]. Activity may be 
elementary [e.g., motor (a  movement)]; or  elaborate 
[e.g., cognitive function (reading, chess playing)], or 
both (reading aloud). 
 
5.2 STATE DEPENDENT 
Occurring exclusively or  primarily in  the  various 
stages of drowsiness, sleep, or arousal. 
 
5.3 CATAMENIAL 
Seizures occurring principally or exclusively in any 
one phase of the menstrual cycle. 
 
6.0 DURATION 
Time between the beginning of initial seizure mani- 
festations, such as the aura, and the cessation of experi- 
enced or observed seizure activity. Does not include 
nonspecific seizure premonitions or postictal states. 
 
6.1 STATUS EPILEPTICUS 
A seizure that shows no clinical signs of arresting after 
a duration encompassing the great majority of seizures of 
that type in most patients or recurrent seizures without 
interictal resumption of baseline central nervous system 
function. 
 
7.0 SEVERITY 
A multicomponent assessment of a seizure by observ- 
ers and the patient. 
Components primarily of observer assessment include 
duration, extent of motor involvement, impairment of 
cognitive  interaction  with  environment intraictally, 
maximal number of seizures per unit of time. 
Components primarily of patient assessment: extent of 
injury; emotional, social, and vocational consequences of 
the attack. 
 
8.0 PRODROME 
A  preictal phenomenon. A  subjective or  objective 
clinical alteration (e.g., ill-localized sensation or agita- 
tion) that heralds the onset of an epileptic seizure but 
does not form part of it. 
 
9.0 POSTICTAL PHENOMENON 
A transient clinical  abnormality of central nervous 
system function that appears or becomes accentuated 
when clinical signs of the ictus have ended. 
9.1 LATERALIZING [TODD’S (OR BRAVAIS’)] 
PHENOMENON 
Any unilateral postictal dysfunction relating to motor, 
language, sensory, and/or integrative functions including 
visual, auditory, or somatosensory neglect phenomena. 
 
9.2 NONLATERALIZING PHENOMENON 
Impaired cognition, amnesia, psychosis. 
 
9.2.1 IMPAIRED COGNITION 
Decreased cognitive performance involving one or 
more of perception, attention, emotion, memory, execu- 
tion, praxis, speech (cf., Dyscognitive, 2.3). 
 
9.2.1.1 ANTEROGRADE AMNESIA 
Impaired ability to remember new material. 
 
9.2.1.2 RETROGRADE AMNESIA 
Impaired ability to recall previously remembered ma- 
terial. 
 
9.2.2 PSYCHOSIS 
Misinterpretation of external world in an awake, alert 
person; involves thought disorder of emotion and social- 
ization. 
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Appendix 4 Data base collected for encephalitis and status epilepticus 
study (Chapter 2) 
Patients demographic Name 
Medical record number (MRN) 
Sex 
Date of birth (DOB) 
Date of presentation 
Age at presentation 
Ethnicity (if known) 
Paediatrician 
Neurologist 
Transfer from other hospital 
 
Sample Sample date  
Sample accession number 
Sample timing in relation to 
presentation (days) 
 
Past medical history Previously normal Yes or no 
 Preceding epilepsy  
 Preceding intractable epilepsy  
 Previous status epilepticus  
 Previous febrile seizures  
 Learning difficulty/ developmental 
delay 
 
 Behavioural/psychiatric disorder  
 Motor deficit  
 Other neurologic diagnosis  
 Other medical diagnosis  
Family history Of epilepsy in first degree relatives  
Status epilepticus Status type Convulsive or non convulsive 
 Status type Focal or generalised 
 Clusters or prolonged seizures  
 Febrile or afebrile  
 Duration of status  
 Status treatment  
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Hospital admission Length of stay (days)  
 PICU admission Yes or no 
 Length of PICU admission (days)  
Features of presenting illness Encephalopathy  
 Movement disorder  
 Behavioural alteration  
 Cognitive alteration  
 Inter-current infection  
 Recent infection  
 Type of infection  
 CNS infection  
 Vaccination  
 Other  
Investigations EEG Slow- focal or generalised 
  Epileptic- focal or generalised 
  EEG seizure- yes or no 
 MRI Normal or abnormal  
  MRI details if abnormal 
 CSF Cells (value) 
  Protein (value) 
  Neopterin(value) 
  OCB (yes or no) 
  PCR for HSV and enterovirus 
-if done (positive or negative) 
 Serology- if done mycoplasma pneumoniae , 
enterovirus, cytomegalovirus , 
Epstein-Barr virus , herpes 
simplex virus , human 
herpesvirus 6 , influenza , and 
adenovirus .  
 Other relevant investigations Serum sodium, ANA, other 
autoimmune screening 
Immunotherapy Steroids  
 IVIG  
 Other 
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Outcome Length of follow up (months)  
 Isolated event Yes or no 
 New deficit Yes or no 
 Motor or focal deficit  
 Cognitive difficulties  
 Behavioural /psychiatric 
impairment 
 
 Other deficits  
 Ongoing epilepsy  
 Intractable epilepsy  
 Epilepsy type Focal or generalised 
 ILAE classification on follow up  
 Death Yes or no 
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Appendix 5: Data base collected for new onset seizures study (Chapter 3) 
Patients demographic Name 
MRN 
Sex 
DOB 
Date of onset 
Age at onset 
Ethnicity (if known) 
Paediatrician 
Neurologist 
Transfer from other hospital 
 
Sample Sample date  
Sample accession number 
Sample timing in relation to 
presentation (days) 
 
Past medical history Previously normal 
Learning difficulty/ 
developmental delay 
Behavioural/psychiatric disorder 
Motor deficit 
Other neurologic diagnosis 
Other medical diagnosis 
Yes or no 
Family history Family history of epilepsy In first degree relatives 
Presenting seizure seizure type  Focal, focal dyscognitive or 
generalised 
 Febrile or afebrile  
 Clusters   
 Status   
Hospitalisation Hospital admission Yes or no 
 Length of stay (days)  
 PICU admission Yes or no 
 Length of PICU admission (days)  
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Features on presentation Encephalopathy  
 Movement disorder  
 Behavioural alteration  
 Cognitive alteration  
 Motor impairment  
 Inter-current illness  
 Type of illness  
 Vaccination   
 Other symptoms or features  
Investigations EEG Background abnormality 
  Slow- focal or generalised 
  Epileptic- focal or generalised 
  EEG seizure- yes or no 
  EEG diagnosis 
 MRI Normal or abnormal  
  MRI details 
  MRI diagnosis 
 CSF Cells (value) 
  Glucose (value 
  Protein (value) 
  Neopterin(value) 
  OCB (positive/negative/not done) 
  PCR for HSV and enterovirus -if 
done (positive or negative) 
 Serology- if done mycoplasma pneumoniae , 
enterovirus, cytomegalovirus , 
Epstein-Barr virus , herpes 
simplex virus , human herpesvirus 
6 , influenza , and adenovirus , 
others 
 Other relevant investigations Serum sodium, ANA, other 
autoimmune screening,  nuclear 
medicine scans genetic tests etc 
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Treatment AEDs Acute and long term 
 Steroids  
 IVIG  
 Response to steroids or IVIG 
Other immunotherapy 
 
Positive or negative 
Outcome Length of follow up (months)  
Epilepsy outcome Isolated event Yes or no 
 New deficit  
 Ongoing epilepsy  
 Intractable epilepsy  
 Number of AED  
 Seizure type on follow up  
Other outcomes  Motor or focal deficit  
 Developmental delay  
 Cognitive difficulties  
 Behavioural /psychiatric 
impairment 
 
Epilepsy classification ILAE classification 
(electroclinical syndromes and 
others) 
 
 Aetiology classification (ILAE)  
Other diagnosis   
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Autoantibodies to neuronal antigens in children with new-
onset seizures classified according to the revised ILAE
organization of seizures and epilepsies
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SUMMARY
Purpose: Potentially pathogenic autoantibodies are found increasingly in adults with
seizure disorders, including focal seizures and those of unknown cause. In this study,
we investigated a cohort of children with new-onset seizures to see whether there
were autoantibodies and the relationship to any specific seizure or epilepsy type.
Methods: We prospectively recruited 114 children (2 months to 16 years) with new-
onset seizures presenting between September 2009 and November 2011, as well as 65
controls. Patients were clinically assessed and classified according to the new Interna-
tional LeagueAgainst Epilepsy (ILAE) organization of seizures and epilepsies classifica-
tion system. Sera were tested for autoantibodies to a range of antigens, blind to the
clinical and classification details.
Key Findings: Eleven (9.7%) of 114 patientswere positive for one ormore autoantibodies
compared to 3 of 65 controls (4.6%, p = ns). Patients had antibodies to the voltage-gated
potassium channel (VGKC) complex (n = 4), contactin-associated protein-like 2 (CAS-
PR2) (n = 3), N-methyl-D-aspartate receptors (NMDARs) (n = 2), or VGKC-complex
and NMDAR (n = 2). None had antibodies to glutamic acid decarboxylase, contactin-2,
or to glycine, 2-amino-3-(3-hydroxy-5-methyl-4-isoxazolyl) propionic acid (AMPA), or c-
aminobutyric acidB receptors. Ten of these 11 patients were classified as having epilepsy
according to the new ILAE organization of seizures and epilepsy. Although, there were
no significant differences in the demographic and clinical features between antibody-
positive and antibody-negative patients, the classification of “unknown cause” was
higher in the antibody positive (7/10; 70%) comparedwith the antibody negative subjects
(23/86; 26.7%; p = 0.0095, Fisher’s exact test). Furthermore, four of these seven patients
with epilepsy (57.1%) were classified as having predominantly focal seizures compared
with 12 of the 86 antibody-negative patients (13.9%; p = 0.015).
Significance: Because autoantibodies were more frequent in pediatric patients with
new-onset epilepsy of “unknown cause,” often with focal epilepsy features, this group
of children may benefit most from autoantibody screening and consideration of
immune therapy.
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FULL-LENGTHORIGINALRESEARCH
A clear clinical diagnosis of patients who present with
seizures and the subsequent accurate classification of their
epilepsies is extremely important to the neurologist for
treatment and prognosis and to the neuroscientist for
facilitation of focused, robust research. To meet these dual
needs, the revised International League Against Epilepsy
(ILAE) system for the organization of seizures and
epilepsies, published in 2010, presented a conceptualized
framework for everyday clinical practice that also tried to
reflect the advancement of basic epilepsy research (Berg
et al., 2010). The most important and subsequent controver-
sial recommendation, involved the replacement of the terms
“idiopathic, symptomatic, and cryptogenic” with “genetic,
structural/metabolic, and unknown cause” when describing
etiology (Shinnar, 2010; Panayiotopoulos, 2011, 2012).
It is estimated that epilepsies of unknown cause account
for approximately one third of all cases of epilepsy in adults
(Berg et al., 2010) and 23–35% in children (van Campen
et al., 2013). They are an important group for the identifica-
tion of new etiologies, and an area in which the emerging
identification of specific antibodies may be increasingly
important. Antibodies (Abs) directed against neuronal sur-
face proteins such as the voltage-gated potassium channel
(VGKC) complex and its associated proteins, leucine-rich,
glioma inactivated 1 (LGI1), contactin-associated protein-
like 2 (CASPR2) and contactin-2, the N-methyl-D-aspartate
receptor (NMDAR), c-aminobutyric acid B receptor
(GABABR), and 2-amino-3-(3-hydroxy-5-methyl-isoxazol-
4-yl) propanoic acid receptor (AMPAR) and against intra-
cellular proteins such as glutamic acid decarboxylase
(GAD) have already been described. The association
between these antibodies and seizures is manifest in patients
with limbic encephalitis who often have temporal lobe sei-
zures, and NMDAR-Ab encephalitis in which patients can
have focal or generalized seizures. In addition, each of the
antibodies has been identified in a proportion of patients
with epilepsy but without other encephalitic clinical signs or
symptoms, such as cognitive impairment or neuropsychiat-
ric features (Peltola et al., 2000; McKnight et al., 2005;
Majoie et al., 2006; Irani et al., 2008; Niehusmann et al.,
2009; Barajas et al., 2010; Quek et al., 2012; Brenner et al.,
2013), prompting the increased recognition of “autoimmune
epilepsy” (Palace & Lang, 2000; Bien & Scheffer, 2011;
Irani et al., 2011a; Vincent et al., 2011; Nabbout, 2012;
Quek et al., 2012). The identification of a putative autoim-
mune etiology in some forms of epilepsies suggests that
early identification of specific autoantibodies and subse-
quent treatment with immunotherapy could lead to reduced
seizure frequency and may improve outcomes (Irani et al.,
2011b; Quek et al., 2012).
In children, NMDAR-Ab encephalitis and VGKC-com-
plex-Ab–associated encephalitis have also been recog-
nized, with seizures being an important presenting
symptom (Dale et al., 2009b; Florance et al., 2009; Haber-
landt et al., 2011; Suleiman et al., 2011a). Fewer reports
are available regarding the association of neuronal antibod-
ies in defined pediatric epilepsies (e.g., Dhamija et al.,
2011; Suleiman et al., 2011b, 2013). Here, we recruited a
prospective cohort of children with new-onset seizures,
recorded their clinical features, and classified them accord-
ing to the revised ILAE organization of seizures and epilep-
sies. At the end of the study period, and blinded to the
clinical and classification details, the sera taken at admis-
sion were tested for autoantibodies.
Methods
Recruitment criteria of patients with new-onset seizures
We prospectively recruited children aged 2 months to
16 years with new-onset seizures presenting to the Chil-
dren’s Hospital at Westmead Hospital, Sydney between
September 2009 and November 2011. One hundred and
fourteen children were included in the study (58 females,
mean age 4.39 years, median 2.55 years, range 0.13–
15.25 years). All patients with a well-described paroxysmal
episode compatible with a clinical seizure and who had
serum collected within 6 months of seizure onset were
included (in and outpatients). Neonates (0–60 days), and
patients with clear etiologies for their seizures such as brain
tumor, bacterial meningitis, and brain injury (traumatic or
ischemic) were excluded from the study.
Control group
The control group for antibody testing consisted of hospi-
tal patients (n = 65, 27 female, mean age 9 years, median
9.14 years, range 1–16 years) who had serum collected as
part of their routine investigations during 2007. The under-
lying medical problems were immunologic/inflammatory
or allergic (n = 28); hematologic/oncologic (n = 20); or
other medical condition such as respiratory, gastrointestinal,
and endocrine (n = 17). Recruitment of the patients and
control groups for this study was approved by the hospital
ethics committee, and written consent was obtained from
the patients or their families.
Antibody assays
Patients were tested for antibodies to VGKC complex and
NMDAR (n = 114); LGI1, CASPR2, and GAD (n = 113);
glycine receptor (GlyR), AMPAR, contactin-2 (n = 112);
and GABABR (n = 92). The antibodies to VGKC complex
and GAD were tested by radioimmunoassays as described
previously (McKnight et al., 2005). VGKC-complex-Abs
and GAD levels >100 pM and 100 >U/ml, respectively,
were considered positive. All other neuronal antibodies were
tested by cell-based assays (CBAs) (for full descriptions see
Irani et al., 2008, 2010a,b; Dale et al., 2009b). The CBAs
were scored on a visual scale 0 (no binding), 1 (low but spe-
cific binding)-4 (strong binding to all transfected cells) by
two independent observers. If positive, samples were titrated
by serial dilution, and the final dilution at which the sample
Epilepsia, **(*):1–10, 2013
doi: 10.1111/epi.12405
2
J. Suleiman et al.
remained positive (score of 1) was given. The 65 controls
were tested at the same time as the new-onset seizure
patients for the following antibodies: LGI1, CASPR2, cont-
actin-2, NMDAR, AMPAR, GABABR, GAD, and GlyR
(n = 65) and VGKC complex (n = 62). Assays were per-
formed and read by SWwho was blinded to the clinical data,
and re-scored by an additional reader. Incomplete testing
was due to insufficient sample available. Cerebrospinal fluid
testing could not be performed in this study owing to limited
sample availability.
Epilepsy classification
Classifications of seizure types, epilepsy, electroclinical
syndrome, and etiology were performed by the primary
investigator, a pediatric neurologist (JS), and were cross-
checked by a pediatric neurologist and epileptologist (DG).
Both were blinded to the results of the antibody testing at
the time of performing the classification. The seizure type at
presentation was determined for the 114 patients and classi-
fied where possible using the new ILAE organization of
seizures and epilepsies (Engel, 2006; Berg et al., 2010)
and terminology for ictal semiology (Blume et al., 2001).
Classification of a patient’s condition into an epilepsy
syndrome was made by reviewing the child’s age, neuro-
logic and developmental state, seizure semiology (at onset
and on follow up), electroencephalography (EEG), imaging,
and other relevant investigations findings. The structure of
the latest proposed ILAE organization of seizures and
epilepsies (Berg et al., 2010) was used for this purpose in
addition to previous ILAE classification when required
(including ICE 1989, Engel, 2001; Engel, 2006). Patients
who had features compatible with one of the electroclinical
syndromes described in the new ILAE organization of sei-
zures and epilepsies were classified as such irrespective of
the etiology of their epilepsy. For example, patients with
epileptic spasms and hypsarrhythmic EEG were classified
as West syndrome, despite some of these patients having a
known structural or metabolic cause. Patients who did not
fit into any electroclinical syndrome were classified (as per
the ILAE 2010 recommendation) on the basis of presence of
metabolic diseases or structural abnormalities. The term
“epilepsy of unknown cause” was used to classify those
patients who did not fit into an electroclinical syndrome and
who had no structural or metabolic cause found for their epi-
lepsy. Patients with seizures that are traditionally not diag-
nosed as a form of epilepsy including febrile seizures were
kept in a separate group as per Berg (2010). We also added
patients with acute symptomatic (provoked) seizures (Beghi
et al., 2010; Beleza, 2012) and with single unprovoked sei-
zures to this group.
Statistics and data analysis
Fisher’s exact test was used to compare categorical data
and the Mann-WhitneyU test to compare continuous data
variables.
Results
Demographic, clinical features, investigations, and
treatment of total cohort
One hundred and one of the 114 patients in the study were
admitted to the hospital during their initial presentation or
during the first 6 months after seizure onset (median length
of stay 4.5 days, range 1–360 days). Eighteen patients
required admission to intensive care. Thirty-six patients had
one or more preexisting developmental, motor, or psychiat-
ric abnormalities including 33 with developmental delay
and/or learning difficulty, 14 with motor deficits, and 4 with
behavioral or psychiatric disturbance. There was a positive
family history of seizures or epilepsy (including febrile sei-
zures) in the first-degree relatives of 19 patients (16.7%).
Nearly half of the patients (n = 56) presented with focal
seizures (Table S1) including 12 with focal dyscognitive
seizures. Twenty-one patients presented in status epilepticus
and 77 patients had an early recurrence of seizures (occur-
ring within 48 h of first seizure onset). At the time of pre-
sentation, 32 patients had intercurrent infections including
21 with fever (defined as 37.8°C or higher [axillary temper-
ature]), 7 of whom fulfilled the definition of febrile seizures
(Berg et al., 1992). Seizures were associated with other fea-
tures in 48 patients including encephalopathy (n = 33),
behavioral or psychiatric alteration (n = 27), motor impair-
ment (n = 17), cognitive alteration (n = 12), and movement
disorder (n = 5).
EEG findings were abnormal in 86 (76.1%) of 113
patients, and contributed significantly to the epilepsy diag-
nosis and classification in 22 patients (19.5%). Brain mag-
netic resonance imaging (MRI) scans were abnormal in 52
of 105 patients and were diagnostic or suggestive of a cause
of the epilepsy in 30 patients (28.6%). CSF analysis for ple-
ocytosis, protein, neopterin, or infections was performed in
66 (57.9%) of 114 patients and contributed to epilepsy diag-
nosis in 13 patients (19.7%). Other investigations were per-
formed as clinically indicated including metabolic, genetic,
infectious, and immunologic investigations, and contributed
to the epilepsy diagnosis in six patients.
Forty-six patients received acute seizure treatment and 85
patients received long-term (7 days or longer) antiepileptic
drugs (AEDs). Twenty-three patients received variable regi-
mens of immunotherapy; including steroids alone (oral
prednisolone, intramuscular synthetic adrenocorticotropic
hormone [ACTH] and intravenous methyl prednisolone) in
18 and steroids and intravenous immunoglobulins (IVIGs)
in 5. In all cases the decision to treat with immunotherapy
was made on the basis of a clinical presentation suggestive
of an immune-mediated cause (e.g., Rasmussen encepha-
litis); a recognized immunotherapy responsive seizure
syndrome (e.g., West syndrome); or as adjunctive treatment
in intractable epilepsy, prior to and independent of autoanti-
body test results. A positive clinical response, seen in 15 of
23, was defined as clinical improvement in seizures and/or
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encephalopathy as judged by the treating clinician. Thirteen
of 18 patients given steroids alone showed improvement,
including West syndrome (n = 5), epilepsy of unknown
cause (n = 4), Lennox-Gastaut syndrome (n = 2), epilepsy
attributed to malformation of cortical development (n = 1),
and epilepsy attributed to perinatal insult, encephalomalacia
(n = 1). Two of five patients who received steroids in com-
bination with IVIG also showed a positive clinical response
(Rasmussen encephalitis, n = 1; and basal ganglia encepha-
litis, n = 1).
Ten (8.8%) of the 114 patients had no follow-up informa-
tion available; for the remaining 104 patients, the mean
length of follow-up (from seizure onset) was 11.7 months
(median 11 months, range 1–36 months) at the time of
assessment. Eighty-four patients had ongoing epilepsy,
including 23 with drug-resistant (refractory) epilepsy
(Kwan et al., 2010). Thirty-two patients had new long-term
deficits (other than epilepsy), including one or more of the
following: developmental delay or cognitive impairment
(n = 24), behavioral/psychiatric impairment (n = 18), and
motor deficits (n = 13).
Epilepsy subgroups separated by classification
The 114 patients with new-onset seizures were classified
according to the structure of the latest proposed ILAE orga-
nization of seizures and epilepsies (Berg et al., 2010), Eigh-
teen patients had seizures not traditionally diagnosed as a
form of epilepsy; the remaining 96 patients had epilepsy: 30
with electroclinical syndromes, 33 with epilepsy attributed
to structural-metabolic causes, and 33 with epilepsy of
unknown cause (Table 1).
Antibodies and clinical features of positive patients and
controls
Eleven (9.7%) of 114 patients with new-onset seizures
were positive for one or more of the tested antibodies:
VGKC-complex (n = 4), CASPR2 (n = 3), NMDAR
(n = 2), and VGKC-complex and NMDAR (n = 2)
(Fig. 1A). None of the patients or controls were positive for
GAD, GlyR, AMPAR, GABABR, LGI1, or contactin-2 anti-
bodies.
All antibody-positive patients had been admitted to hos-
pital on presentation, compared to 87.4% of the antibody-
negative group. The mean duration of hospital stay for the
positive patients was 3.72 days (median 3 days, range
2–11 days), but none required admission to the intensive
care unit. Two of the antibody-positive patients had preex-
isting developmental delay, which was severe in one. There
was a positive family history of epilepsy in two patients.
One of the patients (case 8) had status epilepticus of 45 min
duration at presentation. Early seizure recurrence in the first
48 h of presentation occurred in 7 of the 11 patients. Fea-
tures associated with seizures on presentation are presented
in Table 2. Overall there were no significant differences in
the demographic and clinical features between antibody-
positive and antibody-negative patients (Table 3). The tim-
ing of the samples from symptom onset for the positive
patients was less but not significantly different from that of
the antibody-negative patients (mean 17.5; median 4, range
Table 1. Epilepsy classification as for the new ILAE
organization of seizures and epilepsies (Berg et al., 2010)
Conditions with epileptic seizures that are
traditionally not diagnosed as a form of epilepsy (n = 18)
No. of
patients
Febrile seizures 7
Acute symptomatic (provoked seizures)
Infection mediated 7a
Posterior reversible encephalopathy
syndrome (PRES) secondary to hypertension
1
Asthma 1
Single unprovoked seizure 2
ILAE classification/electroclinical syndrome (n = 96) No. of patients
Electroclinical syndrome (n = 30)b
Infancy
West syndrome 9c
Benign infantile epilepsy 3
Dravet syndrome 3
Myoclonic epilepsy in infancy (MEI) 1
Childhood
Lennox Gastaut syndrome (LGS) 4d
Febrile seizures plus (FS+) 2
Panayiotopoulos syndrome 2
Epilepsy with myoclonic–atonic seizures 2
Benign epilepsy with centrotemporal spikes (BECTS) 1
Childhood absence epilepsy (CAE) 1
Late-onset childhood occipital epilepsy (Gastaut type) 1
Adolescence
Autosomal dominant epilepsy with
auditory features (ADEAF)
1
Epilepsy attributed to structural-metabolic causes (n = 33)
Infections/inflammation
Encephalitis 11e
Rasmussen syndrome 1
Malformation of cortical development (MCD) 10
Perinatal insults 5
Metabolic 3f
Neurocutaneous syndrome 3
Epilepsies of unknown cause (n = 33)
Focal 16
Generalized 10
Spasms 4
Undetermined 3
aThese patients had a systemic infection that was presumed to have pro-
voked the seizure, but no evidence of CNS infection or inflammation, and
either had no fever or were outside the age definition for febrile seizures. The
precipitating infections were gastroenteritis (n = 3), upper respiratory tract
infection (n = 2), H1N1 influenza (n = 1), fever alone (n = 1).
b“The arrangement of electroclinical syndromes does not reflect etiology”
(Berg 2010).
c3 genetic, 2 metabolic (congenital glycosylation disorder), 1 structural
(perinatal insult), 3 unknown.
d2 structural (malformation of cortical development, holoprosencephaly), 2
unknown.
eEncephalitis patients include the following: five with potential infectious
etiology, one with dopamine receptor 2 encephalitis, and five not otherwise
specified.
fMELAS, propionic acidemia, ornithine transcarbamylase deficiency.
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1–75 days vs mean 40; median 20 and range 1–180 days,
respectively). The mean age was 4.39 years for both posi-
tive and negative patients; median was 3.4 years for anti-
body-positive patients and 2 years for antibody-negative
patients.
EEG and MRI brain were performed in 10 of 11 anti-
body-positive patients. The EEG results were abnormal in 8
and MRI abnormalities were recorded in 4 (Table 2). CSF
was tested in only 4 of the 11, and it was normal apart from
CSF neopterin, which was elevated in 1 of 3 tested at 68 nM
(normal <30; case 1), suggestive of central nervous system
(CNS) inflammation (Dale et al., 2009a).
Nine of the positive patients received long-term antiepi-
leptic drugs, but none of the antibody-positive patients
received immunotherapy during the period of disease course
studied. Two antibody-positive cases were lost to follow-up
(cases 8 and nonepileptic case 6). The mean length of fol-
low-up for the remaining nine cases was 10.33 months
(median 11 months, range 6–11 months), and was not dif-
ferent from the remaining antibody-negative cases. All of
the nine patients with follow-up had ongoing epilepsy, and
one had drug-resistant epilepsy (case 9). Five patients were
on one AED, three were on two AEDs, and one was on four
AEDs. Two patients had a new neurologic or developmental
deficit (other than epilepsy) including speech impairment
and hyperactivity (case 3), and motor deficit and behavioral
alteration (case 5).
Three of the 65 controls (4.6%) were positive for antibod-
ies. Control 1 (VGKC-complex-Abs 497 pM) was a 3-year-
old boy with type 1 diabetes mellitus. Control 2 (VGKC-
complex-Abs 200 pM) was a 2-year-old boy with vomiting
illness and poor weight gain. Control 3 (NMDAR score 2,
end point dilution 1 in 100) was an 8-year-old boy with an
acute lymphocytic leukemia relapse treated with bone mar-
row transplantation, complicated by chronic graft-versus-
host disease. No neurologic abnormality was noted in any of
these controls, although no natural follow-up was recorded
in control 2.
Patients with antibody-positive new-onset epilepsy
according to the new ILAE organization of seizures and
epilepsies
One patient with low levels of CASPR2 antibodies had
nonepileptic (provoked) seizures (patient 6, Table 2). The
remaining 10 antibody-positive patients with epilepsy had
the following ILAE epilepsy classifications: electroclinical
syndrome (n = 2), epilepsy attributed to structural meta-
bolic causes (n = 1), and epilepsy of unknown cause
(n = 7). In the total epilepsy cohort, after exclusion of
nonepileptic patients (n = 96), only 2 of 30 patients with
electroclinical syndromes (6.7%) had positive antibodies
(cases 9 and 11). Case 9 had Lennox-Gastaut syndrome
(LGS) and antibodies to NMDAR, and case 11 had febrile
seizures plus with antibodies to both the NMDAR and
VGKC-complex. Similarly, only one of 33 patients with
epilepsy attributed to a structural-metabolic cause (3%) had
positive antibodies (case 7), again not significantly different
from the controls; this case had mitochondrial encephalo-
myopathy, lactic acidosis, and stroke -like episodes
(MELAS) and was positive for CASPR2 antibodies.
In comparison, 7 of 33 patients from the epilepsy cohort
with epilepsy of unknown cause (21.2%) had positive anti-
bodies, which was different from the controls (4.6%;
p = 0.03, Fisher’s exact test) (Fig. 1). Overall, the propor-
tion of antibody-positive patients classified with epilepsy of
unknown cause (7/10; 70%) was significantly higher than
the remaining proportion of antibody-negative epilepsy sub-
jects (23/86; 26.7%; p = 0.0095, Fisher’s exact test)
(Fig. 1B). Furthermore, 4 (57%) of these 7 patients had
focal epilepsy compared with 12 of the 86 antibody-nega-
tive patients (13.9%; p = 0.059, Table 3).
Of these seven antibody-positive patients with epilepsy
of unknown cause, four had VGKC-complex-Abs only
(cases 1–4), three of whom presented with focal seizures,
and three had early seizure recurrence (cases 1, 3, and 4)
(Table 2). Case 5 had CASPR2 antibodies, presented with
focal tonic–clonic seizures and had intercurrent infections.
Case 8 was positive for NMDAR-Abs and had focal dyscog-
nitive seizures and focal status epilepticus on presentation.
A
B
Figure 1.
ILAE organization of seizures and epilepsies in patients positive for
one or more antibodies. (A) Antibody positivity (%) in all patients
presenting with new-onset seizures, n = 114. (B) ILAE classifica-
tion of antibody-positive patients with epilepsy (n = 10) in relation
to the total epilepsy cohort (n = 96). Antibody positive, dark blue;
antibody negative, light blue.
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Case 10 was double positive for NMDAR and VGKC-com-
plex and had a number of comorbidities. She presented with
seizures following an infliximab infusion given for
her treatment-resistant Crohn’s disease. Infliximab is a
monoclonal antibody used in the treatment of some autoim-
mune diseases and previously described to be associated
with seizures (Brigo et al., 2011).
Discussion
The finding of pathologically relevant autoantibodies to
neuronal proteins in a small but significant minority of
patients with epilepsy (9–13%, McKnight et al., 2005; Maj-
oie et al., 2006; Brenner et al., 2013) is becoming increas-
ingly recognized, but there have been limited studies in
children with epilepsy. Herein we studied a large group of
children presenting with new-onset seizures to a tertiary
children’s hospital and related the results to the recently
revised ILAE organization of seizure and epilepsy. The
cohort included a heterogeneous group of patients with a
wide spectrum of seizure severity and etiology. Overall
antibody positivity was detected in 9.6% of the cohort, and
surprisingly in 4.6% of the controls. Nevertheless, in
patients with epilepsy of “unknown cause,” often with focal
seizures, antibodies were more frequent than in the other
categories of seizures.
Many patients in the cohort were young and complicated,
required intensive acute treatment, or had ongoing refrac-
tory epilepsy, as they represented an inpatient sample rather
than a community outpatient sample.
The cohort description and classification represented a
challenging exercise, particularly at a time when the ILAE
classification and terminology is still evolving. It is notable
that the patients were classified with investigators blinded
to the result of antibody testing. Nearly one third of the
patients were determined to have an “unknown cause” for
Table 3. Comparison of features of positive and negative cases by ILAE organization of seizures and epilepsies (A) and
by clinical characteristics (B)
ILAE classification
Presence of characteristic in
Ab-positive patients (%) n = 11
Presence of characteristic in
Ab-negative patients (%) n = 103 p-Value
(A) Epileptic seizures not diagnosed as a form of epilepsy (n = 18) 1 (9.1) 17 (16.5) ns
Patients with epilepsy n = 10 n = 86
Electroclinical syndrome (n = 30) 2 (20) 31 (36) ns
Epilepsy attributed to structural-metabolic causes (n = 33) 1 (10) 32 (37) ns
Epilepsy of unknown cause (n = 33) 7 (70) 23 (26.7) 0.0095
Epilepsy of unknown cause (focal) (n = 16) 4 (40) 12 (13.9) ns (0. 059)
Epilepsy of unknown cause (generalized) (n = 10) 2 (20) 5 (5.8) ns
Epilepsy of unknown cause (spasms) (n = 4) 0 (0) 4 (4.7) ns
Epilepsy of unknown cause (undetermined) (n = 3) 1 (10) 2 (2.3) ns
(B) Clinical characteristic
Past medical history
Previously normal (n = 78) 9 (81.8) 69 (67.0) ns
First seizure
Focal 7 (63.6) 49 (47.6) ns
Generalized 4 (36.4) 38 (36.9) ns
Status epilepticus 1 (9.1) 20 (19.4) ns
Early seizure recurrence 7 (63.6) 70 (68.0) ns
Hospitalization (n = 101) 11 (100) 90 (87.4) ns
Intensive care (n = 18) 0 (0) 18 (17.5) ns
Associated features
Fever 1 (9.1) 20 (19.4) ns
Infection 3 (27.3) 28 (27.2) ns
Encephalopathy 2 (18.2) 31 (30.1) ns
Movement disorder 0 (0) 5 (4.8) ns
Behavioral abnormality 1 (9.1) 26 (25.2) ns
Cognitive abnormality 0 (0) 12 (11.8) ns
Motor deficit 2 (18.2) 15 (14.6) ns
Outcome
Ongoing epilepsy 9 (81.8) 75 (72.8) ns
New deficit 2 (18.2) 30 (29.1) ns
Developmental delay 0 (0) 16 (15.5) ns
Behavioral/psych impairment 2 (18.2) 16 (15.5) ns
Cognitive impairment 0 (0) 17 (16.5) ns
ns: not significant, corrected for multiple comparisons.
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their epilepsy, as also noted in a recent study comparing the
new and old systems (van Campen et al., 2013). Of note, 7
of the 10 antibody-positive results were in this epilepsy
category. The most frequently found antibody was to the
VGKC-complex (4/10). These four patients, however, were
negative for the VGKC-complex proteins LGI1, contactin-
2, and CASPR2. The lack of an identified complex protein
has been reported previously in children (Dhamija et al.,
2011; Ilingworth et al., 2011; Suleiman et al., 2011b; ) and
contrasts with adults in whom antibodies to LGI1, and less
frequently to CASPR2, are often found (Irani et al., 2008,
2010a,b; Lai et al., 2010), although not inevitably (Patter-
son et al., 2013). It is likely that the VGKC-complex anti-
bodies bind to other antigenic targets that are yet to be
identified in children (Hacohen et al., 2013). On the other
hand, three patients were positive for CASPR2 antibodies,
which have not been identified before in children, but were
negative for VGKC-complex antibodies in the radioimmu-
noassay, so would have been missed with standard VGKC-
complex-Ab screening.
None of the VGKC-complex or CASPR2 antibody-posi-
tive patients had a phenotype typical of limbic encephalitis,
although most of them presented with focal seizures, sug-
gesting that neuronal antibodies can be present beyond the
spectrum of this recognized syndrome, especially in chil-
dren. Two patients with positive NMDAR antibodies had
epilepsy in the absence of classic autoimmune NMDAR-Ab
encephalitis: one presented with focal dyscognitive seizures
and one had mixed seizure types. This is similar to adult
cases described with new-onset epilepsy associated with
NMDAR Abs (Niehusmann et al., 2009; Brenner et al.,
2013). In addition, two patients in our cohort, both present-
ing with generalized seizures, were positive for both
NMDAR and VGKC-complex-Abs. The finding of two or
more neuronal Abs is beginning to be recognized (Irani
et al., 2010a; Pellkofer et al., 2010; Haberlandt et al., 2011)
and may reflect a wider activation of the immune system,
perhaps by infections or possibly as a secondary response to
neuronal damage. NMDAR-Abs have recently been
reported in one patient with MELAS (Finke et al., 2012),
and secondary activation may be a possible explanation for
the finding of two antibody-positive patients with known
structural or metabolic cause for their epilepsy (cases 7 and
9).
Nine of the 11 positive patients with recorded follow-up
had on going epilepsy and/or seizures, but unfortunately
none of the 11 positive patients received immunotherapy.
These patients did not develop long-term cognitive or
behavioral impairment, although the follow-up was short
and detailed neuropsychology was not done. Because this
was a prospective observational cohort study, we can only
hypothesize that immunotherapy, if given, might have
improved the epilepsy outcome in these patients.
The control group consisted of children with various
immunologic, oncologic, and medical conditions, and three
controls were positive for one of the tested antibodies,
although they did not have apparent neurologic symptoms.
This level of positivity appears to be higher than in adult
control cohorts (e.g., McKnight et al., 2005; Brenner et al.,
2013). However, few other reports have used childhood
controls; indeed all children in this cohort had been hospital-
ized, and approximately one third of the patients had infec-
tious/inflammatory conditions. The ability to develop
antibodies in response to circulating pathogens or environ-
mental factors may be higher in children, particularly in
those who are already unwell. However, if antibody levels
are sustained, it is possible that these children could be at
risk of future neurologic dysfunction.
This study is the first to describe a relatively large pro-
spective cohort of pediatric patients with new-onset sei-
zures, apply the new ILAE system for the organization of
seizures and epilepsies (as for Berg et al., 2010), and test
them for neuronal antibodies within 6 months of seizure
onset. We found that specific neuronal antibodies were
more common, and these may play an etiologic role in chil-
dren with epilepsy of unknown cause, indicating that the
new ILAE system may “facilitate the identification of non-
genetic determinants of epilepsy” (Berg 2010). We suggest
that further antibody testing could be performed in pediatric
epilepsy patients classified in this “unknown” category, par-
ticularly those with focal epilepsy; it has already been sug-
gested that increasing the number of investigations should
help to identify the etiologies of this group (van Campen
et al., 2013). Moreover, because the new ILAE organization
does not incorporate autoimmune forms in the epilepsy or
etiology classification, the possibility of including
“immune-mediated epilepsy” as a separate category (Bren-
ner 2013) needs to be considered. However, it is also possi-
ble that the presence of neuronal antibodies are, in some
circumstances, an epiphenomenon or secondary to struc-
tural damage or generalized immune activation. Further
studies should concentrate on identifying antibodies in chil-
dren with epilepsy of unknown cause closer to disease onset,
with systematic testing of the effects of immune therapies,
and applying the recent guidelines to determine whether
these seizure-related antibodies define forms of “autoim-
mune epilepsy,”
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SUMMARY
Purpose: Antibodies against neuronal surface proteins
are increasingly recognized in autoimmune central ner-
vous system (CNS) disorders in which seizures are the
main or an important feature. The disorders include
antibody-associated limbic encephalitis and N-methyl-
D-aspartate receptor (NMDAR) encephalitis; however,
seizures of autoimmune etiology may exist beyond the
spectrum of these recognized syndromes. Because these
seizures are potentially treatable with immune therapy,
guidelines are needed to help in their early recognition.
Methods: We describe 13 representative children seen at
our tertiary institution over a period of 3.5 years with sus-
pected autoimmune epilepsy. Autoimmune epilepsy was
suspected clinically when there was any of the following:
(1) recognizable syndromes such as NMDAR encephalitis
or limbic encephalitis, (2) evidence of CNS inflammation
in cerebrospinal fluid or on magnetic resonance imaging
(MRI), (3) the presence of other autoimmune diseases, or
(4) positive response to immunotherapy.We tested these
patients for neuronal surface antibodies (voltage gated
potassium channel [VGKC]-complex, leucine rich glioma
inactivated 1 [LGI1], contactin-associated protein-like 2
[CASPR2], and NMDAR) and glutamic acid decarboxy-
lase (GAD) antibodies. We modified the J Neurol Neuro-
surg Psychiatry, 83, 2012, 638 guidelines that were
designed to classify adults with neuronal surface antibody
syndromes (NSAS), to be more appropriate for children
with suspected autoimmune epilepsy. Using the modified
guidelines, the 13 patients were classified into definite,
probable, possible, unlikely, or unknown autoimmune epi-
lepsy according to the presence of neuronal surface or
GAD antibodies, and the response to immune therapy
when given.
Key Findings: Of the 13 patients, 11 were females, and the
mean age was 6 years (range 1–13 years). Three patients
had classical NMDAR encephalitis, two had VGKC
encephalitis, two had limbic encephalitis with negative
antibodies, three had epilepsy with other autoimmune
diseases (one with high titer GAD antibodies), two had
fever-induced refractory epileptic encephalopathy in
school-aged children (FIRES), and one epileptic encepha-
lopathy associated with VGKC antibodies. Seven patients
of the 13 children with suspected autoimmune epilepsy
were positive for neuronal surface antibodies (NMDAR,
n = 3; VGKC-complex, n = 3; and GAD, n = 1). Immuno-
therapy was given to nine cases, and a positive response
was more common in patients with positive neuronal sur-
face antibodies (5/5) compared to those with negative
antibodies (2/4). Applying the proposed guidelines, the
classification of autoimmune epilepsy was definite in five,
probable in one, possible in three, unlikely in two, and
unknown in two patients.
Significance: Neuronal surface antibodies and GAD anti-
bodies are present in a proportion of children with sus-
pected autoimmune epilepsy and may define a treatable
subgroup of childhood epilepsy. The proposed guidelines
can be useful in the recognition of children with seizures
of autoimmune etiology.
KEYWORDS: Epilepsy, Autoimmune, Antibodies, FIRES,
VGKC,NMDAR,GAD, Pediatrics.
The association between autoantibodies and central ner-
vous system (CNS) disease is increasingly recognized.
Serum and cerebrospinal fluid (CSF) antibodies that bind to
neuronal cell surface proteins including channels and recep-
tors have the potential to be pathogenic and cause CNS dis-
ease. By contrast onconeuronal antibodies are typically
targeted against intracellular antigens and not thought to be
directly pathogenic (Vincent et al., 2011; Bien et al., 2012).
Recently antibodies that bind extracellularly and are associ-
ated with CNS disorders have been called “neuronal surface
antibodies” (NSAbs) and the disorders associated with these
NSAbs are called “neuronal surface antibody syndromes”
(NSAS) (Zuliani et al., 2012). There are well-defined CNS
syndromes associated with NSAbs where seizures are an
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important feature. Examples include N-methyl-D-aspartate
receptor (NMDAR) encephalitis in which 76–83% of
patients will have focal, focal dyscognitive, or generalized
seizures (Dalmau et al., 2007, 2008, 2011; Irani & Vincent,
2011), and voltage-gated potassium channel (VGKC)-com-
plex antibody associated autoimmune limbic encephalitis
(including leucine rich glioma inactivated 1 [LGI1] and
contactin-associated protein-like 2 [CASPR2] antibodies)
in which patients often have temporal lobe seizures (Irani
et al., 2010; Lai et al., 2010). In addition, faciobrachial dys-
tonic seizures are seen in adults in association with LGI1
antibodies and often precede the onset of the limbic enceph-
alitis (Irani et al., 2011). Other NSAbs are less fre-
quently found in adults with limbic encephalitis such as
alpha amino-3-hydroxy-5-methyl-4-isoxazolepropionic
acid (AMPA) and c-aminobutyric acid B (GABAB) receptor
antibodies (Lai et al., 2009; Lancaster et al., 2010; Boronat
et al., 2011). Antibodies to glutamic acid decarboxylase
(GAD) have been associated with limbic encephalitis
(Malter et al., 2010). Although GAD is an intracellular anti-
gen and therefore GAD Abs themselves may not be patho-
genic, it is possible that unrecognized NSAbs coexist with
GADAbs (Zuliani et al., 2012).
Zuliani et al. proposed guidelines for the recognition,
testing, and treatment of suspected autoimmune CNS disor-
ders. They used clinical criteria, supportive features, neuro-
nal antibody testing, and the response to immune therapy to
classify patients into categories of definite, probable, and
possible NSAS (Zuliani et al., 2012). Lancaster and
Dalmau have proposed an alternative laboratory-based
algorithm for identification and assessment of antibodies to
neuronal cell-surface antigens using cell based assays as
well as rat brain immunohistochemistry and cultures of neu-
rons for serum and CSF antibody binding (Lancaster &
Dalmau, 2012).
In children, NMDAR encephalitis is well described
(Florance et al., 2009), whereas limbic encephalitis has
been described in association with a number of different au-
toantibodies including VGKC-complex Abs (Haberlandt
et al., 2011; Suleiman et al., 2011a). In children there are
other epileptic conditions where immune-mediated mecha-
nisms are suspected such as febrile infection-related epi-
lepsy syndrome (van Baalen et al., 2010) or fever-induced
refractory epileptic encephalopathy in school-aged children
(Nabbout et al., 2010, 2011), both called fever-induced
refractory epileptic encephalopathy in school-aged children
(FIRES). Previous terms used to describe similar syndromes
include devastating epileptic encephalopathy in school-
aged children (DESC) (Mikaeloff et al., 2006) and acute
encephalitis with refractory repetitive partial seizures
(AERRPS) (Sakuma, 2009). These conditions are character-
ized by new-onset refractory focal status epilepticus, pre-
ceded by fever or infection in previously normal children,
followed by a chronic phase of refractory focal epilepsy and
severe neurologic impairment (Sakuma et al., 2010). The
cause of these conditions is unknown and underlying
immune mechanisms have been proposed (Sakuma et al.,
2010; Specchio et al., 2010; Nabbout et al., 2011) but not
proven.
Herein we present a representative case series of 13 chil-
dren suspected to have an autoimmune basis for their epilep-
sies. We propose modified guidelines for the recognition of
autoimmune epilepsy and apply these guidelines to the 13
children with suspected autoimmune epilepsy to test their
utility.
Methods
Cases identification
Through our clinical practice at The Children Hospital
at Westmead (CHW) we identified cases with seizures
that may have an autoimmune etiology. The neurology
department at CHW is a busy tertiary children’s hospital
that sees 300–400 children with new onset seizures per
year, as well as other acute and chronic neurologic dis-
eases in children. The patients presented in this cohort
were discussed in detail by JS and RCD as they were sus-
pected to have an autoimmune cause of their epilepsy (as
defined below), and were investigated for neuronal sur-
face antibodies. This cohort does not represent all children
with encephalitis (of all etiologies) seen during this time
(n = 33) and are currently being tested in a separate study
at this hospital. It is also likely that other autoimmune epi-
lepsies were missed by the investigating team and were
not tested for antibodies. Instead this cohort should be
considered a representative sample of children with sus-
pected autoimmune epilepsy, which were used to test the
utility of the modified guidelines.
We suspected autoimmune epilepsy in children with
acute or subacute onset of seizures once other causes (infec-
tion, structural, metabolic, or genetic) were excluded, and
when any of the features described in Table 1 were present.
Herein we describe 13 representative patients seen
over a three and a half year period (late 2008 to mid-
2012), who we suspected may have an autoimmune cause
for their epilepsy, and who had serum available for test-
ing for neuronal antibodies. No patients have been previ-
ously reported except for case 5 (Suleiman et al., 2011a)
and case 10 (Suleiman et al., 2011b), and these two cases
were included as they test the utility of the guidelines.
This study was approved by the hospital ethics commit-
tee.
Ten patients had serum testing in the acute phase of their
illness, whereas in three the serum was from the chronic
symptomatic phase. All samples were taken before immune
therapy, if given. Antibody assays were all performed in
Oxford, United Kingdom using previously published meth-
ods (Irani et al., 2010), apart from case 3, for which the
assay was performed in National NMDAR antibody referral
laboratory (Brisbane, Qld, Australia).
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Proposed modified guidelines
To improve recognition and diagnosis of children
with suspected autoimmune epilepsy, we modified the
guidelines proposed by Zuliani et al. for identification
of children with neuronal surface antibodies syndromes
(Table 1). Then, based on antibody testing and the
response to immunotherapy (when given), we proposed
five categories for classification (in descending order of
likelihood of autoimmune epilepsy) including definite,
probable, possible, unlikely, or unknown autoimmune
epilepsy (Table 2, Fig. 1). We applied the modified
guidelines to our 13 cases to test their usefulness
(Table 3).
The main differences to the Zuliani et al. guidelines for
adults include the following:
1 In children a paraneoplastic cause of epilepsy is very rare,
and testing for onconeural antibodies is rarely necessary.
However; children with positive NMDAR Abs should be
screened for ovarian teratomas.
2 In children fever and intercurrent infections are common
and less likely to be a supportive feature for an autoim-
mune process as has been proposed in adults, so this was
not used as one of the supportive features (Zuliani et al.,
2012).
3 We used elevated CSF neopterin as an additional marker
of CNS inflammation (Dale et al., 2009).
4 In Zuliani et al., abnormalities on functional imaging
including hypermetabolism on positron emission
tomography or hyperperfusion on single proton com-
puted tomography were used as features to suggest
CNS inflammation. However, there is inadequate
research to demonstrate their ability to discriminate epi-
lepsy etiologies in children and therefore we did not
include these features.
Table 1. Criteria and supportive features to suspect autoimmune epilepsy in children with seizures
The following two clinical criteria are used to suspect autoimmune epilepsy associated with NSAbs and GAD antibodies (both are needed)
1 Acute or subacute (<12 weeks) onset of symptoms.
2 Exclusion of other causes (CNS infection, trauma, toxic, tumor, metabolic, previous CNS disease).
The following supportive features would strengthen the suspicion of autoimmune epilepsy (patients should have at least 1 of the following):
1 The presence of a well-defined clinical syndrome such as NMDAR or limbic encephalitis
2 CNS inflammation manifested by at least one of:
a CSF pleocytosis (defined as >5 white cells/mm3) or presence of oligoclonal bands, elevated IgG index, or elevated
neopterin (defined as >30 nM)
b MRI abnormality compatible with an inflammatory or autoimmune encephalitis including increased signal in the
mesiotemporal lobe (LE – like syndrome)
c Inflammatory neuropathology on biopsy
3 History of other antibody mediated condition (e.g., myasthenia gravis), organ specific autoimmunity or other autoimmune
disorders.a
4 Response to immunotherapy
aIt is recognized that epilepsy is more common in many autoimmune disorders including multiple sclerosis, systemic lupus erythematosus, type 1 diabetes mell-
itus (T1DM), celiac disease, and autoimmune thyroid disease (Vincent & Crino, 2011).
Table 2. Classification categories of suspected autoimmune epilepsy in children identified using the criteria and
supportive features in Table 1 (Zuliani et al., modified)
Classification categories expressing the likelihood of autoimmune epilepsy based on the presence of NSAbs and GADAbs and the response to
immunotherapy (see Fig. 1):
Definite autoimmune epilepsy is present if:
KnownNSAbs are present in serum or CSF
AND there is response to immunotherapy
Probable autoimmune epilepsy is present if
KnownNSAbs are present and no immunotherapy responsiveness demonstrated (immunotherapy unsuccessful or not given)
ORGAD antibodies are present AND there is response to immunotherapy
Possible autoimmune epilepsy is present if known NSAbs are negative and
GAD antibodies are present and no immunotherapy responsiveness demonstrated (unsuccessful or not given)
ORGAD antibodies are negative and there is a response to immunotherapy
Unlikely autoimmune epilepsy is present if
KnownNSAbs and GAD are negative and there is no response to immunotherapy
Unknown autoimmune epilepsya is present if
KnownNSAbs and GAD are negative and immunotherapy is not given
aPatients in this category may move to a different category if they receive immunotherapy, such as “possible” if they respond or “unlikely” if they did not respond
to immunotherapy.
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5 Antibodies included in the guidelines are those available
at international laboratories including antibodies against
VGKC-complex proteins, LGI1 and CASPR2, NMDAR,
and GAD. We did not include neuronal binding or neuro-
pil antibody testing (using immunohistochemistry or
immunofluorescence on rat brain tissue) for recognizable
staining patterns (Lancaster & Dalmau, 2012), as these
are done in research settings and are less available to cli-
nicians routinely.
6 Response to immunotherapy was defined as significant
clinical improvement of encephalopathy or reduction of
seizures as judged by the treating clinicians. We accept
the subjective nature of this, and the fact that there are a
number of confounders that could be responsible for
improvements such as the concomitant change in anti-
epileptic drugs.
7 We incorporated patients who did not receive immuno-
therapy into the classification either because an immune-
mediated mechanism was not initially suspected or
because of spontaneous improvement.
Results
The 13 patients with seizures of suspected autoimmune
origin (11 female, age range 1–13 years, mean age 6 years)
are presented in Table 3. All patients had other potential
causes for their seizures excluded. All 13 patients had new-
onset seizures and at least one supportive feature of CNS
Figure 1.
Flow chart for approach to children with seizures of suspected autoimmune etiology (modified from Zuliani et al., 2012). OCB, oli-
goclonal bands; *, onconeuronal Abs testing is rarely necessary in children; #, if NMDAR, look for ovarian teratoma in females;
@, GAD positivity is defined as >1,000 u/ml. Immunotherapy refers to high-dose steroids and/or intravenous immunoglobulins.
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inflammation or the presence of other autoimmune diseases
(Tables 1 and 2). Three patients had the clinical characteris-
tics of NMDAR encephalitis (all with CSF and serum
NMDAR antibodies), two had encephalitis associated with
VGKC-complex antibodies, two had features suggestive of
limbic encephalitis (with negative antibodies), three had
epilepsy in association with other autoimmune diseases
(one with GAD antibodies), two had FIRES, and one had
epileptic encephalopathy with CNS inflammation (VGKC
antibody positive).
Seven patients (53.9%) of the 13 were positive for one of
the tested antibodies including NMDAR (n = 3), VGKC-
complex (n = 3), and GAD (n = 1). Immunotherapy was
given in nine patients: five with positive neuronal antibodies
and four negative. The immune therapy was steroids alone
(n = 4), steroids and intravenous immunoglobulin (IVIG)
(n = 3), steroids, IVIG and mycophenolate (n = 1) and ste-
roids, IVIG, and rituximab (n = 1). All five patients with
positive neuronal antibodies who received any immune ther-
apy improved after receiving therapy, whereas only two of
four with negative neuronal antibodies improved after receiv-
ing immune therapy. Three of the four patients who did not
receive immunotherapy had poor outcome including ongoing
epilepsy, and cognitive and psychiatric impairment (Table 3).
Patients were classified according to the proposed modi-
fied guidelines (Table 2, Fig. 1), and their classification is
presented in Table 3. Five patients had definite, one had
probable, three had possible, two had unlikely, and two had
unknown autoimmune epilepsy.
We present the case histories for 8 of the 13 patients in
details in the Data S1 as representative examples.
Discussion
The recognition of immune mechanisms in neurologic
disorders is important as this can prompt early treatment
and may lead to better outcomes. The identification of
specific and potentially pathogenic NSAbs is increasing,
and the spectrum of the clinical syndromes associated
with NSAbs is widening (Zuliani et al., 2012). Recently
guidelines have been developed to help in the diagnosis
and management of adults with suspected NSAS (Zuliani
et al., 2012). In children the lack of large studies regard-
ing NSAbs and their related syndromes makes it harder to
identify these cases; therefore, guidelines may help in the
identification of NSAS particularly when seizures are an
important feature.
In this paper, we describe 13 representative patients with
seizures of suspected autoimmune etiology and we propose
features for identification of these pediatric patients, and a
classification system testing the strength of evidence of
autoimmune epilepsy based on the presence of neuronal
antibodies and response to immunotherapy.
There were some general features common to the cohort.
Females were over-represented in this cohort, as is often
described in autoimmune disorders in general. The seizures
were often focal, and generally occurred in association with
encephalopathy or other features of CNS dysfunction.
Three cases had typical features of NMDAR encephalitis
in children, as represented by case 3 description in the Data
S1. The patients with NMDAR encephalitis generally had
focal epilepsy, and the presence of psychiatric manifesta-
tions, behavior alteration, and movement disorder was a
strong indicator of NMDAR encephalitis. However, it is
possible that NMDAR Abs are present in children with epi-
lepsy in the absence of the classic phenotype as has been
described in adults (Niehusmann et al., 2009), and therefore
testing for NMDAR Abs in children with suspected autoim-
mune seizures may provide further information about the
spectrum of NMDAR antibody-associated disease.
Two cases had VGKC-complex Ab-associated encephali-
tis, characterized by fever-associated focal seizures and sta-
tus epilepticus; one was previously reported (case 5) and the
clinical phenotype of the second case (case 4) was similar to
our previously reported pediatric patients with VGKC-com-
plex Ab-associated encephalitis (Suleiman et al., 2011a).
The seizure semiology was suggestive of temporal lobe
onset, a finding that is commonly seen in both adults and
children with this syndrome (Vincent et al., 2004; Suleiman
et al., 2011a). In case 4, mycoplasma immunoglobulin M
(IgM) was positive and was consistent with acute infection.
Mycoplasma infection has been described in association
with NMDAR encephalitis in children and may be a trigger
of autoimmune CNS disorders (Florance et al., 2009). How-
ever, mycoplasma pneumonia is a common respiratory
infection in children and positive mycoplasma serology
may therefore be incidental in some patients (Waites &
Talkington, 2004). Antibodies against LGI1 or CASPR2,
which have been identified as the target of VGKC-complex
Abs in adults, were negative in this case, a finding that is
common in children with positive VGKC-complex Abs. It
is possible that in children, VGKC-complex Abs are tar-
geted against other antigens in the VGKC-complex that are
yet to be identified. Patients with VGKC-complex Ab-asso-
ciated encephalitis often respond to immune therapy, but
spontaneous improvement can also occur (Irani et al., 2010)
as was the case in this patient.
Case 6 had a syndrome of limbic encephalitis; however,
NSAbs and GAD Abs were negative, possibly due to late
testing and because the patient received no immunotherapy,
the classification was “unknown.” Early recognition, test-
ing, and treatment might have improved her outcome. Case
7 had a limbic encephalitis syndrome and was negative for
NSAbs but responded to immune therapy (classification
possible). Antibodies against AMPAR and GABABR (not
tested) or other unrecognized NSAbs could be the cause of
limbic encephalitis in these patients. The diagnosis of lim-
bic encephalitis can be challenging in children, where its
existence is reported but probably underrecognized (Haber-
landt et al., 2011). The diagnosis of limbic encephalitis is
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partly clinical, with new-onset temporal lobe seizures and
cognitive disturbance sometimes associated with radiologic
mesial temporal or hippocampal changes. Because hippo-
campal signal change is described in a proportion of chil-
dren with febrile status epilepticus (Shinnar et al., 2012), it
is difficult to discriminate radiologic seizure-induced
hippocampal swelling from limbic encephalitis.
Cases 8 and 9 were typical of “FIRES” (van Baalen et al.,
2010; Nabbout et al., 2011). Neuronal antibodies were neg-
ative, and there was no response to immunotherapy in both
patients. The absence of antibodies and the negative
response to immune therapy make an autoimmune etiology
“unlikely.” Negative response to immunotherapy has been
reported in a series of seven cases of FIRES, and NSAbs
were negative in the tested patients (three were tested for
VGKC-complex Abs and one for NMDAR Abs) (Howell
et al., 2012). In addition a series of 12 children with FIRES
was negative for neuronal surface antibodies and GAD (van
Baalen et al., 2012). There is one report of a boy with posi-
tive VGKC antibodies associated with FIRES who bene-
fited from immunotherapy (Illingworth et al., 2011);
however, this case did not have a typical course of FIRES
and it is possible that the case had VGKC-complex anti-
body-associated encephalitis instead. The markers of CNS
inflammation seen in our two cases (8 and 9) have been
reported in the acute phase of FIRES, and may be explained
by the extreme high seizure load, seizure-related neuronal
injury, or cytokine release (Howell et al., 2012). Rather than
an autoimmune epilepsy syndrome, FIRESmay be a genetic
channelopathy or a chronic epilepsy syndrome with explo-
sive onset (Ismail & Kossoff, 2011; Howell et al., 2012).
Three of our cases had epilepsy in association with other
autoimmune diseases including type 1 diabetes mellitus
(T1DM) and autoimmune thyroid disease (case 11), anti
MuSK myasthenia gravis (case 12), and T1DM and possible
autoimmune ataxia (case 13).
T1DM is a T cell–mediated autoimmune disorder, and
there is an increased prevalence of epilepsy in children with
this disease (Schober et al., 2012).
Seizures can occur in Hashimoto’s encephalopathy, which
is a rare association of autoimmune Hashimoto’s thyroiditis
associated with Abs against thyroid peroxidase and thyroglob-
ulin (Castillo et al., 2006). Patients described with Hashimoto
encephalopathy present with broad clinical manifestations
and are classically reported to be steroid responsive. The role
of thyroid antibodies in Hashimoto encephalopathy is uncer-
tain, and the term “steroid responsive encephalopathy associ-
ated with autoimmune thyroiditis” (SREAT) has been used to
reflect the hypothesis that Hashimoto encephalopathy may be
caused by unidentified neuronal autoantibodies (Castillo
et al., 2002; Schauble et al., 2003).
Graves’ disease is an antibody mediated autoimmune
disorder and juvenile myoclonic epilepsy (JME) has been
previously associated with Grave’s disease, and may be due
to thyroxine causing a lower seizure threshold (Su et al.,
1993). Our case 11 was diagnosed to have an idiopathic
myoclonic epilepsy (JME) based on her age, seizure pheno-
type, and EEG abnormality. JME is considered to be a
genetic epilepsy, and indeed in this case there was limited
evidence that the epilepsy was autoimmune despite the pres-
ence of other autoimmune diseases, and her classification
was “unknown” as she was negative for NSAbs and
received no immunotherapy.
Seizures in association with anti MuSK Ab myasthenia
gravis are rare but have been reported in an adult patient
(Bhagavati et al., 2007). Case 12 had anti-MuSK Ab associ-
ated myasthenia gravis and concurrent focal epilepsy. Her
seizures did not respond to carbamazepine but improved
when high dose steroids were used to treat her myasthenia
gravis. It is possible that myasthenia gravis and epilepsy in
our patient is a chance association, although both clinical
entities presented, remitted and relapsed concurrently.
Case 13 had seizures in the context of T1DM. This patient
had an acute transient ataxia followed by chronic epilepsy,
with very high GAD antibodies. GAD antibodies are associ-
ated with a variety of CNS syndromes including stiff person
syndrome, immune ataxia, epilepsy, and limbic encephalitis
(Honnorat et al., 2001; Saiz et al., 2008; Malter et al.,
2010). In our patient the immune-mediated ataxia, cognitive
impairment, focal epilepsy, and high GAD antibodies were
supportive of the autoimmune epilepsy hypothesis.
Patients with epilepsy and other systemic autoimmune
diseases may have other as-yet-unidentified NSAbs.
However, other explanations for increased epilepsy inci-
dence in systemic autoimmune disorders include incidental
coexistence, a common genetic predisposition, or secondary
effects of the primary disease (Vincent & Crino, 2011).
One important feature of the adult guidelines is that
response to immunotherapy is used as a retrospective fea-
ture to help with classification. In other words the “guideline
classification” cannot be completed until immunotherapy is
used. Our modified guidelines partly address this issue and
incorporate patients who did not receive immunotherapy. In
our case, series some patients did not receive immunother-
apy either because an autoimmune etiology was not initially
suspected at presentation or due to spontaneous improve-
ment without the need for immunotherapy. A positive
response to immunotherapy was more common in patients
who had positive NSAb (five of five given immunotherapy)
compared to those who were NSAb negative (two of four).
However, in a recent study of 48 children with suspected
autoimmune encephalitis, only 21 had specific antibodies
detected, and beneficial treatment responses were seen in
both antibody-positive and antibody-negative groups
(Hacohen et al., 2012).
In our clinical practice over the last few years we have
been increasingly using immunotherapy empirically once
an underlying immune-mediated disorder is suspected while
awaiting the specific investigations. Children suspected of
potential autoimmune epilepsy undergo investigations to
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exclude infectious, toxic, metabolic, or genetic causes, and
neuronal surface and GAD antibodies are requested. While
awaiting the results of the neuronal antibodies, empiric
immunotherapy may be commenced if the clinical
syndrome is severe and impairing. We suggest that immu-
notherapy be used early in the disease course to optimize its
potential effect. The regimen we have been using includes
intravenous pulse methylprednisolone at 30 mg/kg/day for
3 days followed by a tapering course of oral prednisolone
(variable duration of weeks to months according to the
disorder), often in conjunction with intravenous immuno-
globulins at 2 g/kg given over 2 days. Patients with partial
response or no response after 1–3 weeks may receive fur-
ther doses of intravenous immunoglobulins or plasma
exchange if the condition is severe and concerning, and the
autoimmune hypothesis remains possible. Patients who fail
to respond or who have a partial response may be considered
for second-line therapy, such as rituximab or cyclophospha-
mide. However the side effect profile of these drugs is more
concerning, so a “risk versus benefit” assessment is neces-
sary. In our case series immunotherapy was generally toler-
ated well, particularly when given short term (such as the
NMDAR encephalitis cases). Two patients developed sig-
nificant side effects attributed to immunotherapy including
behavioral alteration with prolonged steroid use (case 12)
and prolonged hypogammaglobulinemia requiring IVIG
replacement presumed to be secondary to rituximab (case
8), a finding that has been described previously (Makatsori
et al., 2012). Some patients with seizures of autoimmune
etiology can have complete recovery without immunother-
apy (similar to case 4); however, it is hard to predict which
cases will spontaneously recover, and therefore early immu-
notherapy is suggested when the patient is severely
impaired. Similar treatment regimens have been used in
adults with VGKC Ab-positive encephalitis with good
effect (Reid et al., 2009; Wong et al., 2010). Although
plasma exchange is used commonly in adults, the use of
plasma exchange in children as a modality of immune ther-
apy is limited due to its invasiveness, the need for intensive
care treatment, and potential side effects.
Although a positive response to immunotherapy supports
immune-mediated mechanisms, steroids (and IVIG to a les-
ser extent) are used in the treatment of refractory and severe
epilepsies that are not proven to be autoimmune.
In conclusion, autoimmune mechanisms play an impor-
tant role in a proportion of children presenting with seizures.
We propose guidelines that may help clinicians in the
approach to identify children with suspected autoimmune
seizures. Although helpful, the guidelines are not perfect
and represent only an attempt to identify and classify these
patients. These guidelines do not predict treatment respon-
siveness or outcome. Future studies may improve the under-
standing of clinical phenotypes of autoimmune epilepsy in
children and help further develop syndrome-specific and
treatment-oriented guidelines.
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ABBREVIATIONS
CASPR2 Contactin-associated protein 2
GAD Glutamic acid decarboxylase
LGI1 Leucine-rich glioma-inactivated 1
NMDAR N-methyl-D-aspartate receptor
OCB Oligoclonal band
VGKC Voltage-gated potassium channel
Autoantibodies that bind to voltage-gated potassium-channel complex proteins (VGKC-complex
antibodies) occur frequently in adults with limbic encephalitis presenting with cognitive impair-
ment and seizures. Recently, VGKC-complex antibodies have been described in a few children
with limbic encephalitis, and children with unexplained encephalitis presenting with status epilep-
ticus. We report a case of infantile-onset epileptic spasms and developmental delay compatible
with epileptic encephalopathy. Our patient was a female infant, aged 4 months at presentation.
She had evidence of immune activation in the central nervous systemwith elevated cerebrospinal
fluid neopterin and mirrored oligoclonal bands, which prompted testing for autoantibodies.
VGKC-complex antibodies were elevated (201pmol ⁄L, normal<100), but extended antibody test-
ing, including leucine-rich glioma-inactivated 1 (LGI1) and contactin-associated protein 2 (CAS-
PR2), was negative. The patient showed a partial response to steroid treatment, which was started
late in the disease course. On review at 13 months of age, her development was consistent with
an age of 5 to 6 months. These results suggest that VGKC-complex antibodies might represent a
marker of immune therapy responsiveness in a subgroup of patients with infantile epileptic
encephalopathy.
Epileptic encephalopathies are a group of conditions in which
cognitive and neurological functions deteriorate in association
with epileptic activity.1 Epileptic encephalopathy can occur at
any age; however, it is most common and severe in infancy
and early childhood, when global and profound cognitive
impairment might occur.2 The encephalopathy might result
from the underlying cause, the epileptic process, or a combi-
nation of both. Epileptic spasms are a severe form of epilepsy
and epileptic encephalopathy that usually affect infants and
was previously called infantile spasms.2 Epileptic spasms are
difficult to treat and are typically associated with delayed
development.3 Interictal electroencephalography (EEG) in
patients with epileptic spasms often shows a characteristic cha-
otic and high-voltage pattern, which, when typical, is called
hypsarrhythmia.4 Epileptic encephalopathy and epileptic
spasms can be caused by multiple aetiologies including struc-
tural, metabolic, and genetic causes;1,4 however, in some cases,
no aetiology can be found.4
There is increasing interest in the role of inflammation in
epilepsy and status epilepticus.5 The immune process can be
primary and cause seizures or, alternatively, inflammation can
be secondary to seizures themselves.5 Antineuronal antibodies
binding to N-methyl-D-aspartate receptor (NMDAR),
glutamic acid decarboxylase (GAD), and voltage-gated potas-
sium channels (VGKCs) have been associated with a spectrum
of syndromes in the central nervous system including seizures
and limbic encephalitis, and are proposed to be causative.6–10
Limbic encephalitis associated with VGKC-complex
antibodies classically presents with seizures and cognitive
impairment and is immune responsive.6 These antibodies were
originally thought to be directed towards the VGKCs
themselves, but it is now clear that most bind to proteins that
are part of the VGKC complex, particularly leucine-rich
glioma-inactivated 1 (LGI1) and contactin-associated protein 2
(CASPR2).11,12 Antibodies to LGI1 are particularly found in
patients with immune-responsive limbic encephalitis and in the
recently described epileptic syndrome, facio-brachial dystonic
seizures.13 Recently, VGKC-complex antibodies have been
reported in children with limbic encephalitis,14 and in
encephalitis presenting with status epilepticus.15 These
paediatric patients had a variable outcome including temporal
lobe epilepsy and cognitive impairment15 but they were not
treated promptly with immune therapy. VGKC-complex
autoimmunity has also been recently described in children with
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various neurological manifestations including one with early-
onset symptomatic generalized epilepsy associated with
mesotemporal magnetic resonance imaging (MRI) changes.16
These findings support the importance of autoimmune
mechanisms in some children with epilepsy.
We report a femalewith early-onset epileptic encephalopathy
and epileptic spasmswhohad elevated cerebrospinal fluid (CSF)
neopterin andmirrored oligoclonal bands (OCBs) suggestive of
immune activation.17Thepatient had elevatedVGKC-complex
antibodiesandshowedapartialresponsetosteroidtherapy.
METHOD
Over the past 5 years we have measured CSF neopterin17 and
CSF OCBs in all patients who undergo CSF testing. Of 19
patients with epileptic encephalopathy tested, only two had
raised neopterin and positive OCBs. One case, which is not
reported here, had immunodeficiency and epileptic encephalo-
pathy. The second had unexplained epileptic encephalopathy
with epileptic spasms and is described here. As we suspected a
possible autoimmune process in this reported case, we retro-
spectively tested serum for autoantibodies against neuronal
antigens including VGKC, NMDAR, GAD, LGI1, and
CASPR2 using serum collected 10 months after seizure onset.
The study of autoantibodies in children with epilepsy was
approved by the Children’s Hospital at Westmead ethics com-
mittee. Informed consent for publication of this report was
obtained from the parents of the patient.
CASE REPORT
A female of South Pacific origin was referred to our hospital
with epileptic spasms. She was delivered at term with no com-
plications. She started to have epileptic spasms at the age of
4 months that occurred in clusters of up to four per day (one
to four spasms per cluster). Vigabatrin was started by the
referring doctors, which helped initially; however, the spasms
recurred and did not respond to increasing doses of vigabatrin
(maximum dose of 100mg ⁄kg ⁄day). The patient had signifi-
cant developmental delay and on review at 13 months of age
her development was consistent with an age of 5 to 6 months.
Examination revealed truncal hypotonia, but normal neuro-
logical examination otherwise. She developed eczema at the
age of 3 to 4 months, which was resistant to topical treatment.
EEG showed slow background with high amplitude
multi-focal spike and slow-wave complexes compatible with
‘modified hypsarrhythmia’ and consistent with epileptic
encephalopathy. Brain MRI showed mild diffuse cerebral
atrophy and mild delay in white matter myelination. The
following investigations were normal: blood for lactate,
ammonia, blood count, thyroid, renal and liver function tests,
biotinidase, transferrin isoforms, very-long-chain fatty acids,
white cell enzymes and plasma amino acids, urine for meta-
bolic screen, CSF for glucose, lactate, amino acids, cells, and
culture. CSF neopterin was mildly elevated at 33.3nmol ⁄L
(normal<28) and mirrored OCBs were detected in CSF and
serum.
Pyridoxine and biotin were started at age 13 months with
no effect. Levetiracetam was added with some benefit and
vigabatrin was stopped. Progress EEG on levetiracetam
showed improvement in the background activity and persis-
tence of multifocal epileptiform discharges.
Over the next few months, the patient had no obvious clini-
cal seizures; however, she made no progress in her develop-
ment and her eczema deteriorated. She lived internationally
and was 2 years old at the time of reassessment. The patient
had severe eczema and abnormal dyskinetic movements of
both arms. Her central hypotonia persisted. She was able to
roll from supine to prone, but was not reaching for objects.
She was fixing and following, vocalizing, but had no words.
Her EEG remained encephalopathic with a modified hypsar-
rhythmic pattern, and repeat MRI was unchanged. Oral pred-
nisolone at 40mg daily was started according to the United
Kingdom Infantile Spasms Study (UKISS).3,18 This was fol-
lowed by improvement in encephalopathic state within a few
days with improved awareness and interactions. Her eczema
also improved. Repeat EEG 8 days after starting steroids
showed marked improvement.
Retrospective testing of serum taken at 13 months of age
revealed antibodies to VGKC-complex (201pmol ⁄L, nor-
mal<100pmol ⁄L), but negative NMDAR, GAD, LGI1, and
CASPR2 antibodies.
DISCUSSION
The recognition of autoimmune mechanisms in children with
encephalitis and epilepsy is growing.14–16 Our young patient
presented with encephalopathy and early-onset epileptic
spasms but did not have an obvious encephalitic illness. She did
not have MRI findings typical of limbic encephalitis, indeed
most of the children we have described with VGKC
encephalitis so far had normal or non-specific acute MRI
findings.15 This is the first evidence for a specific autoimmunity
in a patient with epileptic spasms. The clues to the possible role
of autoimmunity in this case were the presence of raised CSF
neopterin levels and mirrored OCBs. The presence of OCBs in
CSF without corresponding serumOCB represents intrathecal
synthesis of immunoglobulin-G and is highly suggestive of
immune activation within the central nervous system. The
presence of mirrored OCBs in both CSF and serum (as in our
case) might reflect systemic synthesis of immunoglobulin-G
with overflow into CSF, possibly related to blood–brain barrier
dysfunction. Although mirrored OCBs might not be as diag-
nostically important as intrathecal OCB synthesis, mirrored
OCBs are seen in some patients with acute disseminated
encephalomyelitis and early NMDAR encephalitis, and might
support an immune-mediated hypothesis.19 The seizures in our
case were refractory to conventional antiepileptic medications
and partly responsive to steroids. Steroids are used in the
treatment of epileptic spasms, and although the mechanism of
What this paper adds
• We present a female infant with epileptic spasms and epileptic encephalopa-
thy who had immune activation in the central nervous system.
• This is the first report of specific antibodies in a patient with epileptic spasms
and epileptic encephalopathy.
• Immune mechanisms might be important in some of these cases and early
immune therapy might improve outcome.
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their action is unclear, different theories have been proposed.5
It is possible that steroid therapy might have a direct immune
suppression effect in some patients. Although our patient
appeared to respond to steroids, the treatment was late in the
course owing to the patient’s location and loss to follow-up. It
is tempting to speculate that early and aggressive therapy could
improve outcomes in such patients. The presence of clinical
and biochemical markers of immune activation in this case
prompted us to search for antineuronal antibodies. Antibodies
against GAD, NMDAR, LGI1, and CASPR2 were negative.
VGKC-complex antibodies in this case were 201pmol ⁄L, using
a threshold of 100pmol ⁄L as defined in adults. We have previ-
ously tested 15 healthy children for VGKC-complex antibodies
(mean 18pmol ⁄L, mean+3SD=96), suggesting the threshold of
100pmol ⁄L is appropriate for children. Using 69 paediatric
comparisons with other neurological disorders, we have previ-
ously shown that an elevated VGKC-complex antibody is rare
in children.15 Haberlandt et al.14 have proposed the following
diagnostic range for VGKC-complex antibodies in children:
normal, less than 100pmol ⁄L; low positive, 100 to 150pmol ⁄L;
positive, 150 to 400pmol ⁄L; high positive, greater than
400pmol ⁄L. It is unclear whether VGKC-complex antibodies
are pathogenic in children. Alternatively, they might represent
a marker of immune activation and potential immune therapy
responsiveness. Larger cohorts of early-onset epilepsy will help
answer some of these questions. Some of the VGKC-complex
antibodies found in adults with limbic encephalitis were found
to be directed against proteins that are tightly complexed with
VGKC such as LGI1.11,12 However, this has not yet been dem-
onstrated in children withVGKC-complex antibodies,15 which
suggests that these antibodies bind to either one of the VGKC-
complex subunits or other proteins within the VGKC complex.
The case reported here suggests that VGKC-complex anti-
bodies might be associated with a broader clinical spectrum
than limbic encephalitis in children. Identifying these cases is
important as early aggressive immune therapy might improve
the outcome. Larger studies to address a possible autoimmune
role in infantile epileptic encephalopathy are needed.
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ABSTRACT
Background: Voltage-gated potassium channel antibodies (VGKC Ab) are associated with limbic
encephalitis and neuromyotonia in adults. There have been no systematic investigations in chil-
dren to date.
Methods: We looked for antibodies that are associated with CNS syndromes in adults including
antibodies to VGKCs, NMDARs, glutamic acid decarboxylase (GAD), and glycine receptor (GlyR) in
the stored acute serum from 10 children with unexplained encephalitis presenting with encepha-
lopathy and status epilepticus. We also looked for antibodies to leucine-rich glioma-inactivated 1
(Lgi1) and contactin-associated protein-like 2 (Caspr2), which are now known to be tightly com-
plexed with VGKCs in vivo. Sixty-nine pediatric controls were used for comparison.
Results: An elevated VGKC Ab (100 pM) was detected in 4/10 patients with encephalitis com-
pared to only 1/69 controls (p  0.001). The outcome in the 4 VGKC Ab-positive patients with
encephalitis was variable including good recovery (n  1), cognitive impairment (n  3), temporal
lobe epilepsy (n  2), and mesial temporal sclerosis (n  1). No other antibodies were detected,
including those to Lgi1 and Caspr2.
Conclusion: Encephalitis associated with VGKC Ab occurs in children and presents with status
epilepticus and focal epilepsy. These antibodies are not directed against Lgi1 or Caspr2.
Neurology® 2011;76:1252–1255
GLOSSARY
Ab  antibody; AERRPS  acute encephalitis with refractory, repetitive partial seizures; Caspr2  contactin-associated
protein-like 2; DESC  devastating epileptic encephalopathy in school-aged children; GAD  glutamic acid decarboxylase;
GlyR  glycine receptor; ICU  intensive care unit; IgG  immunoglobulin G; IgM immunoglobulin M; LE  limbic encepha-
litis; Lgi1 leucine-rich glioma-inactivated 1; SE status epilepticus; TLE temporal lobe epilepsy; VGKC voltage-gated
potassium channel.
Encephalitis, inflammation of the brain parenchyma, has infectious and immune-mediated etiolo-
gies.1 However, in more than 50% of cases, the cause remains undefined.2 Recently, there have been
descriptions of autoimmune encephalitis associated with specific neuronal autoantibodies.3 Autoan-
tibodies against voltage-gated potassium channels (VGKC) are found in a proportion of adult
patients with immune-responsive limbic encephalitis (LE) and neuromyotonia.4-6 With the excep-
tion of a case report of a child with temporal lobe epilepsy (TLE) and elevated VGKC antibodies
(Ab) 2 years following a suspected LE episode, there have been no descriptions of VGKC encepha-
litis in children.7 VGKC Ab are measured by immunoprecipitation of VGKCs extracted from
mammalian brain and labeled with 125-I--dendrotoxin that binds specifically to certain VGKC
subtypes. However, recent reports suggest that many of the antibodies are directed toward other
proteins, such as leucine-rich glioma-inactivated 1 (Lgi1) and contactin-associated protein-like 2
(Caspr2), which are tightly complexed with VGKCs in vivo and in tissue extracts6,8 so that antibod-
ies to these VGKC-complex antigens coimmunoprecipitate the 125-I--dendrotoxin-labeled
VGKCs.6 We screened for VGKC Ab by immunoprecipitation in a cohort of children with unex-
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plained encephalitis presenting with status epi-
lepticus (SE) and refractory seizures, and then
asked whether they were directed against Lgi1 or
Caspr2.
METHODS We identified 10 patients with unexplained en-
cephalitis presenting with status epilepticus and refractory seizures
between 2003 and 2009 (4 boys, mean age 7.5 years, range 1–14
years). All 10 patients had no previous seizures; 8 had no preceding
neurologic abnormality and 2 had preceding mild developmental
delay. All 10 patients fulfilled the case definition of encephalitis as
previously described.1,2 A case was defined by the presence of en-
cephalopathy (depressed or altered level of consciousness lasting
more than 24 hours, lethargy, or change in personality or behavior)
with 2 or more of the following symptoms: fever, seizure, focal neu-
rologic findings, CSF pleocytosis, or electroencephalograph or neu-
roimaging findings consistent with encephalitis.1,2 The mean length
of hospital stay for the encephalitis event was 19.7 days (median
24.5 days, range 6–36 days). Nine of the 10 patients (90%) were
admitted to the intensive care unit (ICU); the mean length of ICU
stay was 9 days (median 5 days, range 2–25 days). The SE was
convulsive in all 10 patients, focal in 2, generalized in 5, and second-
ary generalized in 3. The following results were negative or normal:
CSF HSV PCR (n  8), CSF enterovirus PCR (n  6), serology
for mycoplasma pneumoniae (n  9), enterovirus (n  7), cyto-
megalovirus (n  6), Epstein-Barr virus (n  6), herpes simplex
virus (n 5), human herpesvirus 6 (n 3), influenza (n 4), and
adenovirus (n  3). The stored serum used for antineuronal anti-
body testing was acute serum from the first week of the encephalitis
admission in all 10 patients. Sera were tested for antibodies to
VGKC, NMDAR, GAD, and GlyR with methods currently in use
for routine diagnosis.5,6,9-11 Lgi1 and Caspr2 antibodies were tested
using newly developed cell-based assays.6 The project was approved
by the local ethics committee and consent to test the stored serum
was obtained from families. The mean length of follow-up was 22
months (median 15.5 months, range 1–66 months). Two patients
had ongoing epilepsy, 5 had cognitive impairment, and 1 had died.
Only 2 patients were normal on follow-up.
Control group. To determine the specificity of VGKC auto-
antibodies in children, we used 69 childhood controls including
15 healthy children (8 male, mean age 11 years, range 9–13
years), 14 with noninflammatory neurologic disorders (6 male,
mean age 7.8 years, range 3–15 years), 19 with immune-
mediated ataxia (11 male, mean age 6 years, range 1–11 years),
10 with encephalitis lethargica and parkinsonian features (6
male, mean age 9.4 years, range 5–15 years), and 11 with
NMDAR encephalitis (2 male, mean age 6.53 years, range
1.3–13 years).12 The routine laboratory cutoff for VGKC Ab is
100 pM, which is the adult healthy control mean  3 SD. The
mean VGKC Ab in our pediatric healthy control group was 18
pM (SD 26, mean  3 SD  96). We therefore used the estab-
lished cutoff of 100 pM. The VGKC Ab findings in the enceph-
alitis/SE group were compared with the total control group
using the Fisher exact nonparametric 2  2 test.
RESULTS Four of 10 patients with encephalitis/SE
had a positive VGKC Ab titer (100 pM) compared
with only 1/69 of the pediatric control group (mean
20 pM, SD 32, p 0.001, 95% confidence interval).
The positive control (VGKC Ab 173 pM) had
NMDAR encephalitis with refractory clinical sei-
zures. The 10 encephalitis/SE patients were all nega-
tive for antibodies against Lgi-1, Caspr2, NMDAR,
GAD, and GlyR.
The clinical features of the VGKC Ab-positive
patients are presented in the table (1 male, age range
1–14 years). All 4 patients were normal before the
acute encephalitis, and had SE at presentation. The
duration of SE was 30–60 minutes in one patient,
60 minutes–24 hours in one patient, and longer than
24 hours in 2 patients. Patients had ongoing refrac-
tory seizure clusters for 5–20 days with up to 15 sei-
zure clusters per day (table). In addition to seizures,
all patients had encephalopathy and behavioral or
cognitive alteration during the acute illness. The 4
patients had a mean hospital admission of 20 days
(range 7–28 days), and all required admission to in-
tensive care for a mean of 7 days (range 2–18 days).
Table Patients with encephalitis presenting with status epilepticus who had VGKCAb>100 pM
Age,
y/sex
Predominant seizure
type, course Other clinical features
CSF
microscopy and
protein EEG MRI
VGKC
Ab (pM)
Outcome (length of
follow-up, months)
1/F Generalized Sx,
seizure cluster (5 days)
Encephalopathy,
behavioral alteration,
fever
9 cells/mm3,
0.24 g/dL
Left temporal
slowing
Normala 207 Temporal lobe epilepsy,
cognitive impairment (66)
9/F Secondary generalized
Sx, seizure
cluster (20 days)
Encephalopathy, behavior
alteration, fever
11 cells/mm3,
0.55 g/dL
Generalized with
dominant right
temporal slowing
Subcortical
hyperintensities
(bifrontal, left
parietal)
107 Temporal lobe epilepsy,
cognitive impairment,
psychiatric disorders (54)
12/M Generalized Sx,
seizure cluster
(10 days)
Encephalopathy, cognitive and
behavior alteration
25 cells/mm3,
0.52 g/dL
Generalized slowing Generalized mild
cerebral edema
214 Cognitive impairment
(mild) (17)
14/F Secondary generalized
and focal Sx, seizure
cluster (16 days)
Encephalopathy, cognitive
and behavior alteration,
fever
6 cells/mm3,
0.21 g/dL
Generalized slowing;
right and left temporal
epileptic discharges and
electrical Sx
Normal 640 Complete recovery
(15)b
Abbreviations: Ab antibody; Sx seizure; VGKC voltage-gated potassium channel.
a This patient had mesial temporal sclerosis on convalescent imaging.
b This patient was treated with IV immunoglobulin and oral steroids due to persistent cognitive impairment 6 months after acute encephalitis (see case
report in appendix e-1 on the Neurology® Web site at www.neurology.org).
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The CSF was abnormal in all 4 VGKC-positive
patients with mild pleocytosis (n  4) and elevated
CSF protein (n  2) (table). CSF PCR for herpes
simplex virus and enterovirus was negative in all 3
patients tested. Serology for neurotropic infectious
agents was negative. ANA was elevated at 1:640 in 2
patients but resolved on follow-up. One patient (case
1) had hyponatremia (Na 126 mmol/L). Brain MRI
showed abnormalities in 2 (table). EEG showed
slowing in all 4 patients, generalized in 2 and focal
(temporal) in 2. Epileptic activity or electrical sei-
zures were seen in one patient and were of focal (tem-
poral) onset.
The 4 VGKC-positive patients were followed for
a mean of 38 months (range 14–66). Only one
made a good recovery: 2 patients had ongoing tem-
poral lobe epilepsy, cognitive impairment, and be-
havioral/psychological alteration, and one had
cognitive impairment only. The patient who made a
good recovery (case 4 in the table) is presented in
appendix e-1 on the Neurology® Web site at
www.neurology.org. Convalescent MRI showed
left mesial temporal sclerosis in case 1 and persis-
tence of the hyperintensities in case 2. Of the 6
VGKC-negative encephalitis patients who were
followed up for a mean of 11 months (range
1–20), one has died, 2 have neurodevelopmental
disability, and 3 are normal.
DISCUSSION VGKC Ab are associated with a form
of LE in adults, termed VGKC Ab-associated en-
cephalitis, which is usually seen in patients over 40
years of age. In contrast to the paraneoplastic forms
of LE, this form of LE is usually nonparaneoplastic
and thought to be immune responsive with a good
outcome if treated adequately.4-6 Our retrospective
study suggests an encephalitis associated with VGKC
Ab exists in children and is characterized by enceph-
alitis with seizures and cognitive and behavioral alter-
ation. VGKC Ab detection is performed on serum
rather than CSF, as CSF levels are usually relatively
low and sometimes negative. The VGKC Ab assay
measures immunoglobulin G (IgG) rather than im-
munoglobulin M (IgM). Longitudinal studies of
VGKC IgG and IgM would help understand the
evolution of the autoimmune process relative to the
clinical encephalitis. Although these patients had ele-
vated VGKC Ab, they did not have antibodies to
Lgi1 or Caspr2, suggesting that these pediatric pa-
tients are different from the LE associated with Lgi1
antibodies described recently in adults.6,8 Further
analysis of their sera is in progress to determine
whether their antibodies are directed against the
VGKC subunits or other proteins in the VGKC
complex. Our control group suggest that elevated
VGKC Ab are rare in children: the only control with
an elevated VGKC Ab titer had a clinical phenotype
of NMDAR encephalitis and had both NMDAR
and VGKC Ab.12 The finding of more than one an-
tibody associated with autoimmune encephalitis has
been recently reported in an adult patient.13
The encephalitis in these patients was previously
unexplained and CSF testing for common infectious
agents and serologic investigations were negative. As
the diagnosis of VGKC Ab-associated encephalitis
was made retrospectively using stored acute serum,
none of our patients received immunotherapy dur-
ing the acute illness. The 4 VGKC Ab patients
have generally done poorly: 2 patients have ongo-
ing TLE and one has cognitive impairment. Pro-
spective studies including longitudinal VGKC Ab
measurement before and after immune therapy are
required to improve our understanding of VGKC
encephalitis in children.
The initial clinical course of case 4 was reminis-
cent of devastating epileptic encephalopathy in
school-aged children (DESC). DESC is a pseudoen-
cephalitis syndrome of unknown cause that affects
previously well children, causes refractory seizures
and encephalopathy, and has severe morbidity and
mortality.14 The cases are also reminiscent of acute
encephalitis with refractory, repetitive partial seizures
(AERRPS), an unexplained encephalitis associated
with seizures which is described mainly in Japanese
patients.15 It is possible that autoimmune mecha-
nisms may be important in some cases of DESC and
AERRPS, and this requires investigation.
One case with VGKC Ab encephalitis (case 1)
had a normal MRI during her acute encephalitis
while follow-up imaging showed left mesial temporal
sclerosis. This patient has ongoing TLE; the evolu-
tion from LE to TLE and mesial temporal sclerosis
has been described in adults.16 Elevated VGKC Ab
were recently described in a 13-year-old girl with
TLE and hippocampal sclerosis 2 years after a sus-
pected LE.7
The role of VGKC Ab requires further investiga-
tion in larger cohorts of pediatric encephalitis, and
children with TLE and mesial temporal sclerosis.
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